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Thesis Summary 
Antibiotic resistance is an increasing global public health problem. Resistance is increasing 
sharply in gram-negative organisms, including Escherichia coli (E. coli), the main causative 
organism for community-acquired urinary tract infection (UTI). Antimicrobial stewardship 
strategies in primary care to help contain antibiotic resistance include supporting general 
practitioners (GPs) in deciding whether to prescribe an antibiotic for UTI and selecting the most 
appropriate antibiotic.  
In this thesis, I aim to describe the management of uncomplicated UTI in primary care and 
evaluate potential point of care tests (POCT) to assist the diagnosis and/or appropriate 
prescribing of antibiotics for uncomplicated UTI. The program of work includes:  
1. Laboratory evaluation of a culture-based test that allows the quantification, 
identification and susceptibility profile of infecting bacteria from urine (FlexicultTM).  
2. Evaluation of a novel chromatic sensing technique to identify bacterially infected urine 
compared to visual assessment of urine turbidity and urinalysis dipsticks.  
3. Systematic review and analysis of data (descriptive and multi-level modelling) from an 
international primary care based observational study to describe UTI management. 
I identified unwarranted variation in clinical management of UTI between countries and 
between general practices within countries. Empirical antibiotic prescribing for UTI in Europe is 
high and treatment is generally prescribed for longer than guidelines recommend. FlexicultTM 
was comparable to UK ‘reference standard’ NHS laboratory microscopy and culture for 
identifying bacterial UTI. The use of FlexicultTM in practice may support GPs in screening out 
negative samples reducing the proportion of patients that are prescribed antibiotics empirically. 
Chromatic sensing and visually assessing turbidity were equally useful at identifying negative 
urine samples and both improved the analytic performance of urinalysis dipsticks. The chromatic 
sensing system requires development prior to further evaluation.
 iv  
Glossary Terms and Abbreviations 
95% CI 95% Confidence Interval 
ASP Any small particles (microscopy) 
ATCC American Type Culture Collection (biological resource company) 
AUROC Area under receiver operating characteristic 
BMS Biomedical scientist 
BNF British National Formulary 
BSAC British Society for Antimicrobial Chemotherapy 
CRD Centre for reviews and dissemination 
CRF Case Report Form 
CSU Catheter specimen of urine 
DIC Deviance information criterion 
DID Defined Daily Dose 
EQA External Quality Assurance 
ESAC European Surveillance of Antimicrobial Consumption 
ESBL 
Extended Spectrum Beta Lactamase; enzymes produced by bacteria that are  
resistant to certain antibiotics 
ESCMID European Society of Clinical Microbiology and Infectious Diseases 
EUCAST MIC 
European Committee on Antimicrobial Susceptibility Testing Minimum Inhibitory 
Concentration 
EUG European Urinalysis Guidelines 
GI Gastrointestinal tract 
GP General Practitioner 
HPA Health Protection Agency; now Public Health England and Public Health Wales 
ICC Intraclass correlation 
IDSA Infectious Diseases Society of America 
IQR Inter-quartile range 
ITU Intensive treatment unit 
LE Leucocyte esterase 
LHR or LR Likelihood ratio 
LRTI Lower Respiratory Tract Infection 
Maldi-TOF Matrix Assisted Laser Desorption Ionization Time-of-Flight 
MCMC Markov chain Monte Carlo estimate 
MDR-GNB Multidrug resistant Gram negative bacteria 
MIC Minimum Inhibitory Concentration 
MQL Marginal quasi-likelihood estimate 
MRSA Methicillin Resistant Staphylococcus aureus 
MSU Mid-stream urine 
 v  
NHS National Health Service 
NLR Negative likelihood ratio 
NPV Negative Predictive Value 
OD; BD; TDS; 
QDS 
Pharmaceutical dosing terminology for: once daily; twice daily; three times a day; 
 and four times a day  
OR Odds Ratio 
PHW Public Health Wales 
PICO Population/Intervention/Comparison/Outcome 
PIL Patient Information Leaflet 
PLR Positive likelihood ratio 
POCT Point Of Care Test 
POETIC study Point of care testing for urinary tract infection in primary care 
PPV Positive Predicitve Value 
PQL Penalized (predictive) quali-likelihood estimate 
RBC Red blood cell 
RCT Randomised Controlled Trial 
REC Research Ethics Committee 
R-GNOSIS Resistance in Gram-Negative Organisms: Studying Intervention Strategies 
ROC Receiver operating characteristic 
SD Standard Deviation 
SE Standard Error 
SIGN Scottish Intercollegiate Guidelines Network 
SMAC Standing Medical Advisory Committee (UK Department fo Health) 
SMI Standard for Microbiology Investigations 
SOP Standard Operating Procedure 
SPA Suprapubic aspirate 
SSI Statens Serum Institut, Denmark 
UHW University Hospital Wales 
UKECA United Kingdom Ethics Committee Authority 
UTI Urinary Tract Infection 
VPC Variance partition coefficient 
WBC White blood cell 
WHO World Health Organisation 
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Section 1: Introduction 
Chapter 1: Introduction, aims and objectives 
 
Overall research aim 
The overall aim of this thesis is to describe the management of patients presenting with 
symptoms of uncomplicated urinary tract infection (UTI) in primary care, and to evaluate 
potential point of care tests to assist clinicians in the diagnosis of uncomplicated UTI 
and/or the appropriate prescribing of antibiotics for uncomplicated UTI in this setting. 
 
The importance of this research: antibiotic resistance 
Antibiotics have been used for decades to save millions of people from life threatening 
infections. Indeed,  the practice of technologically advanced medicine has been possible 
only  with the aid of antibiotics, and food animals can now be reared more intensively  
with the use of antibiotics as growth promoters and herd/flock therapy (1). However 70 
years after the introduction of antibiotics (the mass production of penicillin was in the 
early 1940’s) we find ourselves on the edge of a post-antibiotic era, where there would 
be limited options for the treatment of infections and prophylaxis for surgical procedures, 
increased length of hospital stays and increased patient morbidity and mortality due to 
the global emergence of antibiotic resistance in bacteria. A 2009 European Centre for 
Disease Control and European Medicines Agency joint report stated that 25,000 deaths 
in Europe were a direct consequence of multi-drug antibiotic  resistance (2). Likewise in 
the Unites States of America a report by the Centre for Disease Control estimated that 2 
million people become infected with bacteria that are resistant to antibiotics and at least 
23,000 die each year as a result of these infections (3). The World Health Organisation 
(WHO) Global Tuberculosis Report (2013) estimated that world-wide 170,000 people 
died from multi-drug resistant tuberculosis in 2012 (4).   
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A key finding from the WHO antimicrobial resistance global report on surveillance 2014 
included information that resistance to one of the most widely used antibacterial - the 
fluoroquinolones - is very widespread. In the 1980s, when these drugs were first 
introduced, resistance was virtually zero. Today, there are countries in many parts of the 
world where this antibiotic is now ineffective in more than half of patients (5). Until 
recently, it was considered that the hospital, and especially the intensive care units, were 
the major source of antibiotic resistant bacteria, with many reporting problems worldwide 
with Pseudomonas aeruginosa, Acinetobacter baumanii, the Enterobacteriaceae and 
Staphylococci (1).  However resistance is increasing sharply in Escherichia coli, the main 
causative organism of urinary tract infection and an organism where infections are 
acquired in the community, or, even if they arise in hospital, usually involve strains from 
the patients endogenous gut flora. In accord with the WHO report, resistance to 
fluoroquinolones in E. coli, are increasing steadily as shown in Figures 1.1.1 (A) for 
England and Wales (data from the Health Protection Agency), and (B)  Europe 
respectively (data from European Antimicrobial Resistance Surveillance System)  (6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1. (A) Resistance trends to ciprofloxacin in E. coli from bacteraemias in 
England and Wales, 1990–2004. (B) Resistance trends to fluoroquinolones in E coli from 
European countries, 2001–04. Sources: (A) Health Protection Agency, data on file; (B) 
European Antimicrobial Resistance Surveillance System (http://earss.rivm.nl).(6) 
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AT=Austria, BE=Belgium, CZ=Czech Republic, DE=Germany, ES=Spain, GR=Greece, HR=Croatia, 
HU=Hungary, NL=Netherlands, PT=Portugal, SE=Sweden, SI=Slovenia, SK=Slovakia. Countries with 
incomplete reporting over the 3 years (e.g., France, Italy, and Ireland) are excluded. For each county the 
bars, in sequence left to right, represent the 4 years. 
 
The first 30 or so years of antibiotic use saw the introduction of a multitude of new 
antibiotic agents, yet in the last 25-30 years, only one new family, the oxazolidinones, 
has been introduced (1). The discovery and development of new antibiotics remains vital. 
However many pharmaceutical companies have left this area of research possibly due 
to antibiotics being for short-term consumers (even if there is wide usage) and the 
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knowledge that new antibiotics may rapidly be compromised by emerging resistance (6, 
7). Instead companies will be developing specifically targeted antibiotics i.e. strain 
specific Gram-negative antibiotics but in order to use these treatments appropriately 
better POCTs need to be developed so that these infections can be clearly identified 
prior to treatment. The WHO is also calling attention to the need to develop new 
diagnostic tests, antibiotics and other tools to allow healthcare professionals to stay 
ahead of emerging resistance. Included in the report are the following strategies that can 
be undertaken by various facilitators; 
Health workers and pharmacists can help tackle resistance by: 
 enhancing infection prevention and control; 
 only prescribing and dispensing antibiotics when they are truly needed; 
 prescribing and dispensing the right antibiotic(s) to treat the illness; 
Policymakers can help tackle resistance by: 
 strengthening resistance tracking and laboratory capacity; 
 regulating and promoting appropriate use of medicines; 
Policymakers and industry can help tackle resistance by: 
 fostering innovation and research and development of new tools; 
 promoting cooperation and information sharing among all stakeholders. 
A key feature of these strategies (to limit antibiotic resistance) is the promotion of better 
antibiotic prescribing. A report from the UK Department of Health’s Standing Medical 
Advisory Committee (SMAC) Sub-Group on Antimicrobial Resistance in 1998 identified 
that 80% of antimicrobial prescribing for patients was in the community for common 
infections and recommended to clinicians ‘Four things you can do to make a difference’, 
namely; 
(i) no prescribing of antibiotics for simple coughs and colds;  
(ii) no prescribing of antibiotics for viral sore throats; 
(iii) limiting prescribing for uncomplicated cystitis to 3 days in otherwise fit women; 
(iv) limiting the antibiotic agents prescribed over the telephone to exceptional cases 
(8). 
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As part of my research I am interested in the promotion of more appropriate antibiotic 
prescribing for community acquired uncomplicated urinary tract infection. Necessary 
steps to manage this situation include better surveillance to assess accurately the extent 
of problems (i.e. inappropriate prescribing, unwarranted variation in prescribing practice 
and use of diagnostics), more prudent use of the available antibiotics to conserve 
valuable therapeutic resources and improved infection control to limit the spread of 
resistant organisms (4). A complete picture of infectious disease management allows for 
inter-country comparison and analyses of drivers of change (9). The surveillance of the 
management of uncomplicated UTI in primary care (including antibiotic prescribing) and 
evaluation of point of care tests to guide prudent use of available antibiotics for 
uncomplicated UTI are the foundation of my research. 
Policies to reduce inappropriate antibiotic prescribing in primary care, thereby reducing 
the pressure for the emergence and spread of antibiotic-resistant pathogens, have had 
some success, but substantial variations in prescribing rates between- and within- 
countries persist. The European surveillance of Antimicrobial Consumption (ESAC) 
project, monitoring outpatient antibiotic use from 33 countries revealed the total 
outpatient antibiotic use in 2009 varied by a factor of 3.8 between the countries with the 
highest (38.6 defined daily dose (DID) in Greece) and lowest (10.2 DID in Romania). A 
significant increase was found in total outpatient antibiotic use, as well as a significant 
seasonal variation, which decreased over time from 1997 to 2009 (10). Current policies 
are based largely on ecological relationships between prescribing and resistance, and 
there are only limited data at the level of the individual patient that are not subject to the 
serious selection bias of using routinely collected patient data and that are adjusted for 
potential confounders (11). I will be presenting the results of a narrative systematic 
review of observational studies of the management of uncomplicated urinary tract 
infections in primary care in Europe. Additionally, I will present and discuss some of the 
results from a multi-centre, multi-national observational study (phase 2 of a larger 
‘POETIC study’ discussed further in Section 3, Chapter 2) of the presentation and 
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management of patients presenting with suspected uncomplicated urinary tract infection 
in primary care centres in England, Wales, Spain and the Netherlands. 
Another important strategy to reduce antibiotic use is to support general practitioners 
(GPs) in deciding both whether or not to prescribe an antibiotic for patients presenting 
with symptoms of uncomplicated UTI and in selecting the most appropriate antibiotic. 
This need could be met by a diagnostic point-of-care test (POCT) that could rapidly 
identify the presence of either infecting bacteria or surrogate markers of bacterial 
infection (host or pathogen biomarker), and ideally also indicate the antibiotic 
susceptibility profile of any infecting bacteria. A POCT is defined as any test performed 
by or on behalf of the treating doctors, on-site at the time of consultation, which allows 
the test result to be used to guide immediate decisions about patient treatment (12). A 
recent study of clinicians’ and patients’ views of POCTs (for lower respiratory tract 
infection) in primary care showed that the GPs most common reported advantages 
include managing patient expectations for antibiotics and enhancing patient satisfaction 
where clinicians felt that patients were generally reassured by technology that 
augmented clinical assessment.  POCTs can also be helpful in clinicians’ own decision 
making process and contribute to more robust diagnosis and prognosis (13, 14). 
Concerns raised by GPs include test performance sensitivity, specificity and reliability 
and misdiagnosis of serious infections. Problems interpreting values, deciding cut-off 
points, or false positives and negatives are also a concern (14). Patient views are 
generally supportive of POCT use stating that POCTs would be useful and give GPs 
more information to make better decision about their treatment and to establish if 
antibiotics are necessary. Concerns from patients include anxiety waiting for a result, 
aversion to needles or a blood sample being taken and problems of time and cost (14).  
The development stages of any new diagnostic test for infectious disease include 
identifying a clear need for a new test, clearly defining where and how a test is to be 
used, discovery and validation of candidate biomarkers (to incorporate into a new 
diagnostic test) and extensive evaluation of the test. Clinical specimens such as urine 
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are an essential prerequisite for both biomarker discovery and the development and 
evaluation of new diagnostic tests. A systematic approach is needed to test: 
(i) analytical validity, whether the test measures what it is claimed to 
measure; 
(ii)  clinical validity, whether the test answers the clinical question being 
asked (e.g., screening, diagnosis, prognosis, monitoring);  
(iii) clinical usefulness, whether the test leads to better outcomes; and 
(iv) social context, including ethical, economic, and legal issues (15). 
I will be presenting the analytic performance and discussing the clinical usefulness of UK 
FlexicultTM SSI-Urinary kit; a culture based diagnostic and antibiotic susceptibility point 
of care test for urinary tract infections. Additionally I will be presenting preliminary analytic 
performance data on chromatic sensing; a novel approach (and potential POCT) to aid 
GPs in the diagnosis of bacterial UTI. 
 
Thesis layout  
This thesis is divided into four sections: Section 1 – Introduction; Section 2 – Analytic 
Performance of UK FlexicultTM SSI-Urinary Kit, chromatic sensing, visual turbidity 
assessment of urine and dipstick urinalysis in the diagnosis of suspected urinary tract 
infection; Section 4 - Management of uncomplicated UTI in Primary Care; and Section 5 
– Overall Discussion.  
 
Summary of research aims and objectives 
The primary aim of this research is to describe the management of uncomplicated urinary 
tract infection (UTI) in primary care and to evaluate potential point of care tests to assist 
in the diagnosis of uncomplicated UTI and/or the appropriate prescribing of antibiotics 
for uncomplicated UTI in this setting. 
Secondary aims are; 
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1. To evaluate the analytic performance of UK Flexicult™ SSI-Urinary kit by 
comparing performance with routine NHS microbiology laboratory testing, and 
enhanced urine culture techniques.  
2. To explore chromatic sensing technology as a potential point-of-care test to help 
GPs in their decision to prescribe antibiotics to patients with suspected urinary 
tract infection. 
3. To systematically identify and review published studies that have evaluated the 
routine management of adult women with suspected uncomplicated UTI 
attending primary care in different European countries; and to summarise these 
data to determine variation in management between countries. 
4. To evaluate whether a patients’ resident country, age, history of UTI, symptom 
severity, days off work, days with symptoms, dipstick urinalysis testing, urine 
appearance and oral temperature are associated with different management 
decisions (including the use of POCT, requesting a urine culture, antibiotic 
prescribing and follow-up recommendations).  
 
Research objectives: 
 Compare the diagnostic accuracy in determining a bacterial UTI using UK 
Flexicult POCT to routine NHS microbiology laboratory methods, and evaluate 
discrepancies using enhanced urine culture and identification techniques; 
 Evaluate Biomedical Scientists (BMS) and General Practitioners (GP) inter-
observer variation on the interpretation of the UK Flexicult POCT;  
 Determine if diluting turbid urine (potential for over-inoculation) could improve 
identification of predominant uropathogens; and improve Flexicult susceptibility 
concordance with NHS susceptibility results; 
 Assess the analytic performance of chromatic sensing in the laboratory diagnosis 
of UTI with routine NHS microscopy and culture as the reference standard; and 
compare the analytic performance of chromatic sensing to currently available 
POCTs for UTI including urine dipsticks and visual turbidity assessment; 
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 Conduct a narrative systematic review of the literature including critical appraisal 
and data extraction of included studies evaluating the routine management of 
women with suspected uncomplicated UTI in primary care; 
 To describe patient demographics and signs and symptoms at presentation in 
primary care (with symptoms attributable to UTI) and clinical management 
decisions for those patients included into the POETIC observational study of 
uncomplicated UTI in four participating countries;  
 To examine the individual (patient) level factors associated with differences in 
patient management using multilevel statistical modelling. 
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Chapter 2: Background 
In this chapter I will summarise: the evaluation of diagnostics tests; the classification and 
prevalence of uncomplicated UTI; current management options including prescription of 
antibiotics and available point of care tests; and the laboratory diagnostic process for UTI 
in the UK.  
 
Evaluation of diagnostic tests 
Clinical samples are a vital requirement for enabling and facilitating the development and 
evaluation phases of any diagnostic test. These phases include identifying and validating 
candidate biomarkers, establishing proof-of-principle for the new test, establishing 
methodology for sample preparation and evaluating the new test prototype. Once a new 
test has been developed and before it can be recommended for use in routine care, the 
evaluation data should demonstrate that the test is at least as good as the current ‘gold 
standard’ test. Therefore, the test must be compared directly with the existing best 
practice method using the same clinical samples.  
The absolute ‘gold standard’ for diagnosis of UTI is the culture of bacteria from urine 
obtained by suprapubic needle aspiration. This is not generally feasible and can cause 
unnecessary anxiety or pain to patients, so the next best clinical specimen is a mid-
stream urine. There is no bacterial count that can be taken as an absolute ‘gold standard’ 
for the diagnosis of UTI and guidelines vary on this. Due to the limitations of 
microbiological microscopy and culture it may be more appropriate to consider the ‘gold 
standard’ diagnostic test for UTI as the ‘reference standard’. 
When assessing and comparing diagnostic accuracy of a test there are several analyses 
that can be used and are described in later chapters but predominantly sensitivity, 
specificity, positive and negative predictive values are used to assess the tests 
diagnostic accuracy. Sensitivity shows the likelihood of a positive test result if an 
individual were to truly have the disease. The specificity shows the likelihood of having 
 11  
a negative test result if an individual does not have the disease. The sensitivity and 
specificity are characteristics of the test itself and are independent of the disease 
prevalence. Disease prevalence is combined with sensitivity and specificity to create the 
positive and negative predictive values. The positive predictive value (PPV) is the 
probability that the patient has the disease when the test result is positive.  The negative 
predictive value (NPV) is the probability that the patient does not have the disease if the 
test result is negative.  
Classification and prevalence of urinary tract infections 
Urinary tract infection (UTI) refers to the presence of microbial pathogens within the 
urinary tract. Infections can be classified according to their location within the urogenital 
tract. The different parts of the urinary tract, however, communicate with each other to 
some degree. As a result, bacteria in one area can move to infect other areas. For 
practical clinical reasons UTIs (and infections of the male genital tract) are classified 
according to the predominant clinical symptoms: 
• uncomplicated lower UTI (cystitis; bladder) 
• uncomplicated pyelonephritis (kidney) 
• complicated UTI with or without pyelonephritis (bladder ± kidney) 
• urosepsis (blood stream) 
• urethritis (urethra) 
• special forms: prostatitis (prostate), epididymitis (epididymis) and orchitis (testes). 
Asymptomatic bacteriuria is another term defined as the isolation of bacteria from the 
urine in significant quantities consistent with infection, but without the local or systemic 
genitourinary signs or symptoms. Asymptomatic bacteriuria only requires treatment in 
specific populations such as pregnant women (16). Asymptomatic bacteria is common 
in nursing homes.  
Factors that suggest a potential complicated UTI include: male sex; elderly; hospital-
acquired infection; pregnancy; indwelling urinary catheter; recent urinary tract 
intervention; functional or anatomical abnormality of the urinary tract; recent antibacterial 
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use; symptoms for > 7 days at presentation; diabetes mellitus; and immunosuppression 
(17). Table 1.1.1 describes five different categories of urinary tract infection, their clinical 
presentation and laboratory diagnostic criteria (although this is not universal as 
discussed later in the microbiological diagnosis section). 
The clinical presentation and management of different UTI categories may vary during 
life and may depend on the patient’s condition. Therefore, the requirements of special 
patient groups (the elderly, those with underlying diseases and the 
immunocompromised) also need to be considered at the time of consultation (17). 
Uncomplicated UTI is classified as UTI without structural and functional abnormalities 
within the urinary tract (uropathies), without relevant kidney diseases (nephropathies) 
and without relevant comorbidities favouring more serious adverse outcome (18). There 
seem to be no long-term adverse effects on renal function nor increased mortality 
associated with acute uncomplicated UTI/cystitis (in the non-pregnant population), not 
even in women with frequent recurrences.  Untreated cystitis rarely progresses to 
symptomatic upper urinary tract infection and is limited to symptoms, which can, 
however, affect quality of life considerably (18).  
Uncomplicated UTIs affect up to 15% of women each year. More than 25% of women 
who have had an infection will experience a recurrence in their lifetime (19). The 
probability of cystitis in a woman with symptoms of dysuria, urinary frequency, or gross 
haematuria is about 50% in primary care settings (19, 20). Specific combinations of 
symptoms (for example, dysuria and frequency without vaginal discharge or irritation) 
raise the probability of cystitis to more than 90%. When a woman who has previously 
had cystitis has symptoms suggesting a recurrence, there is an 84% - 93% chance that 
an infection is present (19). In an American study of a random digit dialling survey of 
2000 women representative of the United States population on the incidence (and 
associated costs) of UTI; 11% (95% CI: 9.4, 12.1%) of women aged 18 and older 
reported at least one presumed UTI during the past 12 months, with the majority of the 
cases occurring among women with a history of two or more UTI episodes in their life. 
They estimate that by age 26, one-third of women will have at least one physician-
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diagnosed presumed UTI with a lifetime risk of 60% (21). Within three to four months of 
an initial UTI, 20% to 30% of women will experience a recurrence of the infection with 
additional concomitant short-term morbidity (16). 
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Table 1.1.1. Criteria for the diagnosis of a UTI, as modified according to IDSA/ESCMID guidelines (17, 22). 
Category Description Clinical Features Laboratory Investigations1 
1 
Acute uncomplicated UTI in 
women; acute uncomplicated 
cystitis 
Dysuria, urgency, frequency, suprapubic pain, no urinary symptoms in 
four weeks before this episode 
≥ 10 WBC/mm3 
≥103 cfu/mL* 
2 
Acute uncomplicated 
pyelonephritis 
Fever, chills, flank pain; other diagnoses excluded: no history or clinical 
evidence of urological abnormalities (ultrasonography, radiography) 
≥ 10 WBC/mm3 
≥104 cfu/mL* 
3 Complicated UTI 
Any of symptoms from categories 1 or 2 above; one or more factors 
associated with a complicated UTI2 
≥ 10 WBC/mm3 
≥105 cfu/mL* in women 
≥104 cfu/mL in men, or in straight 
catheter urine in women 
4 Asymptomatic bacteriuria No urinary symptoms 
≥ 10 WBC/mm3 
≥105 cfu/mL* in two consecutive MSU 
cultures ≥ 24 hours apart 
5 
Recurrent UTI 
(antimicrobial prophylaxis) 
At least three episodes of uncomplicated UTI documented by culture in 
the last 12 months; women only; no structural or functional 
abnormalities 
≥ 10 WBC/mm3 
 
ISDA – Infectious Diseases Society of America; ESCMID – European Society for Microbiology and Infectious Diseases ; UTI - urinary tract infection; MSU – mid-stream urine; WBC – 
white blood cells; 1 – laboratory diagnostic criteria may vary between countries and laboratories; 2 – as described in text; *Uropathogen in MSU culture. All pyuria counts refer to 
unspun urine. 
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Management of uncomplicated UTI in primary care 
Guidelines recommend treating uncomplicated UTI empirically if there are severe or 
multiple relevant symptoms or the patient has a history of UTI (brief summary in 
Table1.1.2). If there is any uncertainty or if the symptoms are mild, further diagnostic 
tests should be undertaken.  These vary across countries and include evaluating urine 
turbidity, dipstick urinalysis (generally nitrites and leucocytes), dip-slides, urine 
sediment/microscopy and in some countries C-reactive protein tests. Laboratory urine 
culture is generally not recommended for uncomplicated urinary tract infection 
(diagnostic tests are discussed in more detail later).  
Table 1.1.2. Guidelines on management of uncomplicated urinary tract infections in 
women  
Guidelines Treat in presence of First Choice Drugs Duration 
Health Protection 
Agency (England and 
Wales) 
Severe or ≥3 
symptoms alone or if 
mild symptoms cloudy 
urine and dipstick 
Trimethoprim 200mg bid 3 days 
Nitrofurantoin 100mg bid 3 days 
Infectious Diseases 
Society of America 
and the European 
Society of 
Microbiology and 
Infectious Diseases 
Empirical treatment 
for women with 
symptoms of 
uncomplicated cystitis 
and able to take oral 
medication 
Nitrofurantoin  100mg bid 5 days 
Trimethoprim-
sulfamethoxazole 
160/800mg 3 days 
Fosfomycin 
Trometamol 
3gm single dose 
Pivmecillinam 400mg bid 5 days 
 
 
Short-term, higher dose antibiotic therapy (3 days or less) can be considered as the 
treatment of choice because of many advantages: better compliance; less collateral 
effects; lower cost; but as efficient as conventional therapy (11, 17, 18).  Another aspect 
relates to adverse effects in the patient. In general, the antibiotics commonly prescribed 
cause only mild and moderate adverse effects such as vaginal candidiasis and 
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gastrointestinal disorders. Several fluoroquinolones, however, had to be withdrawn from 
the market because severe adverse effects, for example, liver damage. Some antibiotics 
still in use have the potential risk of severe, but very rare adverse effects, for example, 
Lyell syndrome (trimethoprim and sulfamethoxazole) or severe pulmonal and neuronal 
effects (nitrofurantoin) (18). Table 1.1.3 outlines the main antibiotics used for 
uncomplicated urinary tract infections, their potential for causing ecological collateral 
damage and their recommended use. “Collateral damage” is a term used to refer to 
ecological adverse effects of antibiotic therapy; namely, the selection of drug-resistant 
organisms and the unwanted development of colonization or infection with multidrug-
resistant organisms; it is the cornerstone of antibiotic stewardship. There are different 
levels of collateral damage which can be evaluated such as antibiotic use in persons 
infected with an antibiotic-resistant organism (individual level), antibiotic use in an 
institution correlated to rates of antibiotic resistance in that institution (group level), and 
interventions aimed at limiting use of antibiotics of various classes to decrease selection 
pressure leading to antibiotic resistance (23). Costelloe et al. performed a systematic 
review investigating subsequent antibiotic resistance in individuals prescribed antibiotics 
in primary care and found that prescribing for a respiratory or urinary infection individuals 
develop bacterial resistance to that antibiotic. The effect is greatest in the month 
immediately after treatment but may persist for up to 12 months. This effect not only 
increases the population carriage of organisms resistant to first line antibiotics, but also 
creates the conditions for increased use of second line antibiotics in the community (24). 
Nitrofurantoin is fast becoming the first-choice antibiotic for uncomplicated UTI in many 
countries, such as the UK, Germany, Spain, The Netherlands, Italy, Croatia, Sweden, 
and the USA (22, 25-31). Trimethoprim is still first-choice in some countries as long as 
the local resistance rates are less than 20% (22, 25). Other first-choice antibiotics include 
fosfomycin and pivmecillinam but these are not licensed in all countries (including the 
UK) (18, 22, 25).  
Empirical antibiotic prescribing for uncomplicated UTI, however, may often be 
unnecessary, since 34% - 60% of patients with suspected UTI have been shown not to 
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have a microbiologically proven UTI (32-34). This does not necessarily rule out a 
bacterial infection as the diagnostic criteria for UTI is variable, laboratory techniques are 
often basic and subjective, and urine samples can be poor quality/contaminated. Also, 
many women, even those with a bacteriologically proven UTI, will recover at a similar 
rate regardless of whether they received antibiotic treatment or not (35) and some women 
presenting with symptoms of uncomplicated UTI accept or actually prefer to be managed 
without immediate antibiotics for example having the option of delayed back-up antibiotic 
prescription (36).  In a prospective cohort study of 176 women across 20 general 
practices in the Netherlands, Knottnerus BJ  et al. concluded that more than a third of 
women with UTI symptoms are willing to delay antibiotic treatment when asked by their 
GP and the majority of delaying women report spontaneous symptom improvement after 
one week (37). 
The management of UTI in primary care is evaluated and discussed further in Section 3.  
Current POCTs used for UTI and routine diagnostic processes are described further 
below. 
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Table 1.1.3. Description of antibiotics used to treat UTI.  
Antibiotic Collateral* Considerations (18) Further Comments and Recommended Use (22) 
Aminopenicillins 
Restricted impact on Enterobacteriaceae in the 
gastrointestinal (GI) tract, but provides anti-enterococcal 
activity 
Amoxicillin and ampicillin should not be used for empirical treatment given the 
relatively poor efficacy and very high prevalence of antibiotic resistance to these agents 
worldwide. 
Cephalosporins 
Reduce Gram-negative Enterobacteriaceae but select 
Enterococci in the GI tract because of their inherent 
enterococcal resistance. This mechanism may also cause an 
overgrowth of Clostridium difficile and Extended Spectrum 
Beta Lactamase (ESBL) producing bacteria. 
β-Lactam agents, including co-amoxiclav, cefdinir, cefaclor and cefpodoxime-proxetil, in 
3 – 7 days regimens are appropriate choices for therapy when other agents cannot be 
used. Other β-lactams, such as cephalexin, are less well studied but may be appropriate 
in certain settings. The β-lactams generally have inferior efficacy and more adverse 
effects, compared with other antibiotics. For these reasons, β-lactams other than 
pivmecillinam should be used with caution for uncomplicated cystitis. 
Fluoroquinolone
s 
Very high impact on the gastrointestinal and skin flora by 
eradicating susceptible and selectively resistant bacterial 
strains, which are not only fluoroquinolone –resistant 
strains, but also ESBL-producing bacteria, methicillin 
resistant S. aureus (MRSA) and C. difficile. 
Ofloxacin, ciprofloxacin, and levofloxacin highly efficacious in 3-day regimens but have 
propensity for collateral damage* and should be reserved for important uses other 
than acute cystitis and thus should be considered alternative antibiotics for acute 
cystitis. 
Fosfomycin Low impact on the GI flora. 
3g in single dose; minimal resistance but appears to have inferior efficacy compared 
with other short-course regimens according to data submitted to the US Food and Drug 
Administration (FDA). Not licenced globally (e.g. U.K). 
Nitrofurantoin 
Does not concentrate in the gastrointestinal tract. The 
selection of resistant mutants in the GI tract is, therefore, 
generally not a problem. 
100 mg twice daily for 5 days has efficacy comparable to 3 days trimethoprim-
sulfamethoxazole. 
Pivmecillinam Only limited impact on the GI flora. 
Appropriate choice for therapy in regions where available (only available in 
Scandinavian countries, the Netherlands, Austria and Canada), minimal resistance but 
may have inferior efficacy compared with other therapies (400mg 2dd 3 – 7days). 
Trimethoprim 
and 
trimethoprim/sul
famethoxazole 
High impact on the GI flora, resulting in pronounced 
decrease of Gram-negative Enterobacteriaceae. Selection of 
resistant E. coli has been shown to occur easily. The 
resistant genes are usually plasmid encoded and easily 
spread. 
Use if local resistance is less than 20% or if infecting strain known to be susceptible. 
Trimethoprim (200 mg 2dd 3 days) considered equivalent to trimethoprim-
sulfamethoxazole (160/800mg 2dd 3 days). 
* Collateral damage, a term describing ecological adverse effects of antibiotic therapy, such as the selection of drug-resistant organisms and colonization or infection with multidrug-resistant 
organisms and colonization or infection with multidrug resistant organisms, has been associated with use of broad spectrum cephalosporins and fluoroquinolones (22). 
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Current point of care tests for UTI   
In the UK at present only visual assessment of the turbidity of urine and urinalysis 
dipsticks are used as POCTs for UTI in primary care (as recommended by the HPA 
guidelines (25)). 
Dip-slides and rapid microscopy 
POCTs including urine dip-slides and rapid microscopy are used for diagnosis of UTI in 
primary care in other European countries. A dip-slide is a type of culture technique which 
can allow the user to determine bacterial counts and identification in clinical specimens 
such as urine after a 24 hour test incubation period. Dip-slides are sticks coated with 
culture media, which get dipped into urine and come complete with an all-in-one transport 
container and growth chamber. Dip-slides decrease the time between urine collection 
and test inoculation which increases bacterial recovery and accuracy of results. Dip-
slides are suitable for identifying negative urine specimens (no bacterial growth) and 
those with significant growth of E. coli and in these instances are useful in guiding a GP 
in whether to prescribe antibiotics or not. At high bacterial concentrations, confluent 
growth of bacteria on the test necessitates a subculture for identification, mixed flora may 
also be missed and S. saprophyticus cannot be isolated (38). Additionally the sensitivity 
and specificity of dip-slides read in daily general practice decreases when compared to 
the dip-slides inoculated with the same urine read by experienced microbiologists; for 
reliable results, reading by laboratory professionals, or special training for clinical 
personnel is recommended (38, 39). Dip-slides need to be cultured for 24h prior to 
reading the result and do not provide additional information on antibiotic susceptibility; 
although the identification of certain bacterial isolates and the known antibiotic resistance 
levels in that geographical region may aid the general practitioners (GPs) prescribing 
choice. 
Traditional urine sediment microscopy may still be used in primary care. Without 
laboratory procedures including staining the sample, some of the elements (crystals, 
casts, squamous cells, epithelial cells, blood cells and bacteria) that may be present in 
urine may not be seen and with little knowledge of the differentiation of these 
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elements/particles misclassification is common (38). Even if using Gram-stained 
microscopy the sensitivity in detecting UTI with <105 cfu/mL is still low (40). Using the 
above methods also requires the provision and maintenance of additional equipment 
such as incubators and microscopes. 
Currently culture based and microscopy POCT are not universally used  and although 
they can be useful in guiding a GP as whether to prescribe antibiotics or not, these tests 
do not help the user choose the most appropriate antibiotic and can be difficult to interpret 
for less experienced users.  
 
Turbidity of urine 
For women with mild symptoms of UTI, the HPA guidelines advise considering another 
diagnosis to UTI if a urine sample does not appear visually cloudy (i.e. urine is clear or 
non-turbid); this is based on studies reporting Negative Predictive Values (NPV) of 97%, 
91% and 97% (25, 41-43). All of the studies conclude that by disregarding clear urines 
as UTI positive, the number of samples requiring further evaluation is significantly 
reduced. However, the patients included in all these studies are not necessarily reflective 
of the patient demographic for uncomplicated UTI in primary care and none of these 
studies were pragmatic trials so were not performed under the routine processes that 
the HPA guidelines are focused on i.e. routine management of uncomplicated UTI in 
primary care. The study by Bulloch et al., was in an emergency department of a children’s 
hospital in Ohio, USA. The age range was four months to 19 years with both males and 
females recruited. The sampling was not randomised or consecutive and was considered 
a ‘convenience’ sample as only when investigators were in the emergency department 
were patients recruited. The sample size was 159, and the sample used for visual 
inspection was from both mid-stream urine and catheters. Conversely Flanagan et al. 
recruited elderly patients (63 – 100 years, male and female) admitted to a geriatric ward 
in a hospital in Belfast, UK. The sample size was larger with 418 patients but there was 
limited information published on the recruitment process. The final study by Phillips et al. 
recruited adult patients, both male and female, attending nephrology out-patient clinics 
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with a sample size of 363. All three studies varied on their classification of culture positive 
UTI and in the methods they used to determine a visually turbid urine. The studies were 
published between 1989 and 2000 therefore the HPA guidelines are not based on recent 
scientific research. A 2010 study by Little et al., recruiting adult female patients in primary 
care with suspected uncomplicated UTI reported that clinicians can be reasonably 
confident that a patient with cloudy urine has microbiologically proven UTI (based on 
European Urinalysis Guideline criteria ) but must be cautious of excluding patients 
without cloudy urine (44). This opposes the guidelines by ruling out clear urine as 
negative although it encourages further research specifically evaluating urine turbidity as 
a valid preliminary screening tool for UTI when combined with patients’ signs and 
symptoms.   
The European urinalysis guidelines do not discuss visual appearance of urine in great 
detail but give a summary of the most common causes for abnormal appearance of urine 
that are not always caused by bacteria (Table 1.1.4) (38).  
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Table 1.1.4. Characteristic appearances of urine (38). 
Appearance Cause Remarks 
Colourless Dilute urine Polyuria, non-fasting 
specimen 
Cloudy, turbid Phosphates, bicarbonates, urates, leukocytes, 
RBC, bacteria, yeasts, spermatozoa, mucin, 
crystals, pus, tissue, faecal contamination, 
radiographic dye 
 
 
Rectovesical fistula 
possible 
Milky Pyuria 
Chyluria 
Paraffin 
Infection 
Lymphatic obstruction 
Vaginal cream 
Blue-green Biliverdin 
Pseudomonas infection 
Drugs: arbutin, chlorophyll, creosote, 
Indicans, guaiacol, flavins, methylene blue, 
Triamterene, enteral nutrition (if blue dye 
added) 
 
Small intestine infection 
Mouth deodorants 
Yellow Flavines (acriflavine, riboflavine) Vitamin B ingestion 
Yellow-orange Concentrated urine 
Urobilin, bilirubin 
Rhubarb, senna 
Drugs: Salazosulfapyridine, Phenacetin, 
Pyridine derivatives, rifampicin 
Yellow foam 
 
 
Alkaline pH 
Yellow-green Bilirubin-biliverdin 
Roboflavin 
Thymol 
Yellow foam 
Yellow-brown Bilirubin-biliverdin 
Drugs: nitrofurantoin 
Beer brown 
 
Red or brown Haemoglobin, RBC 
Myoglobin 
Methaemoglobin 
Bilifuscin 
Urobilin 
Porphyrin 
Beets, rhubarb, carotene 
Fuchsin, aniline derivatives 
Certain drugs such as chloroquine,  
napthole, metronidazole, nitrite, 
Nitrofurantoin, phenacetin, thymol. 
Positive strip result, 
menstruation 
Positive strip also; muscle 
injury 
Acid pH 
Result of unstable 
haemoglobin 
 
May be colourless 
Alkaline pH 
Foods, candy 
 
Red-pink Urate May be associated with 
(massive) crystalluria 
Red-orange Drug: Rifampicin  
Red-purple Porphyrins May be colourless 
Brown See above  
Brown-black Methaemoglobin 
Homogentisic acid 
Melanin/melanogen 
Blood, acid pH 
Alkaptonuria (alkaline pH) 
Rare 
Darkening 
upon standing 
Porphyrin, homogentisic acid, melanogen, 
Serotonin 
Drugs: cascara, chlorpromazine, methyldopa, 
metronidazole, phenacetin, imipenem 
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There is no agreed standard method for assessing urine turbidity. Some of the methods 
used in published studies include;  
 Assessment against a bright background (42); 
 Assessment against a white background with black printed 11 font text, which is 
then viewed under normal fluorescent lighting conditions.  To be considered a 
clear urine, the printed text had to be as legible through the urine as through 
water (41); 
 Urine collected in an aluminium bowl; sharpness of metal folds in the wall of the 
bowl below as compared to above urine surface level; clear – perfectly 
transparent; cloudy – loss of transparency irrespective of degree (43); 
 Use of a double beam turbidimeter (45). 
All of the methods dichotomised the results into cloudy or clear and all methods gave a 
sensitivity or NPV >90%. Some studies also added acetic acid to the urine to dissolve 
any phosphates, however this was shown not to have any effect on the outcomes (41, 
45). 
The Scottish Intercollegiate Guidelines Network (SIGN) guidelines (46) do not 
recommend using urine clarity as an indicator for no infection due to observer error and 
suggest it may not be a useful discriminator. This has also been highlighted in other 
studies. Lindsay and Johnston (47), although agreeing that there is value in using visual 
assessment of urine to screen out non-infected urine, commented on the difficulty in 
interpreting turbid versus clear urine. They found a disagreement of 21 % (57 out of a 
total 267 samples; only one of which was significant for bacteriuria) in interpretation 
between GPs and laboratory staff (samples assessed within three hours of GP). This 
could be due to change in the appearance of the urine over time between assessing 
turbidity (as some bacteria will continue replicating in urine at room temperature etc.) or 
difficulty in judging clarity. Bulloch et al., had a second observer performing the same 
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visual inspection, and when there was a discrepancy, the specimen was considered 
cloudy. There were disagreements in 8/159 urines with a Cohen’s kappa value 0.876 
indicating an almost perfect agreement between the two observers (only 3 of the clear 
urines were found to be significant for bacteria but they did not state whether these were 
the urines causing disagreement between the observers) (41).  
Although visual inspection of urine is recommended in UK based guidelines there is little 
evidence to show this is being done in practice. Further evaluation ideally in a pragmatic 
study may clarify its usefulness in practice and reassure GPs. 
 
Urinalysis dipsticks 
Urinalysis dipsticks are often used in primary care to diagnose UTI and are the most 
widely used POCT in primary care. Urinalysis dipsticks (multistix or multiple test strips) 
are used simply by dipping into urine, waiting for a few minutes (specified by the 
manufacturer and varies for each tab/test on the dipstick) and comparing the colour 
changes for each test/tab to the colour chart on the dipstick container. Urinalysis 
dipsticks are designed to detect multiple components of urine including glucose, ketones, 
specific gravity, blood (haemolysed and non-haemolysed), pH, protein, nitrites and 
leucocytes. Of most interest for urinary tract infections are the presence of nitrites, 
leucocytes, protein and blood in the urine. Nitrite is based on activity of nitrate reductase 
enzyme that is present in most Gram-negative uropathogenic rod-shaped bacteria, such 
as E. coli. However the enzyme is not present in other uropathogenic bacteria such as 
Enterococcus spp and Staphylococcus spp.  The positive detection of bacteria also 
requires nitrate in the patients’ diet (vegetables), its excretion into urine and sufficient 
bladder incubation time to allow the bacterial enzyme to act. The presence of leucocytes 
is detected by Leucocyte esterase (LE) presence in the urine which is detected on the 
basis of indoxyl esterase activity released from a patients lysed neutrophil granulocytes 
and macrophages cells on the dipstick test pad and can be associated with non-
infectious renal disease as well as a UTI (38). Total urine protein is a mixture of high 
molecular weight proteins (e.g. albumin, transferrin, intact immunoglobulins, α2-
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macroglobulin) and low molecular weight proteins (e.g. α1-microglobulin, retinol-binding 
protein, immunoglobulin light chains) sieved from plasma, from the kidney and from the 
urinary tract (38). Red blood cells reflect pre-renal, renal or post renal disease, but can 
also occur due to menstruation or strenuous exercise (38). The European Urinalysis 
group suggest that the combined positivity ‘either nitrite or leukocyte result positive’ is 
generally useful for diagnosing a bacterial UTI. Specificity of the combination is reduced 
compared to nitrite alone, because not all patients with leukocyturia have bacteriuria. 
The HPA recommends performing a dipstick test in patients with mild symptoms and 
cloudy urine (25). If the test result is positive for nitrite, leucocyte and blood or if positive 
for nitrite alone a UTI is probable (based on Little et al. (48)). If it is negative for nitrite 
but positive for leucocyte it may or may not be a UTI, and further testing (urine culture), 
treatment with antibiotics or delayed antibiotic treatment is recommended depending on 
the severity of the symptoms.  If the dipstick reads negative for nitrite, leucocyte and 
blood or negative for nitrite and leucocytes (positive blood and protein) a UTI is unlikely 
(25). 
The HPA guidelines for dipstick use have been based on a limited number of studies. 
The HPA primarily focuses on the study by Little et al. whereby women (17 – 70 years 
old) with suspected UTI attending primary care were randomised into one of five 
management approaches. The approach of interest here was to target antibiotics based 
on dipstick results. Only nitrite, leucocyte esterase and blood independently predicted a 
bacterial UTI. A dipstick rule based on having nitrite or both leucocytes and blood was 
moderately sensitive (77%) and specific (70%) with a positive predictive value (PPV) 
81% and negative predictive value (NPV) 65%. Predictive values were improved by 
varying the cut-point: the NPV was 73% for all three dipstick results being negative, and 
the PPV was 92% for having nitrite and either blood or leucocyte esterase (LE) (48).  
SIGN recommend using dipsticks for otherwise healthy women less than 65 years old 
with mild or two or less symptoms of UTI. If there is only one sign/symptom present and 
the dipstick is positive for nitrite or leucocyte this is associated with a higher probability 
(80%) of UTI. Negative dipstick results do not completely exclude bacteriuria. However, 
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the probability of having a UTI reduces to ~20% (46). The SIGN guidelines are primarily 
based on a literature review from 1991 which used Receiver Operating Characteristic 
(ROC) function of 2 x 2 outputs from selected papers assessing the use of nitrite and 
leucocyte esterase for predicting UTI. The overall conclusions were that nitrite or LE 
function (disjunctive pairing) had the best diagnostic accuracy (49). A more recent 
systematic review also shows if nitrite is detected, this increases the probability of a UTI, 
with a likelihood ratio of 2.6 – 10.6. In contrast, the detection of leukocyte esterase 
increases the probability to a lesser degree (LR 1.0 – 2.6) (40). 
A study in the Netherlands recruited female patients (n=1993) with symptoms of an acute 
uncomplicated UTI in primary care reported that the nitrite test had a high positive 
predictive value (PPV) (96%) and specificity (94%); and a negative nitrite with a positive 
LE test showed a fairly high PPV (79%) and sensitivity (82%). Almost all patients (94%) 
with a nitrite-positive urine sample and the majority of patients (71%) with urine samples 
negative for the nitrite test but positive for the Leucocyte Esterase (LE) test received 
antibiotic therapy. Only one-fifth of the patients with urine samples showing both negative 
nitrite and negative LE tests were prescribed antibiotics. However when both nitrite and 
LE tests were negative approximately 50% of the samples were found to be culture 
positive (≥103 cfu/mL). Overall 70% of patients were prescribed antibiotics (50).  
In summary, it has been shown that although a dipstick rule does improve diagnostic 
precision,  clinicians still need to take into account the limited negative predictive value 
(NPV) (44). The poor NPV suggests that the offer of some kind of antibiotic safety net – 
such as delayed antibiotic prescribing – to women with negative dipsticks results is 
reasonable. Antibiotic use targeted with dipstick testing with a delayed prescription as a 
backup or empirical delayed prescription has also been shown to reduce antibiotic use 
(33). However, the low NPV of dipstick testing could equally support empirical treatment 
with antibiotics for all women with symptoms, reserving investigation for those failing to 
respond. Particularly if presenting symptoms respond to empirical antibiotic treatment 
regardless of dipstick result (51). 
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Microbiological diagnosis of UTI in the UK 
The routine reference standard for diagnosis of UTI is to submit a sample of the patients’ 
urine to a microbiology laboratory. At the laboratory the urine is usually microscopically 
examined and if microscopy positive the urine is cultured to detect the presence of 
significant pathogenic bacteria (uropathogens). Following positive culture for potential 
pathogens, the antibiotic susceptibility profile of the pathogen is established. This 
process usually takes an average of 24-48 hours. 
Urine samples  
The quality of a urine sample will affect the ability to detect relevant bacteria and confirm 
a diagnosis of UTI. Specimens can be divided into those with high risk of contamination 
(clean catch, CSU or midstream urine samples; MSU), or low risk (suprapubic aspirate 
(SPA) or operatively obtained urine from ureter or kidney) (46). Due to the invasive 
nature of collecting low risk samples, MSU are the routine sample type requested from 
women suspected of having a UTI in primary care. 
MSU or clean catch urine is the middle portion of voided urine. Ideally this should be 
collected from the first morning sample as the urine will be more concentrated and the 
overnight incubation time allows for bacterial growth in the bladder. However, this may 
not be possible as most women (in the UK) will only provide a urine sample after a GP 
requests it at the time of consultation. The urine may then be affected by the ingestion 
of food and fluid and other daily activities. 
There is a need to avoid contaminating fluids and commensal organisms present on the 
skin and surrounding areas.  Women may be asked to clean the genital area prior to 
collecting the sample, to separate the labia when urinating, void the first section of urine 
and to avoid other contaminating factors women should be provided with a sterile urine 
container to collect the urine. Collection devices such as the Whizz® mid-stream device 
(JBOL ltd, Oxford, UK) may aid women in collecting urine and have been shown to 
reduce contamination upon culture (52). To prevent damage or death of diagnostically 
relevant bacteria, the urine should ideally be examined in the laboratory within 2 hours 
of collection (38). This is usually not feasible in primary care and therefore urines should 
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either be refrigerated or collected into tubes containing boric acid (stabilises the white 
cell number and bacterial concentration) and processed in the laboratory within 24 or 48 
hours respectively (38). 
Laboratory process  
Once the urine samples are received in the laboratory the diagnostic process in the UK 
involves automated microscopy which will detect bacteria, red blood cells (RBC), white 
blood cells (WBC), epithelial cells and other small particles in the urine (53).  If the urine 
meets the laboratory defined criteria for microscopy the urines will be cultured.  
Urine culture is a basic manual process that involves inoculating a set amount of urine 
onto a section of an agar plate (using for example a 1µL calibrated loop, filter paper strip 
or multipoint technology).  Often chromogenic UTI agar plates are used as this allows 
bacterial species to grow generating different colour colonies to aid identification. After 
at least 18 hours (usually overnight incubation) at 37°C the microbiologist will then count 
the number of bacterial colonies grown (from viable bacterial cells) on the agar section 
and from this calculate the number of colony forming units per millilitre (cfu/mL). Colony 
forming units are used instead of cells/mL as the number of cells that make up a colony 
cannot be determined using this method. This culture method is considered a semi-
quantitative method as the accuracy in quantification is limited and the detection limit 
restricted (for example using 1 uL urine the detection limit is 1 x 103 cfu/mL; 1 colony). 
For most uncomplicated UTI’s one single causative bacterial species will be cultured. If 
the culture has mixed bacteria this may be due to contamination but true infections with 
two or three bacterial species on culture do occur (38), however, predominance needs 
to be determined. The criteria for predominance has not been validated and may vary 
between laboratories and methods.  
If there is positive growth of a pure or predominant uropathogen (Table 1.1.5.) antibiotic 
susceptibility testing is generally performed to guide the clinician in prescribing the most 
appropriate antibiotic for that patient. 
 
 29  
Table 1.1.5. The pathogenicity and frequency of micro-organism in mid-stream urine 
(38). 
 Frequency (percent of isolates) 
 
A. Common 
(>10%) 
B. Fairly 
common 
(1-10%) 
C. Uncommon 
(0.1 – 1%) 
D. Rare 
 (<0.1%) 
Primary 
pathogens 
E.coli S. 
saprophyticus 
 E.coli CO2-dependent, 
Salmonella spp.a 
(Leptospira, 
mycobacteria) 
Secondary 
pathogens 
 Enterobacter 
spp., 
Enterococcus 
spp., 
Klebsiella spp., 
P. mirabilis, 
P. aeruginosa 
Citrobacter spp., 
M. morganii, 
P. vulgaris, 
Serratia spp., 
S. aureus 
Corynebacterium 
urealyticum, 
Haemophilus spp.b, 
Pneumococcib 
Doubtful 
pathogens 
 GBSc, Yeast, 
CNS (others)d 
Acinetobacter spp., 
Pseudomonas spp., 
Stenotrophomonas 
maltophilia 
A great number of 
reported cases have 
been published with 
exceptional cases of 
infections caused by 
other species 
Usually 
urethral or 
genital florae 
 α streptococci, 
Gardnerella 
vaginalis, 
Lactobacilli, 
etc. 
Bifidobacterium 
spp., 
« Diphtheroid » 
rods, etc. 
 
a Low concentrations are reported even if they are most likely caused by contamination during specimen 
collection. 
b Most often isolated from children. 
c GBS= group B streptococci. 
d CNS= coagulase-negative staphylococci. 
e No identification and susceptibility testing (only exceptionally, if especially indicated). 
 
Susceptibility testing can be performed directly using urine at the same time as culture 
(for example if there is a high white blood cell count i.e. WBC>100 after microscopy) or 
by doing a second culture of the cultured predominant bacteria. If performed directly from 
urine the growth of bacteria must be semi-confluent and of a single species otherwise 
the results should be disregarded.  One of the most commonly used methods is the disc 
diffusion test; this involves placing commercially prepared, paper discs containing a fixed 
concentration of antibiotic onto an inoculated agar plate. After overnight incubation the 
zones of growth inhibition around each of the antibiotic disks are measured to the closest 
millimetre; the diameter of the zone is related to the susceptibility of the isolate (54). 
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Depending if the sample is from an in-patient (hospital) or from an out-patient/GP 
(community) referral and the species of bacteria being tested; different antibiotic disc 
combinations (sets) are used. The guidelines for these processes are based on the UK 
Standards for Microbiology Investigations (SMIs) and British Society for Antimicrobial 
Susceptibility (BSAC) working party and are a comprehensive referenced collection of 
recommended algorithms and procedures for clinical microbiology (55). 
More enhanced methods for culture of bacteria in urine include (but are not limited to) 
serial dilution of urine and spiral plating onto agar plates which allows for total counts to 
be performed (quantitative culture).  Chemical tests for identification of bacteria such 
oxidase test (positive for Pseudomonas), Indole test (positive for coliforms), catalase test 
(positive S. saprophyticus), serology (positive for Salmonella); and Maldi-TOF (Matrix-
assisted laser desorption ionization time-of-flight). The MALDI Biotyper identifies 
microorganisms using MALDI-TOF mass spectrometry to measure a unique molecular 
fingerprint of an organism. Specifically, the MALDI Biotyper measures highly abundant 
proteins that are found in all microorganisms. The characteristic patterns of these 
proteins are used to reliably and accurately identify a particular microorganism by 
matching the respective pattern with an extensive database to determine the identity of 
the microorganism down to the species level (www.bruker.com).  For antibiotic 
susceptibility testing the E-test gradient diffusion method or broth/agar dilution methods 
to determine minimum inhibitory concentration (MIC), the lowest concentration of an 
antibiotic that will inhibit the visible growth of a microorganism after overnight incubation, 
may offer a superior testing method to the disc diffusion method (it is often used to 
calibrate disc diffusion method).   
Definition of a bacterially positive urinary tract infection 
Standard laboratory processing of urine samples is confined to a single initial specimen 
per patient, with detection of conventional aerobic bacteria normally at a value of ≥105 
cfu/mL (46) of  pure or predominant growth of a uropathogen classified to be a UTI.  
The criterion for the presence of significant bacteria was established from early work by 
Kass et al in the 1950’s comparing SPA against MSU specimens in women suffering 
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either from acute UTI or who had asymptomatic UTI during pregnancy. A single positive 
MSU reliably determined the presence of a UTI at 105 cfu/mL in 80% of cases studied 
with two samples improving this to 95% (46, 56-58). Despite the fact that the criteria were 
developed for acute pyelonephritis and asymptomatic bacteriuria in women, this cut-off 
is being used (in the UK) generally for symptomatic lower urinary tract infection to this 
day. 
The HPA guidelines only recommend urine culture for women with failed antibiotic 
treatment or persistent symptoms; their criteria for a positive culture is a single organism 
≥ 104 cfu/mL;  ≥ 105 mixed growth with one predominant organism; or ≥ 103 CFU/mL 
Escherichia coli or Staphylococcus saprophyticus (25). 
The European Urinalysis Guidelines also recommend different significant concentrations 
of bacterial colonies depending on the symptomatic status of the patient and the 
organism identified. For women with symptoms of UTI a significant colony concentration 
of 105 cfu/mL should be used for mixed growth of two secondary pathogens such as 
Enterobacter spp., Enterococcus spp., Klebsiella spp., P. mirabilis, P. aeruginosa, 
Citrobacter spp., or one doubtful pathogen such as group B streptococci, coagulase-
negative staphylococci, Acinetobacter spp. and Pseudomonas spp. For growth of one 
secondary pathogen a significant concentration of 104 cfu/mL is required and finally for 
primary pathogens such as E. coli and S. saprophyticus a growth of 103 cfu/mL should 
be classed as significant. For asymptomatic women growth of at least 105 cfu/mL should 
be classed as significant for all uropathogens (38).  
Problems with the microbiological diagnostic process 
Over half of the samples submitted routinely to UK microbiology laboratories are urine 
samples; the most common of which are mid-stream urine from community patients. The 
most common symptoms for sending urine samples are frequency and dysuria (59, 60).  
Based on published data from 2000, resource costs approximately £3.50 - £12.50 per 
sample for basic culture to susceptibility testing (expert opinions) compared to a cost of 
general empiric treatment (trimethoprim 200mg bd; 3 day course) at £0.05 - £0.50 (61). 
The NHS covers the costs of laboratory procedures and prescriptions but does not cover 
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the cost of all POCTs used in general practice. The use of the microbiology laboratory 
service is difficult to balance; underuse of the laboratory may lead to under-
ascertainment of UTI and over prescribing of antibiotics, while over-use may 
unnecessarily increase laboratory and primary care workload costs (59). 
As already described the quality of the urine sample submitted to the laboratory is very 
important; poor quality urines result in false negative or false positive results and 
contamination is a major issue; all of which lead to unnecessary costs and strain the 
laboratory service, and result in  incorrect or delayed treatment of patients.  
Routine culture is a basic method which could result in additional false negatives and to 
a lesser extent false positives; the method is highly subjective and may vary between 
microbiologists and/or laboratories.  
The use of the diagnostic laboratory by General Practices takes 2-3 days for the results 
to become available (62). Therefore, patients are often treated with empirical antibiotics 
for a presumed UTI based only on their presenting symptoms, either without sending 
urine for microbiological testing or before these results are available (63). 
 
 
 
Section 2: Analytic performance of UK 
FlexicultTM SSI-Urinary Kit, chromatic 
sensing, visual turbidity assessment of 
urine and dipstick urinalysis in the 
diagnosis of suspected urinary tract 
infection  
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Chapter 1: UK FlexicultTM SSI-Urinary Kit 
Introduction and Methods 
Introduction 
The UK Flexicult research in this section has been published in the European Journal 
of Clinical Microbiology and Infectious Diseases (64). 
FlexicultTM SSI Urinary kit 
The Flexicult kit was developed by the Statens Serum Institut in Denmark in light of the 
increasing antibiotic resistance of urinary pathogens and as the overall societal costs of 
UTI is related to the appropriateness of empiric UTI treatment.   
 The kit is a point-of-care test for the diagnosis and susceptibility testing of urinary tract 
pathogens and is already in clinical use in primary care practices in Denmark. It is a 
chromogenic agar plate divided into 6 sections; 1 large section for quantification and 
identification of bacteria (this section contains no antibiotics) and 5 smaller sections for 
susceptibility testing which contain specific concentrations of different antibiotics (Figure 
2.1.1). The kit has an incubation period of at least 18h (generally overnight) after 
inoculation. 
There has only been one publicised evaluation of the Flexicult test; both an in-house and 
‘field study’ of the Danish Flexicult kit were performed. The in-house validation involved 
quantification and susceptibility testing using the Flexicult test for 116 bacterial strains 
collected from a previous study which had identification, quantification and susceptibility 
results performed using validated routine laboratory culture methods. In a ‘field trial’, 19 
Danish GP’s were asked to use the test along with routine diagnostic procedures for 
patients with symptoms of UTI (urine samples were also collected and sent for routine 
culture), and a total of 121 diagnostic specimens were processed. The in-house study 
showed quantification equivalent to 103 cfu/mL if there were ~15 – 20 bacterial colonies 
in the control section; 105 cfu/mL if semi-confluent bacterial growth and 107 cfu/mL if 
confluent growth was observed in the control section. Results from the antibiotic 
susceptibility sections were compared with the minimum inhibitory concentration (MIC) 
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value of the strain for each antibiotic; 90% and 96% resistant and susceptible strains 
respectively were correctly identified.  
Figure 2.1.1. UK FlexicultTM SSI-Urinary Kit 
 
The field trial showed discrepancies in 16% of the quantification results between GP’s 
reading of the plates and the laboratory culture results. The susceptibility profiles showed 
an overall accordance of 93% with the isolated bacterial MIC’s. It was also reported that 
the GP’s found the kit to be easy to use and read (65). This study states that identification 
of bacterial isolates is not a feature of this kit; however, the kit brochure does provide 
detailed guidance on this, and the chromogenic nature of the agar is designed for this 
purpose. 
Although providing useful information on the use and applicability of this test particularly 
with the in-house validation; this study had limited urine sample numbers and 
participating GPs in the field trial. The 19 GPs (and presumably the 121 patient samples) 
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were recruited from one county in Denmark, there is no information on the number of 
samples each GP tested or if the GPs were part of one or numerous practices. 
Additionally, the GPs volunteered to participate; this may not be representative of the 
general GP population.  The study report does not provide information on the urine 
samples apart form that they were collected from patients with suspected UTI. Clinical 
data are not given. When using the kit the GPs were asked only to quantify the bacteria 
and interpret the antibiotic susceptibility profiles; they were not required to identify the 
bacteria and therefore mixed cultures or contaminants would not have been identified. 
Routine practice in Denmark also involves using microscopy, dipsticks and/or dip-slides 
and the GPs participating in this study were advised to follow routine procedure in 
addition to using the Flexicult kit; this may have guided the GPs interpretation of the 
Flexicult quantification results. Other than error rate (which was calculated to include 12 
discrepant samples as acceptable due to contaminants or other reasons rather than 
remaining discrepant or being removed from the calculation) neither measures of 
diagnostic accuracy or statistical uncertainty were provided, nor was reproducibility 
which would be important for evaluation of a subjective test such as this. There was no 
information on any training or guidance that GPs were given to help them interpret the 
plates. There are also no published studies on the Flexicult kit enabling more appropriate 
prescribing to patients, and no economic evaluation or report on clinical outcomes when 
using this kit compared to routine practice.  
A new version of Flexicult has now been developed specifically for evaluation in UK 
primary care. This kit differs from that being used in Denmark by the inclusion of some 
different antibiotics more commonly used in the UK for UTI; cephalothin, ciprofloxacin 
and co-amoxiclav instead of sulfamethoxazole, ampicillin and mecillinam; nitrofurantoin 
and trimethoprim are included in both kits. 
Prior to clinical implementation, performance of a new test should be evaluated against 
the appropriate reference standard using appropriate clinical samples. Routine NHS 
methods including automated microscopy, culture and sensitivity testing of urine is the 
current ‘reference standard’ testing being done in the UK. 
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Rationale  
The availability of rapid diagnostic tests that can be done at the point of care (e.g. GP 
surgery) has the potential to enable faster initiation of appropriate therapy, guide narrow-
spectrum antibiotic use for UTI, and reduce antibiotic prescribing where the cause is not 
bacterial. The current diagnostic tests available for UTI leave considerable room for 
improvement and laboratory referral and diagnosis takes too long. 
The UK Flexicult SSI-urinary kit will be evaluated as part of a randomised controlled trial 
(RCT) in the POETIC study (study website: http://www.poetic-study.co.uk/). However, 
due to the limited published data on the Danish Flexicult kit and the fact that the UK 
Flexicult kit has not been validated with clinical samples previously; this study will provide 
useful preliminary data on the use and analytic performance of the kit prior to being 
evaluated for patient management in the RCT. The UK Flexicult test results should be 
comparable to standard UK laboratory tests; microscopy, semi-quantitative culture and 
susceptibility testing and as the test itself is subjective some measure of reproducibility 
should be investigated.  
 
 
Hypothesis 
The UK Flexicult SSI-urinary kit uses a similar method to standard NHS urine culture and 
susceptibility testing. The analytic laboratory performance of this test in determining a 
microbiologically positive urine sample is expected to be similar to the standard method. 
 
Aim 
The aim of this study was to; 
 Evaluate the analytic performance of UK Flexicult™ SSI-Urinary kit by 
comparing performance with routine NHS laboratory testing and enhanced urine 
culture techniques following the STARD standard [12]; 
 Explore the effect of urine over inoculation of Flexicult on the interpretation of 
positive UTI and antibiotic susceptibility; 
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  Evaluate the subjective nature of the interpretation of the kit result by 
experienced microbiologists and naive general practitioners for whom the test is 
intended. 
Study Objectives 
 
The objectives of this study are to: 
 Use the UK Flexicult urinary kit determine the quantification, identification and 
susceptibility profiles of sequential urine samples selected from those routinely 
submitted to a single NHS microbiology laboratory; 
 Compare the diagnostic accuracy in determining a bacterial UTI using UK 
Flexicult to routine NHS processing methods (as the reference standard) and use 
an enhanced urine culture and identification technique to compare discordant 
results. 
 To determine if diluting turbid urine (potential for over-inoculation) could improve 
identification of predominant uropathogens using Flexicult;  
 To determine if diluting turbid urine could improve Flexicult susceptibility result 
concordance with NHS susceptibility results. 
 To evaluate bacteriology Biomedical Scientists (BMS) and General Practitioners 
(GPs) inter-observer variation on the interpretation of UK Flexicult;  
 To compare variation when reading ‘real Flexicult tests’ vs. corresponding 
‘Flexicult  test images’ (accuracy of evaluating images rather than actual tests 
that may be used for GP training if actual tests unavailable); 
 
Methods 
Setting 
All testing was performed in collaboration between Cardiff University and the Public 
Health Wales Microbiology Department, University Hospital Wales (UHW), Cardiff. The 
routine microbiology testing was performed by NHS staff based in the Clinical 
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Microbiology Laboratory, University Hospital Wales. The spiral plate culture on 
chromogenic medium and Flexicult culture were performed by myself in the Specialist 
Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology, Cardiff.  
 
Ethical approval (12/NE/0306) and Public Health Wales Research Risk Review 
Committee approval (2012PHW0018) were obtained prior to commencement of the 
study (appendix 2.1.1). 
 
Urine samples 
Urine samples submitted from primary and secondary care in the course of routine 
patient care were used for the evaluation and validation procedures. Urine selection was 
not based on any clinical or microbiological information. Rather this was a convenience 
sample with urine samples selected for analysis by Public Health Wales (PHW) 
laboratory staff. The urines came from the general pool of urines submitted from 
inpatients (hospital wards) and outpatients (primary care, outpatient clinics and A&E) to 
this hospital clinical microbiology laboratory. Only excess urine samples (surplus to 
routine NHS laboratory testing requirements) were used for the flexicult evaluation and 
validation procedures. The flexicult and spiral plate culture, were both performed on the 
urines on the same day as NHS routine processing. The only exclusion criteria were 
urine samples collected in boric acid (as this may interfere with the antibiotic sections of 
FSUK) and urines with less than 5mL volume after routine processing.  
Routine tests such as microscopy and culture were carried out on the urine samples 
according to local NHS standard operating procedures (following UK standards for 
Microbiology Investigations B41 Investigations of Urine (66)) in the NHS laboratory. The 
Flexicult culture and spiral plate culture on chromogenic medium, were both performed 
on the urines within 24 hours of receipt in the laboratory; I performed both tests. For each 
urine sample the order of process was inoculation onto Flexicult followed by serial 
dilution of the urine and then spiral plating onto the chromogenic medium. The Flexicult 
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plates were interpreted and recorded prior to the quantification and identification of the 
corresponding spiral plate cultures. 
Sample size 
A sample of 200 was chosen based on a prevalence of laboratory diagnosed UTI 
between 20% and 30% [approximate usual proportion, correspondence with Dr Robin 
Howe, Director and National Lead for Microbiology Services, Public Health Wales, 
University Hospital of Wales] and a FlexicultTM SSI urinary kit  error rate of 4.72% (based 
on quantification only)(65). This would give sufficient power to detect sensitivity of 0.95 
(95% CI 0.82 – 0.99), and specificity between 0.98 - 0.99 (95% CI 0.93 – 0.99). A total 
of 211 urine samples were processed and 200 were included in the analysis; 10 were 
excluded as they were processed 48h after receipt in the laboratory (heavy growth of 
pathogenic and contaminating bacteria could lead to false positives or mixed growth not 
comparable with the routine culture methods performed at the time of receipt in the 
laboratory) and one sample had missing NHS microscopy and culture results. 
NHS microbiology data collection 
NHS microscopy and culture results (if applicable) of the routinely submitted samples 
were provided on a weekly basis by a member of the Public Health Wales Microbiology 
team after the evaluation tests had been performed, read and recorded by myself.  
Routine urine processing through the NHS Microbiology Laboratory first involves 
automated microscopy (iQ200 Sprint), the criteria for positive selection for culture, is as 
follows: 
1. ≥ 5 Bacteria 
2. ≥100 White Blood Cells (WBC) 
3. ≥20000 ASP (any small particles) 
4. ≥50 WBC + ≥ 2000 ASP 
5. ≥50 WBC + ≥1000 ASP + ≥ 3 Bacteria 
6. ≥3 WBC + ≥6000 ASP 
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Bacteria equates to 3 or 5 x 103 cfu/mL from culture. In addition, any samples from 
antenatal clinics, Intensive Treatment Units and children < 2 years old are all 
automatically cultured. 
Any microscopy positive specimens are plated onto ¼ plate of Chromogenic UTI agar 
(Oxoid Chromogenic Brilliance UTI clarity agar) using a 1L microbiology loop. After 
overnight incubation at 37°C the plates are read as follows; 
1 colony = 1 x 103 cfu/mL.  
10 colonies = 1 x 104 cfu/mL  
100 colonies = 1 x 105 cfu/mL  
There are no defined criteria for diagnosing a UTI microbiologically and microscopy and 
clinical evaluation is usually also required. However, the urine samples were associated 
with little useful clinical information on the request form apart from suspicion of UTI. 
Microbiological findings considered positive for a UTI in this study were >105 cfu/mL pure 
or predominant growth (x1000) of a clinically significant UTI pathogen. 
Antibiotic susceptibility testing is performed on significant bacterial isolates (from culture 
positive urine samples) using the standard disc diffusion method (67) and with the 
appropriate urine antibiotic disc sets as described in Table 2.1.1 (only antibiotics relevant 
to Flexicult have been listed). 
 
Table 2.1.1. Antibiotic disc sets for NHS disc diffusion method. 
Gram-Negative 
Bacteria1  
(In-patients) 
Gram-Negative 
Bacteria1 
(General 
Practice) 
S. 
saprophyticus 
Enterococci 
spp. 
Pseudomonas 
spp. 
Trimethoprim  
4 – 2mg/L 
Trimethoprim  
4 – 2 mg/L 
Nitrofurantoin  
64 mg/L 
Nitrofurantoin  
64 mg/L 
Ciprofloxacin  
1 – 0.5 mg/L 
Co-amoxiclav 
32 mg/L 
Co-amoxiclav 
32 mg/L 
Trimethoprim  
4 mg/L 
  
Nitrofurantoin  
64 mg/L 
Nitrofurantoin  
64 mg/L 
   
Ciprofloxacin  
1 – 0.5 mg/L 
Ciprofloxacin  
1 – 0.5 mg/L 
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Cefpodoxime  
1 mg/L 
Cefpodoxime  
1 mg/L 
   
 Cephalexin  
16 mg/L 
   
1 E. coli, Klebsiella spp., Enterobacter spp., Proteus spp.. 
 
Flexicult test procedure  
Sufficient urine from each sample was poured onto the Flexicult test to submerge all the 
compartments (approximately 5ml). If the urine sample did not cover all the agar 
compartments, the plate was tilted in a circular motion so that all the compartments came 
into contact with the urine. After approximately 5 seconds the excess urine was poured 
off the Flexicult test. The Flexicult tests were incubated aerobically overnight at 36°C ± 
1°C with the bottom of the plate facing upwards and lid down. After incubation overnight, 
each test was first inspected for bacterial growth. This procedure follows the 
methodology described in the manufacturer’s brochure and is the process that would be 
used if the test were performed in routine practice. 
The UK Flexicult SSI Urinary Kit brochure was used to interpret the quantification, 
identification, predominance and susceptibility results. If growth was visible the number 
of colonies in the quantification section of the test was quantified and the size and colour 
recorded. This was performed for all different colonies grown (i.e. if mixed growth) if 
possible. For each group of colonies seen the bacteria were identified according to the 
colour and size using the references shown in the (UK Flexicult SSI Urinary Kit) brochure. 
If an amount of ≥103 cfu/mL (approximately 20 colonies) of a urinary tract pathogenic 
bacterium alone or in predominant quantity (greater than 10x growth of any other 
bacteria; as indicated in the brochure) was found in the control section of Flexicult, the 
antibiotic resistance profile was also read. Growth in the antibiotic compartments was 
compared to growth in the large quantification compartment. If growth in one antibiotic 
compartment was much lower than in the quantification compartment – or if there was 
no growth at all – the bacterium was considered susceptible to the antibiotic. If the 
bacterium in the antibiotic compartment had grown to a similar quantity as the 
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quantification compartment, it was considered resistant (procedure taken directly from 
the manufacturers’ brochure instructions). The amount of growth in each compartment 
was recorded as well as the corresponding susceptibility. 
Once the plates had been read, an image of each plate was captured using an Olympus 
620UZ camera; the images were taken using the same camera, settings and 
approximate position for each plate. The plates were disposed of following local 
laboratory guidelines. 
Quality control  
All new batches/Lot numbers of Flexicult plates underwent quality control by inoculating 
with 0.5 McFarland suspension of the following American Type Culture Collection 
(ATCC) organisms; Escherichia coli (#25922), E. coli (extended spectrum beta-
lactamase (ESBL) #35218), E. coli (ESBL #13353), Psuedomonas aeruginosa (#27853) 
and Enterococcus faecalis (#29212) (one organism suspension per Flexicult plate). 
These strains have known antibiotic susceptibility profiles. These strains are used in the 
PHW laboratory for quality control purposes of the routine antibiotic susceptibility testing 
procedures and were therefore used for the quality control of the Flexicult plates. Each 
isolate was maintained on columbia agar with 5% horse blood routinely by PHW staff 
following local laboratory procedures. For each isolate I used a 10µL loop to pick colonies 
from the agar and inoculate 10 mL sterile water to get a suspension resembling 0.5 
McFarland standard turbidity which equates to 1.5 X 108 CFU/mL. Two batches or 
separate Lot numbers of Flexicult tests were used during the study; 2852 (expiry 
10/12/2012) and 2212 (expiry 07/10/2012) both of which had an eight week shelf life. 
Both Lots of Flexicult plates were inoculated at weekly intervals to determine any growth 
prior to the expiry date. The inoculation and interpretation of Flexicult follows the same 
procedure as inoculating Flexicult with urine described above. 
Enhanced culture technique: spiral-plating onto colorex orientation UTI 
medium  
Urine samples were serially diluted to 103 and 106 in sterile water. Using the Whitley 
Automated Spiral Plater (WASP) 50 µL of each dilution 106, 103 and neat urine were 
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spiral plated onto Colorex Orientation UTI medium plates (E&O Laboratories Ltd) within 
15 minutes of preparation. The plates were left until dry, inverted and incubated overnight 
at 35°C.  
After incubation the plates were inspected for growth. For each urine sample only the 
most appropriate plate dilution was counted; this was the dilution that had distinct 
countable colonies visible.  A clear perspex counting grid was used to count colonies in 
sectors and the corresponding counting tables used to calculate the CFU/mL. The 
laboratory provided a local SOP to follow for this procedure. 
Identification of bacteria was primarily performed by comparing the colour of the colonies 
to the Colorex Orientation UTI medium guidelines. For bacteria that were unable to be 
identified by colour further identification was performed using Matrix-assisted laser 
desorption ionization time-of-flight (MALDI-ToF Bruker) mass spectrometry following the 
manufacturer’s instructions (www.bruker.com).   
Analysis 
Data was captured using worksheets developed by myself (appendix 2.1.2) and entered 
into Excel and SPSS spread sheets.  
Both the UK Flexicult and the routine NHS culture process use semi-quantitative 
subjective methods for determining a microbiologically positive urine sample.  Due to the 
different methodologies the comparisons are not exact i.e. UK Flexicult had four 
quantification categories: no growth; <103 cfu/mL; 103 – 104 cfu/mL; ≥105 cfu/mL (which 
included ≥107 cfu/mL) and the results from the NHS culture were: no growth; no 
significant growth; 104 – 105 cfu/mL; >105 cfu/mL. Samples that were ‘not cultured’ 
through the NHS (due to negative microscopy) were included as ‘no growth’ (negative 
for microbiological UTI). When determining predominant growth, the NHS method used 
growth of one organism at 1000x greater than any other as predominant, and the UK 
Flexicult method used 10x greater growth as predominant. Spiral plating was used to 
compare discordant results between the reference standard (routine NHS testing) and 
the UK Flexicult as total quantification and more advanced identification could be 
performed. 
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A variety of diagnostic performance evaluations were calculated including sensitivity, 
specificity, negative predictive value (NPV), positive predictive value (PPV) and error 
rates (as described in appendix 2.1.3). Confidence intervals (95%) were calculated 
using a spread-sheet (CIPROPORTION) developed by a Cardiff University statistician 
Robert Newcombe 
(http://medicine.cf.ac.uk/media/filer_public/2012/11/01/ciproportion.xls)(68).  
 
Urine dilution study method 
Urine dilution was subsequently used to investigate the potential effects of over 
inoculation on UK Flexicult plates. An additional 79 turbid urines (urine samples with any 
degree of visual uniform turbidity) from primary care received in the Clinical Microbiology 
Laboratory, University Hospital Wales were diluted 1:1000, and both undiluted and 
diluted urine inoculated onto UK Flexicult as described above. The results between 
undiluted and diluted urines were compared to determine any differences in identification 
of UTI and susceptibility.  The results were also compared to the corresponding NHS 
results to identify any changes in analytical performance.  
 If there were any discordant susceptibility results with the NHS after dilution the 
minimum inhibitory concentration (MIC) for those organisms were established using 
standardised methods namely gradient E-test (ciprofloxacin, co-amoxiclav, nitrofurantoin 
and trimethoprim) and agar dilution method (cephalexin – used instead of cephalothin 
which was unavailable for this study) as described below. 
 
MIC: E-Test (co-amoxiclav, nitrofurantoin, trimethoprim) 
 Mueller Hinton agar plates were inoculated with a 0.5 McFarland suspension of 
the test organisms and sensitive E. coli strain #ATCC 25922 (and #35218 for co-
amoxiclav) using a cotton swab; 
 Individual E-test strips containing the relevant antibiotics were placed onto the 
inoculated plates; 
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 Plates were inverted and incubated at 37°C over-night; 
 After 18h the plates were read; the point along the antibiotic E-test strip at which 
the bacterial growth is inhibited is the MIC. 
MIC: Agar Dilution (cephalexin used for cephalothin MIC) 
 Cephalexin was prepared at 2560 mg/L (adjusted for 94% potency); 15.6mg 
dissolved into 5mL sterile water (suspension A). A further dilution was made to 
80 mg/L by adding 0.5mL antibiotic suspension to 15.5 mL sterile water 
(suspension B). 
 Plates were prepared by melting Mueller Hinton agar in a water bath, once cooled 
to the touch the antibiotic suspension was added to each agar bottle at the 
following concentrations (immediately after mixing, the agar was poured into petri 
dishes and left to set); 
 
 
 
 
 
Dilution mg/L 
1 mL of A into 20mL agar 128 
500 µL of A into 20 mL agar 64 
250 µL of A into 20 mL agar 32 
125 µL of A into 20 mL agar 16 
62.5 µL of A into 20 mL agar 8 
1 mL of B into 20 mL agar 4 
500 µL of B into 20 mL agar 2 
250 µL of B into 20 mL agar 1 
125 µL of B into 20 mL agar 0.5 
62.5 µL of B into 20 mL agar 0.25 
No antibiotic added 0 (control) 
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 0.5 McFarland suspension of the test organisms and sensitive E. coli strain 
(#ATCC 25922) were made up in sterile water (this equals approx. 108 cfu/mL). 
 Using multipoint inoculum replicating apparatus, 180 µL sterile water was added 
to the wells of the inoculum plate and 20 µL of the bacterial suspension added to 
each well. The automated apparatus then inoculated each plate with 1 µL 
bacterial suspension (i.e. each inoculum at 104 cfu/spot). The plates were left to 
dry, inverted and incubated for at least 18h at 37°C. 
 The plates were read the following day; the MIC for each inoculum is the 
cephalexin plate/agar concentration with <10 colonies per inoculum spot. 
 
Inter-observer reproducibility study method 
Urine samples and Flexicult inoculation 
Anonymised excess urine samples were used for this study. A total of 60 urine samples 
submitted routinely to the Public Health Wales (PHW) Microbiology Laboratory, 
University Hospital Wales were chosen by a member of PHW staff. As this study required 
a focus on positive samples ideally of varying quantification and organisms grown, 54 
microscopy positive samples and six microscopy negative samples were selected. 
Flexicult tests were inoculated on the same day as routine culture; following the method 
described above. 
After overnight incubation the Flexicult plates were firstly read by three qualified 
bacteriology Biomedical Scientists individually and blinded to each-others results (all 
employed in the PHW Microbiology Laboratory, UHW); this was during the morning. In 
the afternoon the same Flexicult plates were then be read by myself and three GPs; all 
Cardiff University Clinical Academic Fellows from the Institute of Primary Care and Public 
health who volunteered to participate in the study. Results were recorded for the 
quantification, identification and susceptibility onto a specifically designed results form 
(appendix 2.1.4). All assessors were asked to refrain from discussing the Flexicult kits 
and results; as I was present during the GP session I know that they adhered to this 
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request. The SSI UK Flexicult brochure was the only guide available when reading the 
plates at this initial session although a link to the POETIC website (http://www.poetic-
study.co.uk/) which provides further information on interpretation of Flexicult was sent to 
all the assessors prior to this session; it was their decision whether to access it. The 
assessors were asked to record if they read the brochure and/or website and if so for 
how long. 
Reading Flexicult™ Plates 
Images of the Flexicult plates were captured once the GPs had finished their session 
which was not time restricted (using the camera function of the Apple iPhone 4 v7.1.1; 
flash off; all images captured in the same position and lighting). 
Reading Flexicult™ images 
The images of the Flexicult plates were renumbered and put into a PDF document. This 
document was then sent to all of the above assessors a week after the initial session to 
interpret once again with only the SSI UK Flexicult brochure and access to the POETIC 
website as a guide; it was again up to the assessors if or for how long they used these 
guides.  The assessors were asked to interpret the images of the plates from the 
computer screen (not to print out the PDF as the colours of the plates may change 
depending on the printer), the same worksheet template as used in the initial session 
were provided to record the results.  All assessors were given one week to read and 
record the results from plate images. They were asked to do this individually and blinded 
from the other assessor’s results. 
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Figure 2.1.2. Reproducibility Design Flow Diagram 
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Flexicult™ training 
Once the results of the Flexicult™ images had been returned from all participants, the 
GPs participated in a training session which I led. This involved approx. 30 minute power-
point presentation on the quantification, identification and susceptibility interpretation of 
various Flexicult plates, followed by a question and answer session (it was the same 
power-point training provided to the participating GPs in the POETIC randomised 
controlled trial (RCT)).   
Repeat reading of Flexicult™ images 
Once the Flexicult™ training was complete the GPs were asked to again read and 
interpret the images of the Flexicult™ plates. All GPs were given one week to do this 
and were asked to do this individually and blinded from the each-others results. The 
images were once again re-numbered to avoid recall (memory effects) and sent in a PDF 
document to be interpreted from the computer screen, the worksheet template was 
provided to record results.  
The SSI UK Flexicult™ brochure and access to the Flexicult training website was 
available when re-reading the images of the tests. 
Analysis  
All the data was entered into Microsoft Excel spreadsheets and STATA 12.1 and 
analysed for accuracy as compared to my interpretation (agreed with my Supervisors as 
I have experience with the interpretation of the UK Flexicult plates). The strength of the 
agreement was calculated using the Kappa statistic (with 95% confidence intervals) 
using STATA 12.1 data analysis program. 
The kappa statistic corrects for chance agreement and informs us of the possible 
agreement over and above chance which the assessors have achieved (69). The 
interpretation of the Kappa statistic is outlined in Table 2.1.2; 
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Table 2.1.2. Qualitative classification of kappa values (69). 
Kappa value Degree of agreement beyond 
chance 
0.0 None 
0.00 – 0.20 Slight 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Substantial 
0.81 – 1.00 Almost perfect 
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Chapter 2: UK FlexicultTM SSI-Urinary Kit Results 
Urine samples 
Approximately ten urine samples were selected by laboratory staff and passed onto me 
each day of the evaluation (Monday – Thursday), over a period of seven weeks from 
September to November 2012. 200 samples were included in the comparison of the 
Flexicult kit with NHS routine culture: 124 (62.0%) were from outpatients; 72 (36.0%) 
from inpatients; and 4 (2.0%) unknown. Fig 2.2.1 details further available information on 
the urines included in the study. Out of the total 200 urine samples; 70% were from 
female patients; 95.5% were from patients aged 18 years or older; and 67% were mid-
stream urine samples  (29.5% unknown collection method and 3.5% from catheters). For 
this study all samples were included in the analysis. 
 
Figure 2.2.1. Summary of urine samples evaluated in study 
 
 
MSU = mid-stream urine; n= number of samples; unknown = unknown sample collection method. 
n = 200 urine samples 
Male 
n = 60 
Female 
n = 140 
<18years 
n = 2 
18 ≤ 65y 
n = 29 
>65years 
n = 29 
18 ≤ 65y 
n = 83 
>65years 
n = 50 
<18years 
n = 7 
MSU 
n = 0 
Catheter 
n = 0 
Unknown 
n = 2 
MSU 
n = 17 
Catheter 
n = 1 
Unknown 
n = 11 
MSU 
n = 17 
Catheter 
n = 1 
Unknown 
n = 11 
MSU 
n = 3 
Catheter 
n = 0 
Unknown 
n = 4 
MSU 
n = 72 
Catheter 
n = 2 
Unknown 
n = 9 
MSU 
n = 25 
Catheter 
n = 3 
Unknown 
n = 22 
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Analytic performance of UK Flexicult compared to the reference standard 
(NHS) 
In total the NHS routine culture identified that 45 (22.5%) urine samples were 
microbiologically positive compared to 66 (33.0%) using the UK Flexicult method; with a 
sensitivity of 86.7% (95% CI 73.8 – 93.7) for all samples and a sensitivity of 87.0% (95% 
CI 67.9 – 95.5) on a sub-group analysis of outpatients samples only. 19.0% of the 
samples cultured using the NHS method showed contamination (no predominant 
organism) compared to 25.5% using UK Flexicult. The most prevalent organism 
identified through both methods was E. coli; 25/45 (55.6%) NHS and 31/66 (47.0%) UK 
Flexicult (Figure 2.2.2 shows a breakdown of the culture results using each method). 
Table 2.2.1 details the number of concordant and discordant positive and negative 
samples for UK Flexicult compared to the NHS processing, as well as the analytic 
performance measurements. This also includes a sub-group analysis for outpatients 
only. When using the UK Flexicult method 13.5% urine samples would be classed as 
microbiologically positive when in current routine NHS processing they would be 
negative.  Using UK Flexicult, 3.0% of samples would be classed as microbiologically 
negative, while when processed in current routine practice they would be considered 
positive.  
By comparing the 27 discordant positive results to the spiral plating method; 16 samples 
were found to be negative (agreeing with the NHS results) and 11 positive (agreeing with 
the Flexicult results). Of these 16 discordant results (Flexicult positive) the spiral plating 
method found 10 samples to have growth <105 cfu/mL and six samples to have growth 
≥105 cfu/mL but no predominant organism (mixed growth indicating contamination rather 
than true positive).  
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Figure 2.2.2. Culture results using both UK Flexicult and NHS culture methods 
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When comparing the six discordant negative results; the spiral plating method found four 
to be positive (agreeing with the NHS results) and two to be negative (agreeing with the 
Flexicult results). Of the four spiral plate/NHS positive results the Flexicult method found 
three to have no predominant growth (contamination) and one to have no growth. A 
figure showing images of concordant and discordant spiral plate cultures and 
corresponding Flexicult culture plates are in included in appendix 2.1.5. 
Table 2.2.1. Cross tabulation of UK FlexicultTM SSI urinary kit results compared to routine 
NHS culture in determining microbiologically positive urine samples 
 
NHS Results UK FSUK Results 
(All patients;  
n=200) 
UK FSUK Results 
(Outpatients only; 
n=124) 
Concordant positives (%) 45 (22.5) 39 (19.5) 20 (16.1) 
Concordant negatives (%) 155 (77.5) 128 (64.0) 84 (67.8) 
Discordant positives (%)  27 (13.5) 17 (13.7) 
Discordant negatives (%)  6 (3.0) 3 (2.4) 
 Statistical measures  
Sensitivity (95% CI)  86.7 (73.8 – 93.7) 87.0 (67.9 – 95.5) 
Specificity (95% CI)  82.6 (75.8 – 87.7) 83.2 (74.7 – 89.2) 
Positive Predictive Value 
(95% CI) 
 59.1 (47.1 – 70.1) 54.1 (38.4 – 69.0) 
Negative Predictive Value 
(95% CI) 
 95.5 (90.6 – 97.9) 96.6 (90.4 – 98.8) 
Error Rate (%)  16.5 16.1 
 
By using a lower cut-point for the UK Flexicult (≥103 cfu/mL) test the sensitivity did not 
improve (86%; 95% CI 73.8 – 93.1). However, by using only quantification irrespective 
of identification or predominance (remaining at the higher cut-off of UK Flexicult ≥105 
cfu/mL) the sensitivity improved to 95.6% (95% CI 85.2 – 98.8) with two false negative 
samples and over half (109/200) found to be true negatives. The sensitivity increases to 
100% (95% CI 92.1 – 100.0) if the lower UK Flexicult cut-off value of ≥103 cfu/mL is used 
for positive UTI. However, this would reduce the number of true negatives identified from 
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109 to 51/200. 
Presumptive identification of bacteria (colour and size of colonies) 
Of the E. coli (n=25) samples identified by the NHS, 25 were also identified as E. coli 
using UK Flexicult kits. Of the coliforms (Klebsiella sp. and Enterobacter sp.) (n=9) 
identified by the NHS, four were identified as coliforms using Flexicult however of the 
remaining five; three were identified as no predominant organism (confluent mixed 
growth) and two were inconclusive for identification using the UK Flexicult guidelines. 
The remaining seven Enterococcus spp., two Staphylococcus saprophyticus, one 
Proteus sp. and one Pseudomonas sp. were correctly identified using UK Flexicult (as 
compared to NHS identification results).  Overall the same pure/predominant organisms 
were identified using UK Flexicult as by the NHS method in 40/45 (88.9%) samples. 
The identification of bacteria using UK Flexicult kit compared to the more advanced SP 
and MALDI-ToF methods gave an accuracy of 84.2% for E. coli; 76% for Enterococcus 
spp.; 40% for coliforms (Klebsiella sp. and Enterobacter); 66.7% for Proteus sp.; 60% for 
Pseudomonas sp and 100% for S. saprophyticus.  The concordance for each organism 
is shown in Fig 2.2.3.  
 
 
 
 
 
 
 
 
 
Figure 2.2.3. Concordance in identification of organisms using UK FlexicultTM SSI urinary 
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kit against Spiral-plating onto Colorex Orientation UTI Medium1.   
 
 
Urine Dilution Study 
Diluting the urine samples resulted in a reduction of false positive samples; eight of 13 
samples which resulted in mixed growth (no predominance) using undiluted urine 
resulted in a positive growth of a predominant organism when urine was diluted as shown 
in Table 2.2.2.  
Table 2.2.2. Cross tabulation of undiluted versus diluted urines inoculated onto UK 
FlexicultTM SSI urinary kit  
 1:1000 Diluted Urine Total 
Negative No 
Predomina
nce 
High 
positive 
(>105 
cfu/mL) 
U
n
d
il
u
te
d
 U
ri
n
e
 Negative 27 0 0 27 
No Predominance 4 1 8 13 
Low positive(≥103 to <105 
cfu/mL) 
10 0 0 10 
High positive (≥105 cfu/mL) 5 2 22 29 
Total 46 3 30 79 
 
                                               
1 Unable to accurately identify ‘white colonies’ using UK Flexicult; therefore grouped together. 
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Diluting the urine would not reduce the number of discordant positive results when 
compared to routine culture and if using the UK Flexicult kit in clinical practice the higher 
levels of positivity would remain. Diluting the urine marginally reduced the proportion of 
discordant negative samples (Table 2.2.3).  
Table 2.2.3. Cross tabulation of NHS routine processing versus UK FlexicultTM SSI 
urinary kit  inoculated with undiluted and diluted urine (1:1000) in determining 
microbiologically positive urine (at ≥ 105 cfu/mL pure or predominant organism) 
 NHS Routine 
Processing 
(Reference 
Standard) 
Undiluted Urine 
FlexicultTM SSI 
urinary kit  
Diluted Urine 
FlexicultTM SSI 
urinary kit  
Raw Results 
Concordant Positives (%) 23 (29.5) 20 (25.6) 21 (26.9) 
Concordant Negatives (%) 55 (70.5) 47 (60.3) 47 (60.2) 
Discordant Positives (%) NA 8 (10.3) 8 (10.3) 
Discordant Negatives (%) NA 3 (3.8) 2 (2.6) 
Statistical Measures 
Sensitivity (95% CI) 
 
 
87.0 (67.9 – 95.5) 91.3 (73.2 – 97.6) 
Specificity (95% CI) 
 
85.5 (73.8 – 92.4) 85.5 (73.8 – 92.4) 
Positive Predictive Value 
(95% CI) 
71.4 (52.9 – 84.8) 72.4 (54.3 – 85.3) 
Negative Predictive Value 
(95% CI) 
94.0 (83.8 – 97.4) 95.9 (86.3 – 98.9) 
Error Rate (%) 14.1 12.8 
 
 
Antibiotic Susceptibility Testing 
The comparison of antibiotic susceptibility disc testing (NHS) and UK Flexicult was 
performed on 40 UTI positive (NHS) samples. Overall susceptibility discrepancies 
between the study NHS results and UK Flexicult kit results were; 22.2% 1st generation 
cephalosporins; 0% ciprofloxacin; 47.6% co-amoxiclav; 15.4% nitrofurantoin; and 6.3% 
trimethoprim. 
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Table 2.2.4. Summary Table of Susceptibility Results for both NHS and UK FlexicultTM 
SSI urinary kit  
Antibiotic 
1st 
Generation 
Cephalosp
orin 
Ciprofloxac
in 
Co-
amoxiclav 
Nitrofurant
oin 
Trimethopri
m 
Study Prevalence (the number of resistant samples identified by each test within this 
study)  
NHS 
Resistance 
(N) 
55.6%2 
(9) 
16.1% 
(31) 
16.7% 
(30) 
7.7% 
(39) 
53.1% 
(32) 
Flexicult  
Resistance 
(N=40) 
52.5% 20% 47.5% 20% 52.5% 
Accuracy (of the susceptibility profiles of the organisms identified using UK Flexicult 
compared to the NHS method considered the gold standard for this study)  
Flexicult 
Sensitive/ 
NHS 
Sensitive  
2/4 
(50%) 
26/26 
(100%) 
11/25 
(44%) 
31/36 
(86.1%) 
14/15 
(93.3%) 
Flexicult  
Resistant/ 
NHS 
Resistant  
5/5 
(100%) 
 
5/5 
(100%) 
5/5 
(100%) 
2/3 
(66.7%) 
16/17 
(94.1%) 
 
Diluting the urine made no difference in interpreting FlexicultTM SSI urinary kit 
susceptibility with ciprofloxacin, co-amoxiclav or nitrofurantoin. On the trimethoprim 
section one sample was interpreted as susceptible after dilution and cephalothin had 
seven urines that were interpreted as susceptible after dilution (resistant with undiluted 
urine). There were still a number of remaining discordant co-amoxiclav (n=7) and 
cephalothin results (n=4) compared to the NHS routine testing. The MICs of the 
organisms showing discordancy (all E. coli) were all 8 mg/L for both co-amoxiclav and 
                                               
2 5/5 Cephalexin resistant; 4/4 Cephradine sensitive. 
 59  
cephalothin and according to the FlexicultTM SSI urinary kit antibiotic break-point 
concentrations should be susceptible (16/8 mg/L for co-amoxiclav and 16mg/L for 
cephalothin). 
Flexicult quality control 
There were quality control failures of the UK Flexicult plates during this study; both 
batches (Lots) of plates showed growth of susceptible E. coli ATCC strain 25922 (>105 
cfu/mL) on the cephalothin and co-amoxiclav sections prior to the expiry date; the batch 
of plates with Lot number 2852 showing growth >103 cfu/mL on the cephalothin section 
at week seven (29/11/212) and growth ≥105 cfu/mL on the co-amoxiclav section at week 
six (22/11/2012).   
 
Reproducibility study results 
Urine samples and corresponding NHS results 
In total 73.3% urine samples were from female patients; 76.6% mid-stream urine with 
41.7% from patients aged 16-65 years and 53.3% from patients >65 years. 
Overall the NHS results for these samples showed 10% (n=6) no significant growth; 25% 
(n=15) no predominant organism; 36.7% (n=22) E.coli; 11.7% (n=7) Coliform (Klebsiella 
spp., Enterobacter spp.); 5% (n=3) Pseudomonas spp.; 3.3% (n=2) S. saprophyticus; 
1.7% (n=1) Enterococcus spp.; 1.7% (n=1) Proteus spp.; and 5.1% (n=3) other 
organisms (unable to be identified using Flexicult). The resistance levels for the positive 
samples (n= 31 to 35 depending on the antibiotic) were 6.7% resistance to 3rd Generation 
cephalosporin; 6.7% resistance to ciprofloxacin; 5% resistance to co-amoxiclav; 8.3% 
resistance to nitrofurantoin; and 20% resistance trimethoprim. 
Use of Flexicult brochure and POETIC website 
The average time spent reading the Flexicult brochure prior to interpreting the plates for 
the Biomedical Scientists was 23 minutes; compared to 11 minutes for the GPs. Only 
one BMS and one GP accessed the POETIC website prior to the evaluation. All of the 
GPs continued to read the Flexicult brochure before interpreting the images both prior to 
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and after training. On average it took the GPs 67 seconds to read each Flexicult plate 
before training and 44 seconds after training (although after training these were images 
rather than actual plates). The BMS took on average 57 seconds to read each plate. 
Accuracy and agreement of Flexicult interpretation 
Identification of a UTI 
The agreement between the Biomedical Scientists and myself  on the identification of a 
positive UTI (pure or predominant growth of a uropathogen at ≥ 105 cfu/mL) using 
Flexicult plates ranged from 76.7% - 78.3% with a moderate strength of agreement. The 
within group Kappa agreement for the BMS was substantial and the BMS within group 
agreement including myself was also substantial. 
The agreement (prior to training) between the GPs and myself on the identification of a 
positive UTI using Flexicult plates ranged from 55.0% - 60.0% with a slight strength of 
agreement between myself and each GP. The within group Kappa agreement for the 
GPs was fair and the GP within group agreement and myself was also fair. 
After training the agreement between the GPs and myself on the identification of a 
positive UTI using the images ranged from 61.0% to 72.9% with slight to moderate 
strength agreement. The within group agreement for the GPs was moderate as was the 
within group agreement with the GPs and myself. These results are shown in Table 2.2.5.  
Susceptibility results 
For all the antibiotic susceptibility profiles interpreted by the Biomedical Scientists and 
myself the strength of agreement was almost perfect (Kappa). For the GPs and myself 
prior to training the strength of agreement varied from moderate to fair and after training 
from substantial to almost perfect. Only the GPs interpretation of nitrofurantoin 
susceptibility compared to mine remained as a substantial agreement rather than almost 
perfect agreement after training, although the 95% confidence interval for co-amoxiclav 
also remains within substantial agreement after training (Table 2.2.6). 
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Table 2.2.5. Agreement in Identification of Positive UTI (≥105 cfu/mL pure or predominant uropathogen) using Flexicult 
 
Agreement (%) 
Kappa 
statistic 
95% CI 
Kappa 
statistic 
95% CI Kappa statistic 95% CI 
Individual compared to experienced reader Within group agreement 
Within group and experienced reader 
agreement 
BMS 1 76.7 0.533 0.337-0.730 
0.707 
0.656-
0.806 
0.620 0.550-0.679 BMS 2 78.3 0.567 0.364-0.769 
BMS 3 76.7 0.533 0.327-0.740 
GP1 55.9 0.114 -0.130-0.358 
0.362 
0.338-
0.432 
0.223 0.125-0.343 GP2 60.0 0.200 -0.010-0.410 
GP3 55.0 0.100 -0.095-0.295 
GP1 (after training) 72.9 0.456 0.231-0.681 
0.535 
0.480-
0.638 
0.428 0.332-0.498 GP2 (after training) 66.1 0.318 0.090-0.546 
GP3 (after training) 61.0 0.216 -0.022-0.454 
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Table 2.2.6. Agreement in interpreting susceptibility profiles of uropathogens using 
Flexicult 
 
Kappa statistic (95% CI) 
Within group and experienced reader agreement 
Cephalothin Ciprofloxacin Co-amoxiclav 
Nitro-
furantoin 
Trimethoprim 
Biomedical 
Scientists 
0.954  
(0.914-1.000) 
0.942  
(0.918-1.000) 
0.959  
(0.954-0.962) 
1.000 
0.937  
(0.859-1.000) 
GPs prior to 
training 
0.653  
(0.588-0.702) 
0.590  
(0.363-0.648) 
0.654  
(0.649-0.731) 
0.631  
(0.598-0.673) 
0.579  
(0.533-0.614) 
GPs after 
training 
0.864  
(0.814-0.957) 
0.886  
(0.840-0.972) 
0.833  
(0.707-0.890) 
0.671  
(0.656-0.787) 
0.861  
(0.807-0.930) 
 
Interpretation of plates versus interpretation of images 
The interpretation of growth (no significant growth, mixed growth or pure/predominant 
growth); Quantification (≥105 cfu/mL yes or no); Identification (E.coli, coliforms, 
Enterococcus spp., S. saprophyticus, Pseudomonas spp., Proteus spp., unsure); and 
susceptibility profiles (resistant, susceptible or unsure) on the Flexicult plates compared 
to the corresponding images, read individually by the each Biomedical Scientist and 
myself showed moderate to substantial agreement for the growth, quantification and 
identification and substantial to almost perfect agreement for the susceptibility profiles.
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Biomedical scientists and General Practitioners comments on interpreting 
Flexicult 
Direct comments from BMS; 
• ‘Difficult to tell if culture is pure or mixed due to heavy growth’ 
• ‘Descriptions of colony colour and identification vague’ 
• ‘Very difficult to be accurate (normally on the bench confirmatory testing 
would be performed)’ 
• ‘More definitive colony counting guidelines would be useful (very 
subjective)’ 
• ‘Difficult to read plates from images – particularly for 
low/no/faint/white/mixed growth’ 
Direct comments from GPs; 
• ‘Definitely need training on interpretation’ 
• ‘Is there any need to differentiate between the two Enterococci?’ 
• ‘Difficult test – hard to know where to look at colour – on the agar or on 
the colonies’ 
• ‘Hard to interpret when different colours in the different antibiotic sections’ 
• ‘Colonies did not match the guide – may be due to mixed growth?’ 
• ‘Sometimes there were no colonies and the agar had changed colour’ 
• ‘Much harder to interpret pictures than the real specimens, especially for 
mixed growth’ 
• ‘Following training I identified more mixed growth; I also looked more at 
the antibiotic sections to determine if growth was mixed rather than just 
using larger section (as instructed in brochure)’ 
• ‘In pure growth determining sensitivities is easy, when growth is mixed 
this is much harder’ 
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Chapter 3: Chromatic sensing, visual turbidity and 
dipstick urinalysis introduction and methods 
Introduction 
The chromatic sensing research in this section has been published in the Journal of 
Physiological Measurement (70).The development and set-up of the chromatic sensing 
system is described in appendix 2.3.1. The current use of visual assessment of urine 
turbidity and urinalysis dipsticks as point of care tests for UTI in primary care have been 
discussed in section 1 chapter 2.   
Colour science and chromaticity 
Chromaticity refers to the aspect of colour that includes consideration of its dominant 
wavelength and purity. Chromatic intelligent monitoring relates to vision and optics; 
physically, human vision is based on rods and cones in the eye (sensors and filters) 
responding to visible light of different wavelengths (colour) to provide signals conveying 
information in terms of the primary colours red, green and blue (Fig 2.3.1). Being based 
on colour science, chromatic processing applies physically to these signals and 
metaphorically in the information domain to aid in the interpretation of the significance of 
a signal (71). 
Figure 2.3.1. Colour spectra of light in visible range (72). 
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Light has three characteristics by which a colour may be specified: hue, saturation and 
brightness. Hue is associated with the dominant wavelength in a mixture of light waves, 
i.e., it represents the dominant colour as perceived by an observer. Saturation refers to 
relative purity or the amount of white light mixed with a hue. Brightness (or lightness) is 
a subjective term, which embodies the chromatic notion of intensity. Hue and saturation 
taken together are called chromaticity. Therefore, a colour may be characterized by 
brightness and chromaticity (72). 
Chromatic sensing uses information technology such as laptop computers and webcams 
or mobile phone systems to capture images of liquid samples, and specific software is 
used to analyse these images. The red, green and blue (RGB) pixels of images are 
translated into a quantitative signature for characterising a spectrum in terms of the three 
chromatic parameters: hue; saturation; and brightness. The RGB outputs can be 
transformed via algorithms from colour science into other representations that 
emphasize different relationships emerging from the relative proportions of RGB.  
Additionally, when light falls on an object or in this study, liquid, it may be reflected, 
transmitted, or absorbed. Reflected light is the part of the incident energy that is bounced 
off the liquid surface, transmitted light passes through the liquid, and absorbed light 
constitutes the part of the incident radiant energy absorbed within the liquid. The degree 
to which these phenomena take place depends on the materialistic nature of the liquid 
and on the particular wavelength of the electromagnetic spectrum being used (72) . The 
refractive index, particle size, homogeneity, and concentration of the liquid contribute to 
its disposition and are all considered when developing a chromatic analytical system for 
miscible liquids. 
Chromatic sensing applications 
Chromatic sensing applications include neonatal bilirubin monitoring (skin colour); direct 
monitoring of a neonates skin colour using a digital camera image and extracting the 
hue, light/brightness and saturation information directly from the RGB pixels in the image. 
Hue represents skin colour with increased yellowness indicating raised bilirubin levels 
associated with jaundice, blueness indicates blood oxygenation, and redness indicating 
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blood circulation); the brightness and saturation of these hues are also analysed (71). 
Chromatic sensing has also been used to differentiate between illicit and authentic 
brands of liquor by simply analysing a photographic image of the liquor. This system 
uses a laptop computer and webcam; chromatic outputs of the webcam directly provide 
a chromatic signature while the luminosity of the computer screen is used to set and 
diffuse the light source aimed at a liquor sample contained within a bottle. Different 
liquors preferentially absorb the light at various wavelengths to different degrees, the 
output of which (RGB or HLS) can be captured and mathematically analysed and 
compared (73).  The above are two examples of chromatic sensing applications most 
comparable to using the system for medical diagnostics and using urine as a miscible 
liquid.  Although details of the chromatic process and application on both these examples 
have been published there were no published data on the diagnostic/statistical accuracy 
of these methods. Additionally, no work has been done on the feasibility of applying 
chromatic sensing to determine the presence of bacteria in human samples such as 
urine.  
Rationale for exploring chromatic sensing as a POCT for UTI 
In 70 – 95% cases the infectious agent responsible for acute uncomplicated UTI is E coli 
(74). E. coli absorbs light in the UV region of the spectrum (75); we should, therefore, be 
able to capture the tail of this UV region through the blue spectrum of the urine images 
and chromatically map differences between bacterial positive and negative urine 
samples. Alternatively there may be some other elements such as metabolites in 
bacterially infected urine that are different to non-infected urine, and may draw a 
chromatically different picture. 
It is reported that clinicians can be reasonably confident that symptomatic patients with 
cloudy urine do have a UTI, but they should be cautious about excluding patients based 
on the absence of cloudiness (44). Chromatic sensing can separate spectral analysis of 
the turbidity as well as the liquid components of the urine (without prior manipulation) 
and thus possibly make a more accurate interpretation than by human vision alone. 
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If we are able to show that chromatic sensing can distinguish between a bacterial positive 
and negative sample, it’s function as a POCT will have a number of added benefits that 
are known to be essential for successful implementation into clinical practice. These 
benefits include: non-invasive sampling; a turnaround time of a few minutes; simple use 
without the need of expensive reagents or technically trained staff; low cost by using 
standard laptop computers or mobile phone technology; and automatically generated 
conclusive results.  
 
Objectives 
 To assess the analytic performance of chromatic sensing in the laboratory 
diagnosis of UTI  with NHS microscopy and culture as the reference standard; 
 To evaluate the analytic performance of chromatic sensing compared to currently 
available POCTs for UTI including urine dipsticks and visual turbidity 
assessment.  
Methods 
Setting, samples, NHS microscopy and culture  
As this study was performed at the same time and with the same samples as the Flexicult 
evaluation study (Section 2 Chapter 1) information on the samples, approvals and routine 
laboratory methods (NHS microscopy and culture) are described there. I have only used 
one cut-off for positive growth of a pure or predominant uropathogen (bacteria infecting 
the urinary tract) >105 cfu/mL.  
Chromatic sensing procedure 
The chromatic sensing analysis was delayed up to 48 hours after receipt in the laboratory 
due to time constraints in being able to undertake all the diagnostic tests during routine 
processing hours. 
For each urine sample two clear, polystyrene, spectrophotometer cuvettes (C5677-
100EA Sigma-Aldrich) were filled with 2.5 mL urine.  The two cuvettes containing the 
urine were then placed onto a stand containing a UV light (developed and provided by 
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Liverpool University). It was decided by the team at Liverpool University to use two 
cuvettes instead of one to increase the optical path length and in so doing be better able 
to discriminate between the changes in lower E. coli concentrations.  
The set-up consisted of a portable computer (Toshiba), whose VDU provided the main 
illumination and a web-cam connected to the computer which captured images of the 
cuvettes containing the urine. The chromatic information was extracted via software 
installed in the computer. The stand holding the cuvettes was placed approximately  2 
cm in front of the laptop screen, with the required background (Microsoft Office 
PowerPoint template on screen, developed and provided by Liverpool University, 
appendix 2.3.2) and the webcam positioned so that the screen was visualised through 
the urine (in the double cuvettes).  The equipment set-up is illustrated in figure 2.3.2 and 
details of all equipment and corresponding settings used are outlined in Table 2.3.1.  
Figure 2.3.2. Set-up and image capture of liquid samples using a laptop and webcam: 
a) diagram of set-up; (b) photograph of an example of the laptop set-up; (c) example of 
images captured using this set-up.  
a) b) 
 
 c) 
 
  
  
 
The screen light source (transmitted light – chromatic indication) and ambient light 
source (scattered light – chromatic turbidity) were analysed for all samples. The red, 
green and blue (RGB) outputs from images captured under these different light sources 
were collected. The images and red, green and blue outputs for each urine sample were 
sent to Liverpool University, where the outputs were analysed according to their 
developed mathematical algorithms. The chromatic data was returned in dichotomous 
form (positive or negative) for chromatic indication (a determination of the liquid 
Webcam 
to capture 
image  
Laptop with screen background 
illumination behind cuvette 
Cuvette 
with urine 
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component of the urine by measuring transmitted light) and continuous numeric form for 
chromatic turbidity (determining the amount of scattered light by measuring the reflection 
of ambient light).  
 
Table 2.3.1. Details of the equipment and settings used for chromatic image capture of 
urines. 
 
For the chromatic indication analysis, the first 67 samples were analysed un-blinded by 
the Liverpool team; (they were aware of the NHS culture results for each samples). This 
enabled them to check the mathematical algorithms in distinguishing between bacterially 
positive and negative urine. The remaining 128 samples were analysed blinded to the 
culture results. 
Visual turbidity procedure 
Visual turbidity was performed within 24 hours of receipt of the urine in the laboratory.  
All urines were visually assessed for turbidity and colour. The urine samples were 
assessed in 20mL clear, plastic, universal containers, inverted twice and held against 
white paper with writing on; the colour was recorded as seen and the turbidity was 
categorised into one of the following groups; 
1) Clear 
2) Clear but with material present (no uniform turbidity) 
3) Slightly turbid (can easily see through urine) 
4) Turbid (difficult to see through urine) 
Laptop/Computer Toshiba Portege R500 Laptop 
Webcam Creative PD1110 
Camera Settings Auto; Exposure 67, Brightness 20, Contrast 
20, Saturation 50, Sharpness 3, Gamma 3 
Screen View (Microsoft Power 
Point) Template) 
UrineTestBackgroundXWhite for EB 
CIMCOM 240912(2) (appendix 2.3.2) 
Number of Cuvettes 2 
Volume of urine 2.5mL per cuvette 
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5) Very turbid (cannot see through urine) 
Urinalysis dipstick procedure 
Dipstick urinalysis was performed within 24 hours of receipt of the urine in the laboratory 
and immediately after visual assessment of turbidity.  
All urine samples had dipstick testing performed according to the manufacturer’s 
instructions (Bayer Multistix® 8 SG). The urine samples were inverted to mix and then 
the urinalysis dipsticks were dipped into the urine sample, ensuring all the test pads were 
immersed. The dipstick was immediately removed from the urine, tapped onto the side 
of the urine container to remove excess urine and the test pads read by comparing to 
the corresponding row of colour blocks on the urinalysis bottle at the indicated time for 
colour development (from 30 seconds  for glucose to 2 minutes for leucocytes). The 
following test pads were included on each urinalysis dipstick; glucose, ketone, specific 
gravity, blood, pH, protein, nitrite and leucocytes 
Analysis 
Data was entered into Microsoft Excel and SPSS spread sheets. Diagnostic performance 
evaluations were calculated for sensitivity, specificity, negative predictive value (NPV), 
positive predictive value (PPV), likelihood ratios, diagnostic odds ratio and accuracy.  
Outcomes were analysed and compared to the reference standard laboratory testing 
(routine NHS microscopy and culture).  ROC curves were analysed to evaluate the 
additive value of chromatic sensing and/or dipstick testing to turbidity of urine. 
Confidence intervals (95%) were calculated using a spread-sheet (CIPROPORTION) 
developed by a Cardiff University statistician Robert Newcombe (68).  
 
 
Chapter 4: Chromatic sensing, visual turbidity and dipstick 
urinalysis analytic performance results 
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In total 195 samples were included in the analysis; 125 (64.1%) bacterially negative and 
70 (35.9%) bacterially positive urine samples (>105 cfu/mL pure or predominant 
uropathogen).  
Visual turbidity 
Of the 195 urine samples visually assessed 22.5% were categorised as clear, 7.5% clear 
with material in, 18.3% slightly turbid, 43% turbid and 8.7% very turbid (shown in Table 
2.4.1 below). 
 
Table 2.4.1. Frequency of urine samples categorised into 5 levels of turbidity through visual 
assessment. 
 
Turbidity classification 
Frequency Per cent 
Cumulative 
Per cent 
 1) clear 44 22.5 22.5 
2) clear but with material in 15 7.5 30.0 
3) slightly turbid 36 18.3 48.3 
4) turbid 84 43.0 91.3 
5) very turbid 17 8.7 100.0 
Total 195 100.0  
 
To dichotomise the data I further sub-categorised the results into not turbid (urines that 
were clear and clear with material in it) and turbid (urines classed as slightly turbid, turbid 
and very turbid); 30.3% were classed as not turbid and 69.7% as turbid. 
Cross-tabulation of the urines categorised into not turbid and turbid with NHS culture 
results (positive if >105 cfu/mL) are shown in Table 2.4.2.  
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Table 2.4.2. SPSS cross-tabulation of non-turbid and turbid urine samples with NHS 
quantification results. 
 
NHS Quantification 
Total 
<=105 cfu/mL >105 cfu/mL 
Visual Turbidity 
not turbid 
 
59 0 59  
 
turbid 
 
66 70 136  
 
Total  125 70 195 
 
When using this categorisation of visual turbidity the sensitivity was 100% (95% CI 94.8; 
100); specificity is 47.2% (95% CI 38.7; 55.9); positive predictive value 51.5% (95% CI 
43.5; 59.7) and negative predictive value 100% (95% CI 93.9; 100). All urines classed 
as non-turbid (59/195) could be safely classed as negative for a UTI. Due to the low 
specificity, all the turbid urines (136/195) could be either classed as positive or negative 
for a UTI. The absence of turbidity may therefore be useful in ruling out a UTI.  
Urinalysis dipstick 
From this evaluation leucocytes were found to be the most predictive of UTI followed by 
nitrite and then blood and protein (Table 2.4.3). Both nitrite and leucocyte urinalysis are 
better predictors of not having a UTI with NPV of 70.8 (95% CI 63.2 – 77.4) and 82.1% 
(95% CI 74.0 – 88.1) respectively and both having low PPVs. 
When combining tests my results give a PPV for ‘positive nitrite, leucocytes and/or blood’ 
of 82% and 76% respectively. Nitrite alone had a PPV of 62%.  
A urinalysis result negative for nitrite, leucocytes and blood gave a NPV of 84% and the 
highest sensitivity of 83.1%. However, there were 12 false negatives samples and 
therefore does not completely rule out a UTI. 
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The sensitivity, specificity, PPV and NPV for various urinalysis tests and combinations 
of tests are shown in appendix 2.3.3.  
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Table 2.4.3. Performance of urinalysis tests in predicting a laboratory UTI diagnosis. 
 
 
True positives 
n (%) 
True negatives 
n (%) 
False 
positives n 
(%) 
False 
negatives n 
(%) 
% Correctly 
classified 
Likelihood 
ratios 
(LR+, LR-) 
Odds 
ratio 
Nitrite 
 
26 
(13.3) 
109 (55.9) 
15 
(7.7) 
45 
(23.1) 
69.2 3.03, 0.72 3.93 
Leucocyte ≥+ 
44 
(22.6) 
100 (51.3) 
24 
(12.3) 
27 
(13.8) 
73.8 3.20, 0.47 6.79 
Blood, 
haemolysed 
≥trace 
39 
(20.0) 
84 
(43.1) 
40 
(20.5) 
32 
(16.4) 
63.1 1.70, 0.67 2.56 
Protein ≥trace 
36 
(18.5) 
73 
(37.4) 
51 
(26.2) 
35 
(17.9) 
55.9 1.23, 0.84 1.47 
 75  
Visual turbidity and dipstick urinalysis prediction rules 
In this study the sensitivity of visual turbidity was 100%, therefore I could safely eliminate 
any clear or non-turbid samples from further testing. However, with the remaining 
samples (approx. 70% in this sample set) it was not possible to safely determine whether 
these were positive or negative for a UTI by turbidity assessment alone. By combining 
the urinalysis dipstick testing with turbidity testing, I hoped to improve the diagnostic 
performance of these manoeuvres for these samples. The remaining 136 samples (59 
removed as non-turbid) were first evaluated using a prediction rule; if nitrite, leucocyte 
AND blood (haemolysed) are negative the urine is unlikely to be positive for UTI. The 
results are as follows; combined sensitivity 82.9% (95% CI 72.4 – 89.9); specificity 70.4 
% (95% CI 61.9 – 77.7); PPV 61.1% (95% CI 51.0 – 70.3) and NPV 88.0% (95% CI 80.2 
– 93.0). Out of 195 samples; 100 would have been deemed negative based on non-
turbidity combined with nitrite, leucocyte and blood urinalysis negative, the risk would be 
12/100 (12.0%), 95 samples would have been  considered probable for a UTI with a risk 
of 37/95 (38.9%).  
Another prediction rule I tested was that if the urine was visually turbid AND nitrite OR 
leucocyte positive, it was likely to be positive for a UTI. The results were as follows; 
sensitivity 77.1% (95% CI 66.1 – 85.4); specificity 80.0% (95% CI 72.1 – 86.1); PPV 
68.4% (95% CI 57.5 – 77.6) and NPV 86.2% (95% CI 78.8 – 91.3). Out of 195 samples; 
116 would be considered negative with a risk of 16/116 (13.8%), 79 samples would be 
considered probable for a UTI with a risk of 25/79 (31.6%). 
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Table 2.4.4. Performance of various visual turbidity and urinalysis prediction rules in 
determining UTI. 
 True 
positive 
n (%) 
True 
negative 
n (%) 
False 
positive 
n (%) 
False 
negative 
n (%) 
Correctly 
classified 
(%) 
Likelihoo
d ratios 
(LR+, 
LR-) 
Visual 
Turbidity 
70  
(36.0) 
59  
(30.2) 
66  
(33.8) 
0  
(0) 
66.2 1.89, 0 
VT negative 
and/or NLB 
negative 
58  
(29.7) 
88  
(45.1) 
37  
(19.0) 
12  
(6.2) 
74.8 
2.8, 
0.243 
VT and N or L 
positive 
54  
(27.7) 
100  
(51.3) 
25  
(12.8) 
16  
(8.2) 
79.0 
3.86, 
0.286 
VT = visual turbidity, N = Nitrite, L = Leucocyte, B = Blood  
 
The superior prediction rule based on likelihood ratios was the visually turbid urine with 
either positive nitrite or leucocyte (Table 2.4.4).  A positive result in this combination of 
tests is approximately 4 times more likely to occur in a patient that does have an NHS 
laboratory diagnosed infection compared to one who does not. The sensitivity and 
specificity for this prediction rule is 77.1% (95% CI 65.6 – 86.3%) and 80.0% (95% CI 
71.9 – 86.6%) respectively. 
Chromatic sensing 
Chromatic indication (transmission) 
The chromatic indication (evaluation of transmission of light) overall gave a sensitivity of 
97.1% (95% CI 90.2 – 99.2); specificity 54.4% (95% CI 45.7 – 62.9); PPV 54.4% (95% 
CI 45.7 – 62.9) and NPV 97.1% (95% CI 90.2 – 99.2) as detailed in Table 2.4.5.  
Although the accuracy of the results (number of correctly classified samples) decreased 
after blinding from 76.1% to 66.4%. 
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Table 2.4.5. Performance of chromatic indication in determining UTI on samples with unblended and blinded culture results. 
Chromatic 
Indication 
True 
positives, n 
(%) 
True 
negatives, n 
(%) 
False 
positives, n 
(%) 
False 
negatives, n 
(%) 
Sensitivity 
(95% CI) 
Specificity 
95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Unblinded 
(n=67) 
23 28 16 0 
100 
(85.7 – 100) 
63.6 
(48.9 – 76.2) 
59.0 
(43.4 – 72.9) 
100.0 
(87.9 – 100) 
Blinded 
(n=128) 
45 40 41 2 
95.7 
(85.8 – 98.8) 
49.4 
(38.8 – 60.1) 
52.3 
(41.9 – 62.6) 
95.2 
(84.2 – 98.7) 
All samples 
(n=195) 
68 68 57 2 
97.1 
(90.2 – 99.2) 
54.4 
(45.7 – 62.9) 
54.4 
(45.7 – 62.9) 
97.1 
(90.2 – 99.2) 
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Chromatic turbidity (dichotomising continuous data) 
ROC and area under the curve 
Looking at the co-ordinates of the ROC curve and to give optimum sensitivity a cut-off 
of 0.152 was selected to dichotomise the data (Figure 2.4.1)); 
CT < 0.152 negative (low turbidity) 
CT≥ 0.152 positive (high turbidity) 
 
Figure 2.4.1. ROC curve of chromatic turbidity results 
 
Using this cut-off chromatic turbidity had a sensitivity of 100%; specificity of 50.4%; PPV 
of 53.0% and NPV of 100%. When comparing the chromatic turbidity results with the 
visual turbidity results (analysing the same sample set) the outcomes were very similar 
as shown in Table 2.4.6. 
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Table 2.4.6. Performance of chromatic and visual turbidity in determining UTI (as compared to NHS culture >105 cfu/mL) 
 
True 
positives, n 
(%) 
True 
negatives, n 
(%) 
False 
positives, n 
(%) 
False 
negatives, n 
(%) 
Sensitivity 
(95% CI) 
Specificity 
95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Chromatic 
Turbidity 
70 
(35.9) 
63 
(32.3) 
62 
(31.8) 
0 
(0) 
100 
(94.8 – 100) 
50.4 
(41.8 – 59.0) 
53.0 
(44.6 – 61.3) 
100 
(94.3 - 100) 
Visual Turbidity 
70 
(35.9) 
59 
(30.3) 
66 
(33.8) 
0 
(0) 
100 
(94.8 – 100) 
47.2 
(38.7 – 55.9) 
51.5 
(43.2 – 59.7) 
100 
(93.9 – 100) 
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Chromatic indication and chromatic turbidity 
Chromatic indication and chromatic turbidity were combined using the following rule; any 
sample with chromatic indication AND chromatic turbidity positive, was considered 
positive; if the sample is either chromatic indication OR chromatic turbidity negative it is 
deemed negative. This gave the following results: sensitivity of 97.1%; specificity of 
64.8%; PPV of 60.7%; NPV of 64.8%; with a ‘positive’ group compromising of 112 (57%) 
of the samples with a risk of 44/112 (39.3%), and a ‘negative’ group compromising of 83 
(43%) of the cases with a risk of 2/83 (2.4%). 
Chromaticity and urinalysis 
As visually turbid urine combined with the urinalysis result of either positive nitrite or 
leucocyte (≥+) gave the best differentiation between bacterial positive and negative 
urine, I repeated the same rule but using Chromatic Indication and Chromatic Turbidity 
positive with positive nitrite or leucocyte (≥+). The results gave a sensitivity of 74.3% 
(95% CI 63.0 – 83.1); specificity of 88.8% (95% CI 82.1 – 93.2); PPV of 78.8% (95% CI 
67.5 – 86.9) and NPV of 86.0% (95% CI 79.0 – 91.0). Out of 195 urine samples 66 
(33.8%) would be categorised as positive (or likely positive for UTI) with a risk of 14/66 
(21.2%) and 129 (66.2%) would be categorised as negative (or likely negative for a UTI) 
with a risk of 18/129 (14.0%).  
 
Using an ROC curve (Figure 2.4.2) the following 6 predictions rules were compared; 
1) Chromatic Turbidity and Indication positive likely UTI 
2) Chromatic Turbidity and Indication positive and nitrite or leucocyte (≥+) positive 
likely UTI 
3) Visually turbid likely UTI 
4) Visually turbid and nitrite or leucocyte (≥+) positive likely UTI 
5) Nitrite or leucocyte (≥+) positive likely UTI 
6) Nitrite, leucocyte and blood (haemolysed) negative unlikely UTI 
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Figure 2.4.2. ROC curves of 6 various chromatic, turbidity and urinalysis prediction 
rules for bacterially positive UTI (NHS culture >105 cfu/mL positive) 
 
The AUROC of 0.815 (for Chromatic Turbidity and Chromatic Indication positive with 
nitrite or leucocyte (≥+) positive) indicated the highest discrimination out of all the rules, 
and the null hypothesis was rejected (p<0.001) for all (Table 2.4.7). 
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Table 2.4.7. Area under the curve (based on ROC curves in figure 2.4.2) for 6 prediction 
rules in determining a UTI 
Prediction Rule Area Std. Errora P-value 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
1)CI and CTpos_sub .810 .031 .000 .750 .870 
2)CT_CI_NorLpos .815 .035 .000 .747 .884 
3)VisualTurbidity .736 .034 .000 .668 .804 
4)VT_NorLpos .786 .036 .000 .716 .856 
5)NorLpos .734 .038 .000 .660 .808 
6)NLB_negative .658 .040 .000 .581 .736 
(CI – chromatic indication; CT – chromatic turbidity; N – nitrite; L – leucocyte; VT- visual turbidity; NLB – nitrite, 
leucocyte, blood) 
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Chapter 5: Section 2 Discussion 
 
UK FlexicultTM SSI urinary Kit 
The completed STARD checklist for reporting the Flexicult diagnostic accuracy study is 
shown in appendix 2.3.4. 
The UK Flexicult results were comparable to routine NHS urine processing in identifying 
microbiologically positive urine samples which may aid the diagnosis of UTI. UK Flexicult 
produced few false negatives (3% when compared to routine NHS method) which is 
important for primary care clinicians: not missing patients that may benefit from 
antibiotics is generally more important in clinical care than prescribing antibiotics to 
patients with culture negative urine. The higher false positivity could lead to over-
prescribing in primary care, although this study did not compare UK Flexicult to empirical 
prescribing in general practice and may still reduce unnecessary antibiotic prescribing 
compared to diagnosis based on clinical symptoms and/or urinalysis dipstick results 
alone. The semi-quantitative nature of Flexicult, over-inoculation or delay in processing 
(allowing organisms within the urine to multiply) may have caused the higher false 
positivity as it is more  difficult to differentiate between a cut-off of less than or greater 
than 105 cfu/mL or determine a predominant organism when there is a high level of 
growth. The only other published study of the FlexicultTM SSI urinary kit by Blom et al. 
which analysed 121 urine samples from patients who consulted participating primary 
care clinicians with suspected UTI in Denmark. The samples were tested for bacteriuria 
using the (Danish) Flexicult kit and the results were compared with urine samples 
obtained simultaneously for control purposes and found an overall error rate of 4.7% 
[11]. The error rate from this study was 16.5%, however, this was based on detection of 
a pure/predominant clinically significant organism as well as quantification which was not 
done in the previous study.  
Identification of the most common uropathogens was comparable to NHS and spiral 
plating methods when using UK Flexicult. However, the inability to differentiate white 
colonies may cause some patients to be treated for a UTI when commensal organisms 
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or Candida spp. are cultured or conversely patients that may have less common 
uropathogens such as S. aureus or Acinetobacter spp. may not be treated appropriately.  
By diluting turbid urine samples (1:1000) prior to inoculation onto the UK Flexicult there 
was an improvement in the determination of predominance (by diluting out the 
contaminating organisms). However diluting the urine had no effect on reducing 
discordant positive results with the NHS and minimal effects on reducing the discordant 
negative results; this is likely due to the improved sensitivity of UK Flexicult when using 
diluted urine. Flexicult has a detection limit of ~5 x 102 cfu/mL[11] and by diluting the 
urine 1:1000 the kit would have a detection limit of >105 cfu/mL which, depending on the 
definition of a microbiologically positive UTI may not be appropriate. 
The higher NHS resistance levels in this study compared to the most recent (2013) 
reported prevalence for community acquired coliforms in Wales [9] may be due to the 
small sample size and the sample population used for this study which included hospital 
inpatient samples and samples that may have been selected due to concerns over 
antibiotic resistance. Trimethoprim is a recommended first-line antibiotic for 
uncomplicated UTI in the UK and the accuracy using UK Flexicult is encouraging. The 
resistance levels using both methods is also similar for 1st generation cephalosporins, 
however the NHS cephalosporin results had a very small sample size and may not be 
comparable to UK Flexicult. Ciprofloxacin had 100% accuracy compared to the NHS 
testing and similar overall resistance levels. However, compared to the resistance levels 
of the other antibiotics included in UK Flexicult  the lower overall proportion of  
ciprofloxacin resistance may encourage prescribing of this antibiotic which is not 
recommended for general use due to its ecologically adverse effects [17]. The resistance 
levels of both co-amoxiclav and nitrofuantoin were much higher than the NHS results 
and this was reflected in the higher number of false resistant samples. Co-amoxiclav is 
not a recommended first-line antibiotic for uncomplicated UTI and clavulanate is known 
to be unstable in vitro making it unreliable for a POC based test which ideally requires 
an extended shelf-life. However, nitrofurantoin is a recommended first-line antibiotic for 
uncomplicated UTI and the higher resistance determined by UK Flexicult kit could lead 
 85  
to its underuse as an alternative to trimethoprim and escalation of other 2nd or 3rd line 
antibiotics. The high false positive resistance levels to co-amoxiclav and 1st generation 
cephalosporin could be due to degradation of the antibiotics in the kit; and further testing 
of the antibiotic concentrations at various time-points (following inoculation) under 
different shipment and storage conditions should be evaluated further. The only way to 
be certain of the resistance of each isolate would be to determine the MIC for the 
corresponding antibiotic showing resistance on UK Flexicult which was not performed as 
part of this study.   
By using quantification only, irrespective of predominance or identification, the sensitivity 
of UK Flexicult increased from 86.7% to 95.6% at the ≥105 cfu/mL and from 86% to 100% 
at the ≥103 cfu/mL cut-points for positivity. Whiting et al reviewed studies that discussed 
factors that may affect clinicians’ decisions to order a test, and found in primary care 
tests are more commonly used to rule out a condition or to help the doctor to make a 
decision about referral. Conversely, in secondary care, tests are more often used with 
the aim of reaching a definite diagnosis (76). The usefulness of the POCT culture 
approach may lie mainly in screening out negative urine samples prior to antibiotic 
prescribing and/or sending samples for routine culture. The higher cut-off used in this 
study would screen out over 50% of the samples with only 1% of true positives being 
missed if this POCT was used in determining whether the sample would meet the 
laboratory definition of a UTI. 
The inter-observer reproducibility study aimed to assess the subjective nature of 
Flexicult. Some of the considerations I had for the design of this study included; the 
feasible number of available suitably qualified ‘assessors’, I required more than two from 
each group (experienced microbiologists and naïve GPs) but was limited to the number 
of assessors who offered to participate. The assessment of the Flexicult plates in ‘real-
time’ on the same day but independently; over time the growth on the plates may change 
so it was important that the assessors were reading the same plates at the same time. 
The feasible number of plates to be read by assessors with varying types of growth; there 
are numerous types of uropathogens that may be identified in practice both of pure or 
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mixed growth and of varying quantification levels. Therefore, I wanted to include as many 
different plates as possible (from real infections rather than spiked urine) without over 
whelming the assessors with too many to read in one session. I also wanted to look at 
the potential benefit of training the GPs so I needed to repeat the assessment of the 
same plates but after a period of time to avoid recall (memory) effects; therefore the 
images of the same plates were captured, re-numbered and sent for interpretation after 
a period of time.  
Biomedical scientists experienced in quantifying bacteria and using chromogenic agar 
for identification had a much higher percent agreement (77%) and strength of agreement 
(substantial) in identifying positive UTIs using Flexicult compared to the GPs (57% 
agreement; fair strength). Even after training the strength of inter-observer agreement 
between the GPs and myself was only moderate with an increased agreement of 67%. 
The Flexicult kit is subjective and appropriate training, guidelines and user experience is 
critical for the diagnostic accuracy and inter-observer reliability of the test.  
A concern I had from this study is that the GPs participating in it did volunteer to do so 
but may not have put in as much time or effort in using the brochure/website and 
interpreting the plates as they would have done in practice when a patient is expecting 
appropriate care. This study also raised some concerns regarding the brochure and 
training for use with Flexicult; I think both could be substantially improved and would be 
fundamental to the success of this test in practice. Depending on the outcomes of the 
clinical trial it may be worth investigating potential user guides or a web-based diagnostic 
tool to be used in the interpretation of Flexicult until the user is confident in their own 
ability to read this test. In Denmark clinicians are invited to send plates back to SSI or 
contact them for help in interpretation of the tests (personal communication with SSI) 
whether this would be practical and effective in other European countries would need to 
be investigated. 
Chromatic sensing 
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Chromatic sensing provides a novel approach to predicting bacterial infections in urine 
and in so doing potentially predicting UTI in patients has been described. The system 
set-up uses everyday technical equipment such as laptops/computers and webcams (or 
even mobile phones although not assessed in this study) and a non-invasive, non-
specialised approach to analysing urine samples. The system set-up, although easy for 
one person using the same equipment and location (same bench in the laboratory) would 
need to be evaluated based on various users, equipment and locations, particularly as 
the fundamental process of this system uses ambient light and screen illumination. 
Changes in room lighting (both natural and artificial) and laptop screen brightness, hue 
and other parameters may completely change the chromatic results. Although this has 
been taken into consideration by providing reference areas on the laptop screen (either 
side of the sample) to be used as a quality control for the analysis when using a 
standardised substance such as water, it has not been tested with multiple equipment 
and users setting up the system.  The economic aspect of this technology would also 
need to be evaluated. 
For this study the images and RGB outputs were captured by the user (myself) but the 
actual analyses were performed by the chromatic experts at Liverpool University; for this 
to be an effective POCT in practice the system would have to be automated with 
immediate results which would require further development at this stage. 
Chromatic analysis is intended as a POCT to avoid unnecessary antibiotic prescribing 
and/or reduce the number of samples referred to the NHS microbiology laboratories. 
Currently in the UK only visual turbidity and/or urinalysis dipstick testing are 
recommended (along with patient demographics and clinical signs and symptoms) at the 
point of care for predicting uncomplicated UTI and therefore prescribing antibiotics 
appropriately. I found chromatic indication and chromatic turbidity to perform as well as 
visual assessment of urine turbidity in predicting negative urine samples. The SIGN 
guidelines do not recommend using visual assessment of turbidity because of observer 
error, suggesting it may not be a useful discriminator (46). Chromatic analysis has the 
benefit of providing a quantifiable and potentially reproducible (although this would need 
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to be investigated) measurement of turbidity. It could also give a finer scale of turbidity 
than the broad categories of human visual assessment as well as quantifying additional 
chromatic parameters which could indicate other conditions of the urine sample. Neither 
chromatic analysis (both indication and turbidity) nor visual turbidity predict positive urine 
samples sufficiently accurately.  
For this study I used dipstick results that were interpreted by the human eye.  There is 
potential to use chromatic analysis to interpret dipstick colour change and in one 
computerised program analyse the urine for chromatic indication and turbidity and dipped 
urinalysis stick for nitrite and leucocyte positivity, producing results within a few minutes. 
 
Visual turbidity 
Assessment of the visual turbidity of urine gave a sensitivity of 100% from this study. If 
this is reflected in practice this could allow GPs to exclude any clear urines from further 
diagnostic tests or from empirical prescribing of antibiotics. 
This study involved one assessor using the same method of interpreting the visual 
turbidity of the urines. In current practice it may be that the GPs ask the patients for their 
own interpretation of the turbidity of their urine or if a sample is requested (for instance 
for dipstick urinalysis) the GP or nurse may evaluate the turbidity of urine themselves; 
either way the method for interpretation most likely varies within and between practices.  
In the determination of sputum colour for lower respiratory tract infections there is some 
concern over the ability of patients to determine their own sputum colour or purulence. A 
study has demonstrated that sputum colour assessed with a sputum colour chart is a 
better marker for bacterial involvement than sputum colour reported by patients; 
assessed sputum colour (using chart) was also shown to be clearly related to bacterial 
load in sputum and, in particular, systemic inflammation consistent with infection, 
whereas patient reported sputum colour was not (77). This may have some parallels with 
the visual assessment of urine; perhaps a chart or comparison with pre-prepared urines 
of varying turbidity read by the clinical staff rather than the patient may be more pertinent 
in avoiding observer error. A larger study or pragmatic evaluation involving the correct 
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sub-set of patients and assessors (GPs or nurses) in routine clinical practice would need 
to be undertaken before any final conclusions can be drawn.  
 
Dipstick testing 
This study showed that a urinalysis result negative for nitrite, leucocytes and blood gave 
a NPV of 84% and the highest sensitivity of 83%. However, there were 12 false negatives 
samples and therefore does not completely rule out a UTI. 
The HPA recommend (for women with mild symptoms of UTI) if a dipstick test is positive 
for nitrite, leucocyte and blood or if positive for nitrite alone a UTI is probable. If the 
dipstick reads negative for nitrite, leucocyte and blood or negative for nitrite and 
leucocytes (positive blood and protein) a UTI is unlikely (25). SIGN recommend if the 
dipstick is positive for nitrite or leucocyte this is associated with a higher probability (80%) 
of UTI. Negative dipstick results do not exclude bacteriuria however the probability of 
having a UTI drops to about 20% when dipstick tests are negative (46). 
The results from my study showed a poorer performance of dipstick urinalysis when 
using nitrite compared to previous published studies. I included all uropathogens as 
positive for UTI (if >105 cfu/mL, pure or predominant).The recommendation by the HPA 
is based on the study by Little et al. (48), which only includes E. coli infection as positive 
for UTI, E. coli is a gram-negative bacteria and only Gram-negative bacteria produce 
nitrites.  Gram-positive bacteria (such as Enterococcus spp. and Staphylococcus spp.) 
do not produce nitrites and could be a reason for the lower performance of nitrite 
urinalysis in my study. The urinalysis assessing leucocytes was marginally better than 
nitrites in my study and again may be for a similar reason (this is an indication of infection 
and may be caused by all bacterial species). 
Reasons for false positive nitrite results include coloured urine and in vitro growth and 
false negative results could be due to no vegetables in the diet (beet ingestion, 
bilirubinuria), short bladder incubation time, presence of vitamin C and Gram positive 
bacterial infection. False positive leucocyte results could be due to oxidising detergents, 
formaldehyde (0.4 g/L), sodium azide and coloured urine and false negative results due 
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to vitamin C, protein > 5 g/L, glucose > 20 g/L, mucoid specimen, presence of 
cephalosporins or nitrofuantoin (38). 
The guidelines only indicate using dipsticks for women with mild symptoms of 
uncomplicated UTI (≤ 2 symptoms). I did not have access to the symptoms of the patients 
included in this study and the samples were from men and women from primary and 
secondary care so comparing these results to the guidelines may not be applicable. 
However, on a fundamental basis of using a dipstick to identify (or exclude) a bacterial 
urine infection the results from this study are not indicative of this test being useful when 
used alone. 
By combining visual turbidity with dipstick testing and using the rule that a person with 
turbid urine and either a positive nitrite or leucocyte dipstick result; the likelihood of them 
having a UTI increases four-fold. This may still not be considered an adequate diagnostic 
process for UTI as (from this study) 14% patients may not have been treated when they 
had a bacterial infection and 32% who did not have a bacterial infection would have been 
treated. 
 
Limitations 
The results of this study were included in the protocol submission for a larger randomised 
controlled trial of the UK FlexicultTM SSI-urinary kit and as such the approvals process 
for this study needed to be as timely as possible. It was therefore decided to use 
anonymised, excess urine samples routinely submitted to the University Hospital Wales, 
Microbiology Laboratory. This did not require full ethical review (proportionate only) 
making the process quicker, and optimising the availability of urine samples (formal 
opinion from Ethics committee). However, this had limitations for this study; the samples 
analysed were not necessarily representative of patients presenting with uncomplicated 
UTI in general practice which is the population this test is aimed at. As clinicians generally 
submit urine samples to the laboratory from patients who have failed initial therapy, the 
study sample may have been bias towards higher positivity and proportion of resistant 
isolates. Additionally, as the samples were anonymised, no patient details (other than 
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gender or age) or symptoms were recorded and so could not be used in the evaluation. 
As boric acid can affect the antibiotic sections of the Flexicult plates urines collected this 
way were excluded; this may have biased the samples towards in-patient rather than 
out-patient samples. However, the sub-group analysis results of outpatient samples did 
not differ from the results using the total sample population.  
From a practical perspective, there was a delay (because of the requirement for excess 
urine) between collection of the urines and NHS processing/culture and evaluation on 
Flexicult, by spiral plating culture (although Flexicult and spiral plating were performed 
at the same time), visual turbidity, dipstick urinalysis and chromatic sensing. The time 
from routine processing to diagnostic evaluation was within ~9 hours (i.e. the same day) 
for flexicult, spiral plating, visual assessment of urine turbidity and dipstick urinalysis and 
within 24 hours for the chromatic sensing procedure with the urine being stored at room 
temperature in the meanwhile. Ideally all tests should have been evaluated at the same 
time and close to the time of urine collection as this is the intended purpose of the POC 
tests; if this was not possible refrigeration of urines in the meantime would have been 
preferable. Time delays can result in multiplication of bacteria (both infecting and 
contaminating organisms) or damage/death of diagnostically relevant bacteria (38) and 
potential loss of resistant elements. 
Some of the discrepancies in determining a microbiologically positive urine culture for 
UTI may be due to the different methods used for inoculation and quantification. Flexicult 
used a third of the test plate (which is flooded with urine), while the NHS method used a 
quarter of an agar plate and a 1 µL loop for inoculation which can only quantify down to 
1 x 104 cfu/mL (10 colonies); identification of predominance of an infecting organism also 
varies. Both these methods are subjective, may have poor reproducibility and be prone 
to contamination and interpretation problems which would need to be evaluated further. 
This subjectivity may be of concern for UK Flexicult used in clinical practice when clinical 
staff inexperienced in microbiological test interpretation are reading the plates and/or 
there is inadequate training. In NHS and research microbiology laboratories diagnostic 
tests, process and equipment are assessed routinely through subscription to an external 
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quality assurance (EQA) scheme. This should be something to consider if UK Flexicult 
is implemented into routine primary care management. However, a study in Sweden 
evaluating an EQA scheme for the use of dip-slides in primary care found no 
improvement in GP user interpretation over a five year period and the need for training 
and continuous education of the clinical personnel using the dip-slides was highlighted 
(78). 
Due to limited resources the spiral plating process was performed by myself as well as 
the UK Flexicult evaluation; ideally it would have been performed by someone blind to 
the study question. However I was blind to the results of the reference standard and only 
evaluated the spiral plate tests after recording the results of the UK Flexicult. No other 
information was available to myself as the reader of the diagnostic tests under 
evaluation. 
Statistical analysis 
The sample size calculation was based on potential sensitivity and specificity calculated 
using previous Flexicult errors rates from analysis of quantification only (from Blom et 
al.(65)). The sensitivity and specificity calculated in this study used both quantification 
and identification (as would be done in routine practice) therefore the actual results were 
not as good and had larger confidence intervals than when based on quantification alone. 
There was no previous published data on the number of false positives or false negatives 
to improve the accuracy of this original calculation, however, the prevalence of UTI found 
in this study was between 20 – 30% as indicated in the initial sample size calculation. 
The prevalence of bacteria at >105 cfu/mL from the field study in the Blom et al. paper 
was much higher at just over 50%; although there was no mention of purity or 
predominance and if not accounted for could result in a higher prevalence. 
There may be concern over the number of comparisons used for these diagnostic 
evaluations and the potential for type I errors. The Bonferroni correction method can be 
used to counteract this problem by reducing the critical significance level according to 
the number of independent tests carried out in the study. However, this may also reduce 
the statistical power of the study and fail to detect true effects as well as false ones and 
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as such I have decided not to use this in my statistical analyses but rather highlight the 
potential issue as a limitation.  
 
The implications for use of all these diagnostic tests in practice are discussed in the 
overall discussion in section 4. 
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Section 3: Management of uncomplicated 
UTI in Primary Care 
 
Chapter 1: A systematic review of the management 
of uncomplicated urinary tract infection 
presenting in primary care in Europe 
 
Introduction 
Patients consulting in even the best general practices experience unwarranted variations 
in health care and health outcomes and much of clinical medicine remains empirical. 
Everyday practice is characterised by wide variations that have no basis in clinical 
science. Unfortunately even the best scientific research does not always get translated 
into routine practice and patient management. National guidelines (that may even vary 
between countries and be based on different scientific research) are often not translated 
into practice. Unscientific personal opinion (GP and patient), local medical opinion, and 
local supply of resources are often more important than science in determining how 
medical care is delivered (79).  
Variation in antibiotic prescribing that does not improve outcomes for patients wastes 
resources, undermines self-care for similar conditions in the future, puts patients at 
unnecessary risk of side effects, and increases selection of resistant organisms, and so 
represents an opportunity for improved care through greater standardisation (80). 
Differences in prescribing in certain settings may be explained by other factors such as 
differences in severity of illness, the patients history of illness (and previous treatment) 
and use of more/different (conclusive) diagnostic tests (or even different 
use/interpretation of the same diagnostic test), or variation in resistance of circulating 
organisms. If factors such as the use of different diagnostic tests are the basis of different 
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prescribing practices then this may be worth standardising between practices, regions 
and countries for a universally better outcome.  
Comparative studies evaluating different patterns of practice are important in identifying 
areas of unwarranted variation prior to development and implementation of scientific 
research. Section three describes the methods and results of a systematic review 
comparing observational studies evaluating the management of uncomplicated urinary 
tract infection in primary care in different countries in Europe. Secondly this section 
covers the comparative data analysis of patient management in general practices 
recruited within four networks in Southampton (England), Cardiff (Wales), 
Madrid/Catalonia (Spain) and Utrecht (the Netherlands) as part of an observational study 
of patients with suspected uncomplicated UTI (part of the POETIC study; Section 3, 
Chapter 2). 
Hypothesis 
Variations in the management of uncomplicated urinary tract infections in primary care 
exist between European countries and general practices within European countries. 
 
Aim 
To identify studies that evaluated the routine management of adult women with 
suspected uncomplicated UTI attending primary care in different European countries. 
Appraise and summarise these data to determine variation in management between 
countries, discuss if variation is warranted, and to contrast with the findings of the new, 
POETIC observational study data.  
 
Objectives 
1. To perform a systematic search of the literature, critical appraisal and data 
extraction of included studies evaluating the routine management of women with 
suspected uncomplicated UTI in primary care; 
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2. To describe the methods and interventions employed to manage uncomplicated 
urinary tract infection (UTI) in women attending primary care in studies conducted 
in Europe; 
3. To summarise and compare the methods/interventions and discuss any 
variations in management between countries included in the review; 
4. To discuss the findings in relation to the observational data from the POETIC 
study. 
 
Systematic Review Method 
Protocol and Registration 
The systematic review protocol has been registered on the PROSPERO website, 
registration number CRD42014007433 http://www.crd.york.ac.uk/PROSPERO/. 
PROSPERO is an international database of prospectively registered systematic reviews 
in health and social care within the University of York, Centre for Reviews and 
Dissemination. 
Eligibility Criteria 
Table 3.1.1 outlines the eligibility criteria that defined the population, interventions, 
comparison and outcomes that made up the basis of this systematic review. The 
population consists of adult, females consulting to primary care in Europe with suspected 
uncomplicated urinary tract infection. This is based on the HPA (25) guidelines for 
uncomplicated UTI. The interventions include any diagnostic processes or medical 
treatment provided for the patient during the clinical consultation. As I am interested in 
observation of routine management there are no comparison groups as there would be 
in a randomised controlled trial, however, comparisons of management choices between 
studies and countries are included in the review.  
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Table 3.1.1. Inclusion and exclusion criteria listed (where applicable) for the population, 
interventions, comparisons and outcomes of interest in the systematic review. 
 
Literature search 
A search strategy was developed in OVIDSP Medline using the keywords and Medical 
Subject Headings (MeSH) outlined in Box 3.1.1. The search strategy was modified to 
search the remaining bibliographic databases. 
Electronic sources (databases and websites) 
Languages 
 English language studies only (due to high translation costs). 
Dates 
 No publication date limit up to January 2014. 
 
 
PICO Inclusion Exclusion 
Population Women (and multi-gender studies); 
suspected 
uncomplicated/lower/acute UTI 
(cystitis); women presenting to 
primary care/general practice in the 
Europe. 
Men only studies; children only 
studies (<16); pregnant women; 
associated with catheter; countries 
outside of Europe; secondary care; 
women with obvious co-morbidities; 
complicated UTI; studies not 
observing routine management i.e. 
randomised controlled trials. 
Interventions Any medical treatment; any 
diagnostic or medical tests for UTI; 
advice and follow up procedures. 
Interventions that are not part of 
routine practice. 
Comparison Between studies: management 
choices. 
NA 
Outcomes As well as describing the 
management decisions and 
processes, congruence to relevant 
guidelines. 
Microbiological 
results/epidemiology of UTI. 
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Databases 
 Medline via Ovid; Medline in Process; British Nursing Index; CINHAL (Cumulative 
Index to Nursing and Allied Health Literature); The Cochrane Library; Embase; 
HMIC (Health Management Information Consortium); Scopus; Web of Science. 
Web sites 
 Google Scholar; I performed the general search ‘UTI management’ and checked 
the first 10 pages for any new references. 
Journals 
 Once the database searches had been performed I selected the most frequently 
used journals from the studies included in the review and searched for new 
references over the past two years (to January 2012). The journals included: 
Family Practice; British Medical Journal; Journal of Antimicrobial Chemotherapy; 
Scandinavian Journal of Infection; International Journal of Antimicrobial Agents; 
and Journal of Infection.  
Additional searches  
Snowballing methods 
 I searched the reference lists of all included studies for potentially relevant papers 
(not already reviewed). 
Study selection 
Quantitative studies describing actual routine care (with real patients) that met the 
inclusion/exclusion criteria listed above were selected. No randomised controlled trials 
(RCTs), qualitative, vignette or case history studies were included as they were not 
representative of actual/observed routine practice. 
After the search strategy was performed (for each database and website listed), I 
reviewed the titles and abstracts of each study after exporting to Endnote (primary 
researcher); any studies that could be excluded at this point (based on the 
inclusion/exclusion criteria) were. I then read the full article of all remaining studies; only 
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studies that met the inclusion/exclusion criteria were included for critical appraisal and 
data extraction.  
Note: Studies were also included if the population included some participants that were 
not relevant to my review as long as the proportion was minimal (<25% of total 
population being analysed) or the outcomes were reported for a sub-group that met the 
inclusion/exclusion criteria listed above.
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Box 3.1.1. OVIDSP Medline search strategy performed on 30th January 2014. 
OVIDSP Medline Search Strategy (1946 to January week 3 2014); 
1. exp Primary Health Care/ 
2. exp General Practice/ 
3. exp Family Practice/ 
4. exp Group Practice/ 
5. primary care.mp. 
6. general practice.mp. 
7. group practice.mp. 
8. family practice.mp. 
9. exp Physicians, Family/ 
10. exp Physician-Patient Relations/ 
11. primary healthcare.mp. 
12. family physician*.mp. 
13. primary health care.mp. 
14. general practi*.mp. 
15. family practi*.mp. 
16. family doctor*.mp. 
17. or/1-16 
18. exp Urinary Tract Infections/ 
19. exp Bacteriuria/ 
20. exp Cystitis/ 
21. exp Cystitis, Interstitial/ 
22. exp Escherichia coli Infections/ 
23. exp Pyelonephritis/ 
24. bacteriuria.mp. 
25. (urinary adj2 infection*).tw. 
26. (Urinary Tract Infection* or UTI).mp. 
27. cystitis.tw. 
28. bladder infection*.mp. 
29. or/18-28 
30. (Albania or Andorra or Armenia or Austria or Azerbaijan or Belarus or Belgium or Bosnia & 
Herzegovina or Bulgaria or Croatia or Cyprus or Czech Republic or Denmark or Estonia or Finland or 
France or Georgia or Germany or Greece or Hungary or Iceland or Ireland or Italy or Kosovo or Latvia or 
Liechtenstein or Lithuania or Luxembourg or Macedonia or Malta or Moldova or Monaco or Montenegro or 
The Netherlands or Norway or Poland or Portugal or Romania or Russia or San Marino or Serbia or 
Slovakia or Slovenia or Spain or Sweden or Switzerland or Turkey or Ukraine or United Kingdom or 
Vatican City or Holland or Great Britain or Britain or England or Scotland or Wales or UK or welsh or 
scottish or irish).tw. 
31. 17 and 29 and 30 
32. "Pregnancy"/ 
33. pregnan*.mp. 
34. exp Catheters/ 
35. or/32-34 
36. 31 not 35 
37. limit 36 to english language 
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 Quality assessment  
The quality assessment was conducted using a checklist I developed to describe the 
individual study’s relevance to the review and a critical appraisal. The critical appraisal 
was based on recommendations and example checklists for observational studies from 
the following systematic review bodies: SysNet (The Cardiff University Systematic 
Review Network); TREND (Transparent Reporting of Evaluations with Nonrandomized 
Designs); CASP (Critical Appraisal Skills Program for cohort studies); and the Cochrane 
collaboration. As the studies included were not RCT’s the main focus of the quality 
assessment was to ensure each study met the inclusion/exclusion criteria of the review 
protocol and that any bias was explicit in the findings (see appendix 3.1.1 for the critical 
appraisal and data extraction form).  
Prior to undertaking the assessment, I discussed and worked through some of the 
studies with a second researcher (a research fellow based in the Institute of Primary 
Care and Public Health, Cardiff University) to finalise the assessment process and to 
ensure a high degree of agreement. A systematic review researcher and member of the 
Support Unit for Research Evidence, Cardiff University (SURE) reviewed my critical 
appraisal and data extraction forms (described in next section) prior to data synthesis. 
I quality assessed all included studies but due to time constraints the second researcher 
assessed 55% (6/11).  We discussed all studies reviewed by both assessors and any 
differences in opinion were resolved at that point. There was no need to gain consensus 
from a third party as all disagreements were resolved between the second researcher 
and myself. 
Data extraction 
Data extraction was performed on all included studies once the quality assessment was 
complete. I extracted the data on all the studies and 36% (4/11) were repeated by the 
second researcher blinded to my results. Comparisons between the duplicated studies 
were then discussed and any disagreements in the data extraction were resolved at this 
point. 
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The following information, where possible, was extracted from the review of each study 
(related to suspected uncomplicated UTI); 
 Design, setting, population, aims and conclusions; 
 Bias within and across studies (when synthesising and comparing data); 
 Key signs/symptoms of patients with suspected uncomplicated UTI; 
 If/what POCTs were used for diagnosing a UTI; 
 If urine samples were sent for microbiological diagnosis (microscopy/culture); 
 The proportion of patients prescribed antibiotics and choice of antibiotics 
prescribed (type, dose and duration if possible); 
 The antibiotic management; delayed prescribing or change in prescription; 
 Adherence to guidelines; 
 Any other information deemed relevant from the review in the management 
of uncomplicated UTI. 
Data synthesis 
As the review describes actual observed practice and does not include any 
RCT/comparison studies the data synthesis was based on textual narrative synthesis. 
Where possible the scope, differences and similarities were used to draw conclusions 
across the studies included in the review. However, due to potential heterogeneity 
between studies in terms of setting, recruitment process, patient characteristics and 
study design this was not always possible and the results should be interpreted with 
caution. I have discussed bias in the data synthesis across studies. Comparisons 
between the results from this review and the results of the observational data analysis 
from the POETIC study are included in the overall discussion (section 4). 
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Results 
Study Selection 
Figure 3.1.1 shows the flow diagram of the literature search. Of the 1540 articles 
retrieved with the systematic search in OVID MEDLINE and the additional databases 
and of 17 articles identified otherwise (all by either reviewing the reference lists of 
included studies or checking the past two years of specific relevant journals), 389 were 
removed as they were duplicates and 1151 were screened by title and abstract only. 
From the preliminary screen 1114 studies were excluded and 37 were included in a full 
article assessment.  25 of these 37 articles were excluded for the following reasons: not 
observing routine management (for example, epidemiology studies describing resistance 
patterns); inappropriate study design (qualitative, vignette, case reports or interventions 
studies); not specific to UTI and unable to extract UTI data; not in Europe; and one study 
was a poster abstract submitted to the European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID) and did not have enough information to include in the 
review. In total 12 articles were included in the final review and their study characteristics 
are detailed in Table 3.1.2. 
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Figure 3.1.1. PRISMA Flow Diagram illustrating literature search and article selection. 
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abstract submitted to ECCMID)  = 1 Studies included in final 
review 
(n = 12) 
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Study Characteristics 
Included in the final review were four studies from the UK (three from England and one 
from Wales); two from Spain; and one from each of the following; Ireland, Germany, 
Sweden, Italy, and Turkey. All were observational studies of routine management in 
primary care. The majority of studies involved GP reports at or just after the time of 
consultation (26, 28-30, 81-83), however, one study involved research students 
observing the consultations (84); one study collected data from a health database 
containing medical records (27); two studies had medical records reviewed by 
independent doctors (85) or members of the research team (86); one study had 
participants complete questionnaires (32)  and one study in addition to GPs completing 
case report forms (CRFs) had patients complete two week diaries (82). The number of 
primary health care centers/practices and GPs participating varied greatly from study to 
study; Nazareth I et al. (83) only had two practices with six participating GPs whereas 
André et al. (28) had up to 155 practices with approximately 600 physicians participating. 
Nazareth I et al. (83) also had the smallest sample size (n=54) compared to the Italian 
study by Galatti L et al (27) which included 13,223 patients. The term ‘uncomplicated 
UTI’ was often not used, instead studies used ‘lower’ or ‘acute’ UTI/cystitis. A description 
of the study populations are given in Table 3.1.2. Ten of the studies allowed the 
participating GPs to diagnose UTI without input from the research teams, although André 
M et al. (28) and Skerk V et al. (30) used pre-set diagnosis lists to categorize patients 
with various types of UTI. All studies captured data on whether an antibiotic was 
prescribed, additional information on antibiotic type, dose and duration data varied 
between studies as did the availability of data on consultation, signs and symptoms, use 
of diagnostics and adherence to guidelines (described further under data synthesis). 
Table 3.1.2 describes the study design, setting, population, aims and conclusions for 
each study included in the review. 
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Table 3.1.2. Overview of the 12 studies included in the systematic review evaluating routine management of UTI in European primary care settings. 
  
Author  Study Design Study Setting Study Population Study Aim Study Conclusion  
André M 
et al.(28) 
* 
Prospective study; pre-set 
diagnosis form for lower 
UTI/acute cystitis completed by 
GPs. 
155 and 140 primary 
care centres in 5 
counties in Sweden (to 
represent whole 
country) from 1 week 
period in November 
2000 and 2005 
respectively (~ 600 GPs).  
Patients with suspected lower 
UTI; women (88.6%) and men 
(11.4%). Results separated 
out for lower UTIs in women 
(≥15 years), n=1012. 
“To present some 
characteristics of patients 
diagnosed as having a UTI in 
primary care and to analyse 
the use of diagnostic tests 
and the treatment pattern.” 
“A change in antibiotic prescribing with 
improved adherence to national 
recommendations was observed. The current 
guidelines (from 1990) need to be updated 
and actively implemented in order to optimise 
treatment for UTIs.” 
Canbaz S 
et al. 
(84)* 
Cross-sectional study; 
standardised form completed by 
research students observing the 
consultation. 
8 rural health centres in 
Samsun, Turkey; 2 
month period June – 
July 1999. 
Patient with acute cystitis 
n=216; defined as otherwise 
healthy non-pregnant 
women, ≥12y, with a normal 
urinary tract (87). 
“To evaluate the diagnostic 
and therapeutic approach 
to UTIs by GPs working in 
rural health centres in 
Samsun, Turkey.” 
“Polypharmacy widespread in this region; GPs 
need to review their knowledge about 
diagnosis and treatment of UTIs. Up-to-date 
information on rational use of antibiotics 
needed to guide GPs.” 
Fahey T et 
al.(81)** 
Prospective cohort study; data 
collection sheets completed for 
patients with symptoms 
suggestive of UTI by GPs. 
29 GPs from 8 primary 
care practices in Bristol, 
UK from July – 
September 2000. 
135 non-pregnant women 
with suspected UTI; men and 
pregnant women excluded in 
some analyses, no mention of 
age range. 
“To examine actual clinical 
practice of GPs when 
managing UTI.” 
“Individual symptoms of UTI are inadequate 
to guide antibiotic treatment decisions. 
Current clinical practice results in a large 
proportion of patients receiving unnecessary 
antibiotic treatment.” 
Galatti L 
et 
al.(27)** 
Descriptive study using ‘Health 
Search Database’; an Italian 
general practice research 
database containing electronic 
medical records of all patients 
registered in the lists of 
participating physicians whose 
diagnosis could be classified as 
acute or recurrent cystitis. 
320 GPs from Northern, 
Central and Southern 
Italy from 1999-2002. 
Non-pregnant women >16 
≤50 years whose diagnosis 
could be classified as acute 
uncomplicated cystitis, 
n=13223. 
“To explore antibiotic 
prescribing pattern and 
patient-related variables 
associated with prescription 
for acute (and recurrent) 
cystitis.” 
“Data indicate considerable changes in 
treating acute and recurrent cystitis, with an 
evident rise in antibiotic use mostly related to 
fosfomycin trometamol. Prescriptive trend 
finds confirmation from the available 
evidence.” 
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Author  Study Design Study Setting Study Population Study Aim Study Conclusion  
Hummers
-Pradier E 
et al.(29)ᵻ 
Cross-sectional survey; 
short, structured form 
completed by GP at time 
of consultation. 
36 teaching general 
practices of the Dept. of 
General Practice, University 
of Gottingen, Germany from 
November 2000 – February 
2001. 
Adult female patients with 
suspected UTI, age range; 
median 53, interquartile range 
33 – 71. No other definitions 
given but some results 
separated for ‘uncomplicated 
UTI’. 
“To describe German GPs’ 
management of female patients 
with symptoms of UTI.” 
“Most patients with urinary symptoms 
were not treated according to current 
guidelines, and GPs diagnostic and 
therapeutic accuracy was low. Patients 
with uncomplicated UTI were often 
treated for longer than recommended 
and second choice antibiotics were 
prescribed to a large proportion of all 
patients.” 
Little P et 
al. (82)** 
Observational Study; 
CRFs completed by GPs 
at time of consultation 
and patient diaries  
completed by patients 
for up to 14 days after 
consultation. 
117 GPs/nurses from 67 
practices in Southern 
England, UK from January 
2002 to February 2005. 
Non-pregnant women (aged 18 
– 75) presenting with a 
suspected ‘uncomplicated UTI’. 
843 women recruited; 541 
completed diaries. 
“To assess the natural course and 
the important predictors of 
severe symptoms in UTI and the 
effect of antibiotics and antibiotic 
resistance.” 
“Most women with UTI have multiple 
symptoms that they rate as moderately 
bad or worse, half feel unwell and have 
considerable restriction in daily activities. 
Antibiotic resistance and not prescribing 
antibiotics associated with >50% increase 
in the duration of more severe symptoms 
in women with uncomplicated UTI.” 
Llor C et 
al.(26)* 
Cross-sectional study; 
GPs completed audit 
registry form. 
110 primary care physicians 
across Spain, recruiting first 
six consecutive patients 
over an 8 week period, from 
March to July 2009. 
Non-pregnant women >14 
years. Uncomplicated UTI; no 
previous history of interest, 
isolated episode and foreseen 
to be cured with the usual 
short-course empiric treatment 
(n=545). 
“To determine the diagnostic and 
therapeutic approaches 
undertaken by primary care 
practitioners for lower UTIs in 
women and to assess the 
adherence of GPs to evidence-
based guidelines.” 
“Poor adherence to guidelines with high 
number of inappropriate urine cultures 
and low utilization of first line 
antibiotics.” 
Martinez 
MA et 
al.(85)* 
Cross-sectional study; 
clinical records reviewed 
by independent doctors 
48hours after selected 
study days. 
10 emergency departments 
in public hospitals across 7 
autonomous regions in 
Spain (not referred from 
primary care centres) from 
March 2003 – March 2004. 
Women ≥14 years, diagnosed 
with acute community acquired 
UTI with a structurally and 
functionally normal urinary 
tract (n=1411). Sub-analyses for 
lower uncomplicated UTI in 
non-pregnant women. 
“To assess the appropriateness of 
antibiotic prescription for UTI in 
several hospital emergency 
services and to evaluate the 
variability of antibiotic 
prescription among these.” 
“Physicians at Spanish emergency rooms 
prescribed an excessive number of 
second-choice antibiotics for UTI. There 
exists a high variability in antibiotic 
prescription among hospitals from 
different regions.” 
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*1 reviewer;** 2 reviewers; ᵻ 2 reviewers for critical appraisal, 1 reviewer for data extraction. 
Author  Study Design Study Setting Study Population Study Aim Study Conclusion  
Nazareth I 
et 
al.(83)** 
Observational study; GPs 
completed a study specific 
questionnaire after each 
consultation. 
2 primary care practices 
with 6 GPs from 
suburban London, UK 
over a 3 month period 
(no dates given).  
Non-pregnant women, 16 -
45 years with symptoms of 
frequency or dysuria 
(n=54). 
“To identify those factors in 
the management of lower 
urinary symptoms in women 
that assisted GPs in making a 
diagnosis and influenced the 
prescription of antibiotics.” 
“GPs take no particular regard of physical, 
psychological or menstrual factors in making 
their assessments. They were most accurate 
in their prediction of the result of urine 
analysis and least likely to prescribe 
antibiotics when they had good general 
knowledge of the patient. Doctors tended to 
be more conservative in their management of 
older women and those they knew less well.” 
O’Brien K 
et al. (32) 
* 
Exploratory study (nested within 
larger study); participant 
questionnaires completed (self-
completed, via telephone or face 
to face with study researcher). 
9 general practices in SE 
Wales, patients 
recruited during last 
month of larger study, 
March 2004.  
Non-pregnant women 
>17years with suspected 
uncomplicated UTI 
(n=113). 
“To explore association 
between antibiotic prescribing 
and urine culture results when 
urine culture was performed in 
all symptomatic patients.” 
“Current strategies to target empirical 
antibiotic prescribing in clinically suspected, 
uncomplicated UTI require review.” 
Skerk V et 
al. (30)* 
Prospective study; Family 
physicians completed specially 
designed questionnaires at time 
of consultation with later 
updates. 
108 family medicine 
offices in 20 cities 
through-out Croatia 
from 1st October 2006 – 
30th November 2006. 
Patients with acute 
uncomplicated cystitis 
(non-pregnant women), 
age range from 10.2 – 99.4 
years. (2.8% <18 years), 
n=1479. 
“To investigate the 
epidemiology, aetiology, 
clinical presentation, 
complicating factors of UTIs 
treated by family physicians 
and present treatment choice 
for empirical antimicrobial 
therapy of UTI.” 
The authors conclude that the clinicians 
prescribe empirical antimicrobial therapy in 
accordance with national guidelines. 
However, only 15% patients with 
uncomplicated UTI prescribed first-line 
treatments and no information provided on 
the length or dose of treatment. 
Vellinga A 
et al. 
(86)* 
Prospective observational study; 
practices visited by study staff to 
collect demographic variables/ 
prescribing practices from 
patient charts from whom a 
urine sample was received in 
study laboratory. 
22 GP surgeries in 
Galway region, Ireland 
from 14th September to 
9th November 2009. 
Eligible patients presenting 
with suspected UTI 
(n=866). Pregnant women 
excluded but men included 
(77.9% women). Some 
analyses for 
‘uncomplicated UTI’. 
“To describe the current 
management of UTI in general 
practice including evaluation 
of appropriateness of 
antimicrobial treatment in 
relation to the laboratory 
results.” 
“The treatment of uncomplicated UTI was 
considered appropriate for 55% of the 
patients. There appears to be considerable 
scope to reduce the frequency and increase 
the quality of antimicrobial prescribing for 
patients with suspected UTI.” 
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Individual Study Bias 
Only five of the studies included practices in multiple geographic locations through-out 
their respective countries (26-28, 30, 85). The remaining seven studies had study sites 
within a single part of the country or specific town/city and therefore may not be 
representative of the whole country (29, 32, 81-84, 86). The majority of studies did not 
explain how the practices/physicians were selected. Galatti L et al. (27) selected patient 
records from GPs that had met a certain standard to participate and Vellinga  A et al. 
(86) selected 22 GP practices with high level use of routine laboratory culture (25 highest 
ranking practices of 72 in the area). O’Brien K et al. (32)  recruited nine practices; five 
were specifically chosen to balance prescribing rates, size and Townsend deprivation 
scores. For two studies the number of GPs/practices that agreed to participate was low; 
the study by Hummers Pradier E et al. (29) had 31% of eligible GPs participating; and 
Llor C et al. (26) had 62.5% of GPs who agreed to participate with no description of GPs 
who did not agree.  
As all studies included in this review were observational; there was no randomisation 
involved and selection bias when recruiting patients may be unavoidable to a certain 
extent. Some studies recruited a consecutive sample of patients over a specified time 
period (29, 81) or until a certain sample size was reached (26). Limited information was 
provided on patients that agreed to participate versus those that did not or if all patients 
seen by the GPs were asked to participate. Little P et al. (82) analysed their results for 
only the sub-group of patients that returned their diaries and as O’Brien K et al. (32) used 
patient based questionnaires only patients that responded could be included in the 
analyses. Vellinga et al. enrolled all patients presenting with suspected UTI who 
submitted a urine sample with an opt-out methodology (86). The selection criteria for 
patients with UTI in some studies was very broad (often to allow maximum recruitment) 
with sub-analyses performed for different types of UTI (27, 29, 30, 81, 84-86); other 
studies asked GPs to recruit patients they suspected of having uncomplicated UTI (with 
minimal guidance) (26, 32, 82, 83). André M et al. (28) and Skerk V et al. (30) had pre-
set study diagnosis lists that the recruiting GPs used to categorise patients with acute 
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cystitis/uncomplicated UTI which may not represent how the GP would routinely 
diagnose the patient. Five studies did not rely on the physicians themselves to record 
their management decisions; Galatti L et al (27), Martinez M et al. (85) and Vellinga A et 
al. (86) had independent reviewers go through medical records/charts to obtain the 
required information. O’Brien et al. (32) requested patients complete a questionnaire 
including some management decisions by the GP; this in itself could lead to recall bias. 
Canbaz et al. (48) had research students observe and document the GP/patient 
consultations. Galatti L et al. (27) and Martinez M et al. (85) designed studies in which 
neither the physicians nor patients were aware of being part of a study. The remaining 
studies may not be as representative of routine practice due to study requirements or 
changes in behaviour. As part of study procedures four of the studies (29, 32, 82, 86) 
requested urine samples to be collected from all patients for laboratory culture; this may 
have changed GP behaviour in waiting for culture results prior to antibiotic prescribing or 
changing prescription once culture results were available.  
There are three studies which have been included but should be highlighted due to some 
particularly different aspects of their study design. Martinez et al. (85) designed a study 
based in hospital emergency rooms not general practice; patients were diagnosed with 
community acquired acute UTI, had not been seen prior to the visit to the emergency 
room and the GPs/residents that work in these units are not specialist and have a very 
similar profile to physicians who work in primary care clinics. The study by Nazareth et 
al. (83) was a particularly small study with only two practices; six GPs and 54 patients 
and was the earliest study included in the review (published in 1993). The study by 
Vellinga et al. (86) was more focused on appropriate prescribing with regard to 
microbiologically confirmed infection and as such the definition of ‘uncomplicated UTI’ 
was not explicit although this description was used in the conclusion. Men were included 
in the analyses but as they made up less than a quarter of the study population I decided 
to include this study in the review.  
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Key Findings from Individual Studies 
The study by André M et al. (28) found 74% of all consultations for UTI were diagnosed 
as lower UTI with one or more diagnostic tests carried out for 98% women and 95% were 
prescribed antibiotics.  
The study by Canbaz S et al. (84) found 58% patients diagnosed with acute cystitis and 
of these 98.6% were prescribed antibiotics; 74% prescriptions were consistent with 
current Turkish recommendations. 
The Bristol, England based study (Fahey T et al.) found 87% women diagnosed with UTI 
were treated empirically with antibiotics and that GPs were far more likely to treat 
empirically patients with symptoms of dysuria and frequency or dysuria alone and were 
far less likely to perform diagnostic tests in patients with dysuria and frequency (81). 
The study by Galatti L et al. (27) found 77% of patients with uncomplicated UTIs were 
prescribed at least one antibiotic with no regional variation. Antibiotic prescribing 
decreased from 81% to 66% with the use of diagnostic tests. However, antibiotic 
prescribing increased over four year period from 59% in 1999 to 86% in 2002. In 1999, 
of the antibiotics prescribed, norfloxacin was the most common (40%) which reduced to 
11% in 2002. In 2002 fosfomycin trometamol was the most common antibiotic prescribed 
at 34% (from 5% 1999). 
The study based in Gottingen, Germany (Hummers-Pradier E et al.) reported that GPs 
diagnosed UTI in 64% adult females and prescribed antibiotics to 56%. Dipsticks were 
performed in 92% of all cases; a positive nitrite test, dysuria and older age were the only 
predictive factors of culture-confirmed UTI, although the negative predictive value of 
dipsticks was low (29). 
The second English study by Little P et al. (82) found 93% of women diagnosed with 
uncomplicated UTI were prescribed an antibiotic, and trimethoprim was the most 
common antibiotic prescribed (>75%). Among women in whom no microbiological UTI 
was confirmed there was a similar pattern of severity of symptoms to those with 
confirmed infections. 
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The first of two studies set in Spain (Llor C et al.) found the most frequent symptom in 
women with uncomplicated UTI to be dysuria (82%) followed by frequency (71%) and 
suprapubic pain (33%). Dipstick tests were performed for 84% women and laboratory 
cultures for 33%. In total 96% women with uncomplicated UTI were prescribed antibiotics 
and 18% of these women were prescribed first choice empiric antibiotic treatment (26). 
The second Spanish study by Martinez MA et al. (based in hospital emergency 
departments) found almost all prescriptions were empirical (97% for uncomplicated UTI). 
Ciprofloxacin was the most commonly prescribed antibiotic (33%) followed by co-
amoxiclav (28%). In total 51% were prescribed first choice antibiotics for lower 
uncomplicated UTI (fosfomycin, ciprofloxacin, ofloxacin, norfloxacin); 37% were 
prescribed an alternative choice (co-amoxiclav, cefuroxime); and 11% prescriptions were 
inappropriate (the category of antibiotic choice was based on expert opinion developed 
within the study) (85). 
The final English study by Nazareth I et al. (83) found 69% women were prescribed 
antibiotics; equal proportions of women with positive and negative culture results 
received antibiotics, indicating over diagnosis by doctors for the group with negative 
results. When GPs did not know the patient they were four and a half times more likely 
to assume a clinically important infection. When they knew the patient well they were 
four times more likely to make a correct prediction of the test result and 12 times less 
likely to prescribe antibiotics. GPs were also six times more likely to prescribe antibiotics 
for older women (although the age range for recruitment onto this study was limited to16-
45 years). 
The fourth UK study based in South East Wales (O’Brien K et al.) found antibiotics were 
prescribed empirically in 61% cases of women with uncomplicated UTI. Of those 
prescribed empirical antibiotics 40% were subsequently found to have a positive urine 
culture. Overall 32% women had a positive culture; 75% had been prescribed an 
antibiotic where as 25% had not. Of the 68% women who had a negative culture result, 
55% had been prescribed an antibiotic (32). 
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The study by Skerk V et al. (30) based in Croatia, reported 62% UTI patients were 
diagnosed with uncomplicated UTI, this occurred in all age groups but more frequently 
in women aged over 40 years. 92% patients (all types UTI) were prescribed antibiotics; 
66% empirically and 34% targeted (based on culture). In total 21.3% of uncomplicated 
UTIs were microbiologically confirmed by culture. 
The final study included in the review, based in Galway Ireland (Vellinga A et al.) reported 
that 56% of UTI patients were prescribed antibiotics; co-amoxiclav 33.1%; trimethoprim 
26%; fluoroquinolones 17%; and nitrofurantoin nearly 12%. 37% of all prescriptions were 
in accordance with recommended first line treatment of nitrofurantoin or trimethoprim. 
The treatment for uncomplicated UTI was considered (microbiologically) appropriate for 
55% of the patients. General practices showed preferences for certain antibiotics and 
prescribing differed considerably between practices; the proportion of patients receiving 
an antibiotic varied from 39% to 78% between practices and this was most apparent for 
the fluoroquinolones, which was the prescription of first choice in some practices (86).  
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Synthesis of results 
Table 3.1.3 contains data from the 12 studies included in the review and their reported 
patient UTI signs/symptoms, routine use of diagnostics and antibiotic prescribing. 
Because of the variation in participant recruitment methods which may lead to bias 
between source populations in  I have only included studies that recruited patients by 
GPs at the time of consultation; studies by Galatti et al., Martinez et al., O’Brien et al., 
and Vellinga et al. have been excluded from the synthesis of results. 
Signs and Symptoms 
Four of the studies report days with symptoms/time to consultation; the majority of 
patients consult within 10 days and on average experience around three days of 
symptoms prior to consultation. Two of the studies were in England (81, 82), one in 
Sweden (28) and one in Spain (26); there are no obvious differences between countries. 
Frequency and dysuria were reported by six studies. In the three English and one 
German study frequency was the most common symptom; although the German study 
reported a much lower level of prevalence (55% compared to ≥79%). In the Spanish and 
Turkish studies dysuria was the most common symptom reported (82% and 88% 
respectively).  
Use of Diagnostic Tests 
Data on the use of diagnostic test was limited however, four different diagnostic tests 
were mentioned; laboratory culture was reported in four studies (I have not included 
studies where culture was a mandatory study procedure); dipstick urinalysis in four 
studies; sediment microscopy in two studies and a C-reactive protein (CRP) in one study. 
Laboratory culture ranged from 0% in Turkey to 64% in Bristol, England (81). Where 
reported, dipstick urinalysis was performed in 44% of consultations in Bristol, England 
(81); up to 92% in Germany (29). 
Antibiotic Prescribing 
Prescribing rates could not be compared between studies as this would require the 
studies to evaluate antibiotic prescribing over a given period of time in a set population 
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and ideally at the same time. However, prescription of antibiotics was reported in every 
study included in the review to some extent which may provide some comparisons 
between countries. The German study (29, 86) reported the least antibiotic prescribing 
at 56% and highest was reported in the Turkish study at 99% (84). The German study 
was also the study with the lowest reported signs and symptoms and the higher 
prescribing studies the higher prevalence of reported signs and symptoms.  
Seven of the studies described the most common antibiotics prescribed. Two of the 
English studies (81, 82) and the Swedish study (28) most commonly prescribed 
trimethoprim (first-line antibiotic).  The studies in Germany (29) and Turkey (84) found 
cotrimoxazole (first-line antibiotic in Turkey although Germany recommends 
trimethoprim or nitrofurantoin) to be the most common antibiotic prescribed. The Spanish 
study (26) reported fosfomycin (first-line antibiotic) as the most common antibiotic 
prescribed and in the Croatian study it was cephalexin (first-line antibiotic) (30). 
Five of the studies report dose/duration of antibiotic treatment. The study in Bristol, 
England (81) reported that overall 44% of prescriptions were for three days; 21% were 
for five days and 21% were for seven days. The German study (29) reported a median 
duration of antibiotic treatment of five days for all ages of women and that 70% of young 
patients with uncomplicated UTI were treated for more than three days. The Swedish 
study (28) reported treatment duration of seven to ten days irrespective of antibiotic 
prescribed.   The Spanish study (26) reported (for uncomplicated UTI) short-course 
treatments were prescribed in 67% cases and long-course treatments in 33% cases. 
However fosfomycin trometamol (3g OD single-dose) was one of the recommended first-
line treatments for uncomplicated UTI in Spain and only 19% were reportedly single dose 
where as 81% prescribed for two days. The Turkish study (84) reported faults in dosage 
interval in 19% cases; faults in duration in 24% cases; faults in dosage 10% cases; and 
overall irrational prescribing in 53% cases. 
None of the studies reported delayed prescribing.  
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Adherence to Guidelines 
Adherence to guidelines was not described by every study and there were mixed 
outcomes on those that did report this outcome. The German, Spanish and Turkish (26, 
29, 84) based studies acknowledged poor adherence to their respective guidelines in 
terms of prescribing and additionally for the Spanish study inappropriate urine cultures 
being performed (26). 
The Swedish (28) study reported improved adherence to guidelines and/or available 
evidence. The Croatian study (30) concluded that GPs were following prescribing 
guidelines, however, I would disagree as they also report only 15% patients with 
uncomplicated UTI were prescribed first-line treatment. 
Both the Swedish study and the Turkish study recommend updated guidelines with active 
implementation to improve management of UTIs (28, 84).  
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Table 3.1.3. Data synthesis across all studies included in the systematic review including details on signs and symptoms, diagnostics and prescribing 
(the studies highlighted in red are excluded from the synthesis of results due to substantially different study design and recruitment processes). 
Country 
(Reference) 
England 
(81) 
England 
(82) 
England 
(83) 
Wales 
(32) 
Ireland 
(86) 
Germany 
(29) 
Sweden 
(28) 
Italy 
(27) 
Spain 
(26) 
Spain 
(85) 
Croatia 
(30) 
Turkey 
(84) 
Signs and Symptoms 
Days with 
symptoms 
34%≤1d 
(IQR 1-5d) 
Median 3d 
(IQR 3-7) 
    58% ≤3d 
84%≤7d 
 Mean 3.4 
±6.8d 
   
Uncomplicated 
UTI/all UTIs 
      74% 39.2% 82.8% 37.1% 62% 58.2% 
Dysuria 73% 64%3 79.6%   52%   81.9%   88.4% 
Nocturia 28% 57%3          54.6% 
Frequency/ 
polyuria 
79% 78%3 85.2%   55%   70.5%   40.3% 
Urgency 53% 63%3 13%   55%       
Suprabubic pain      14%   33.1%   48.6% 
Blood in urine 15% 16%3 13%   17%      9.7% 
Loin pain 30%  24.1%         31.5% 
Fever   1.9%         9.3% 
Diagnostics 
Dipstick Overall 44%     92%   83.7%    
Dipstick - Nitrite       76%      
Dipstick – 
Leucocyte 
      88%      
Laboratory 
Culture 
64%      16% 26% 32.8% 18.6%4  0% 
Other      44% 
SM 
10% 
CRP 
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9% SM 
 
Country 
(Reference) 
England 
(81) 
England 
(82) 
England 
(83) 
Wales 
(32) 
Ireland 
(86) 
Germany 
(29) 
Sweden 
(28) 
Italy 
(27) 
Spain 
(26) 
Spain 
(85) 
Croatia 
(30) 
Turkey 
(84) 
Prescribing 
Antibiotics 
prescribed (%) 
87% 93% 68.5% 61% 56% 56% 96% 79.1% 95.6% 96.8% 69.5%4 98.6% 
Trimethoprim 60%1 >75%   26% 13% 40% 6.6%2     
Cotrimoxazole      46%    2.3%  47.5% 
Nitrofurantoin     12% 2% 4%  0.3%  15%  
Fosfomycin        33.8% 52.7% 15.9%   
Co-amoxiclav     33.1%    15.3% 27.8% 1.6%  
Amoxicillin             
Cephalosporins      2% 3%  1.1% 4.5% 79.6%  
(Fluoro-) 
/Quinolones 
    17% 33% 18% 11.1%2 24.4% 46.2%  26.3% 
Pivmecillinam       33%      
Other      4% 2%  6.2% 3.3% 3.8% 10.3% 
Guideline recommendations (as reported in the study specific publications) 
First-line 
antibiotics 
    Trimethoprim
nitrofurantoi
n  
Trimethopri
m, 
nitrofurantoi
n 
Pivmecillinam
trimethoprim
nitrofurantoi
n, 
cephadoxil/c
ephalexin 
 Fosfomycin, 
nitrofurantoi
n 
 Nitrofurantoi
n 7d 
(alternative: 
co-amoxiclav 
7d 
cephalexin 7d 
norfloxacin 
3d) 
Trimethoprim
/sulfamethox
azole, 
quinolones 
1 - includes two pregnant women and 13 men; 2 -  data from 2002; 3 - symptoms grade moderately bad or worse by patient; 4 - all UTI;  - indicated but not quantified;  
CRP – C Reactive Protein; SM -  Sediment Microscopy.
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Risk of bias across studies 
I have tried to limit bias caused by study design and variation in recruitment/enrolment 
strategies by excluding studies that did not use data from patients recruited at the time 
of consultation from the synthesis of results. However, the remaining studies will have 
differences in study design and therefore bias with regard to source populations but this 
is unavoidable and why descriptive analysis has been used for this review. 
The earliest study by Nazareth I et al. (83) was published in April 1993. However, the 
authors did not specify when the study actually took place but presumably it was 1992 
or earlier. The remaining studies took place from 1999 (81) to 2009 (26, 86) covering a 
10 year period; this may cause some bias when comparing studies as antibiotic 
resistance patterns may have changed and guidelines may be updated and training of 
GPs change as new research is published.  
Although all studies are observational studies the aims and objectives of the various 
studies are different and I have tried to extrapolate data relevant to the aims and 
objectives of this review. This has resulted in limited data from some studies and to 
particular aspects of the management of uncomplicated UTI.  
The definition of ‘uncomplicated UTI’ is not universally agreed and varies from country 
to country and study to study. All but one of the studies included only females; as already 
mentioned Vellinga et al. (86) also included men but this study was not included in the 
synthesis of results. Age ranges also vary between studies; one study describes only 
‘adult women’ (81) while the others specify varying age ranges, for example, Nazareth 
et al. 16 to 45 years (83) and Skerk et al. 10 to 99 years (30). All studies excluded 
pregnant women and some studies mentioned exclusion criteria such as indwelling 
catheters and co-morbidities such as diabetes. When I originally ran the systematic 
search with one definition of uncomplicated UTI and strict inclusion/exclusion criteria I 
was limited to only three studies (27, 82, 83). Therefore I included studies with broader 
definitions of (uncomplicated/acute/lower) UTI/cystitis on the basis that the patients 
consult in primary care and the prevalence of patients <16 years, male, with co-
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morbidities or indwelling catheters (if not explicitly excluded) are minimal and the data 
still reflects daily practice within their respective studies/settings.  
Different studies used different reporting measures, for example for signs and symptoms  
Little P et al. (82) recorded prevalence of symptoms graded moderately bad or worse 
whereas the other studies reported prevalence of presence of symptoms without grading 
severity (26, 29, 81, 83, 84). I have not looked at management decisions based on fixed 
effects such as symptom severity, prior prescribing and age group. 
Finally, different countries have different drug licences, different guidelines and different 
proportion of antibiotic resistance and therefore comparisons need to be considered with 
these factors in mind.  
 
Main Findings 
A total of 1540 articles were found using the search strategy and 37 full text articles were 
reviewed. Twelve studies met the inclusion criteria but only 8 studies were included in 
the synthesis of results. 
Using the defined search criteria there are limited published studies evaluating the 
routine management of uncomplicated UTI in primary care in Europe. Within the 
published studies definitions of uncomplicated UTI vary and heterogeneity between 
study populations is apparent. 
The only outcome reported by all studies was the proportion of antibiotic prescribing at 
the time of consultation; this was lowest in the German study and highest in the Turkish 
study (29, 84, 86). The German study (as part of the study design) had laboratory culture 
of urine samples for all the patients recruited; this may have resulted in the GPs delaying 
prescribing until the culture results were available and therefore having an overall lower 
level of empirical prescribing (although delayed prescribing was not reported). 
Conversely, the Turkish study reported that no urine laboratory cultures were requested 
by the GPs in their study (84).  
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For most of the studies that reported the type of antibiotic prescribed the most common 
was the first-line recommendation for their respective countries. The UK (based on HPA 
guidelines (25)) Sweden, Germany and Ireland all recommend trimethoprim or 
nitrofurantoin (and Croatia – nitrofurantoin only) as first-line antibiotic treatments, 
however, there was still a wide range of antibiotics prescribed (second choice and 
irrational) both within studies and across studies. Nitrofurantoin was particularly less 
commonly prescribed even though it was a recommended first or second choice 
antibiotic for the majority of countries included in the review (unable to confirm for Italy 
or Turkey).   Prescription of broad –spectrum fluoroquinolones was also frequently 
reported in England, Ireland, Germany, Sweden, Italy, Spain and Turkey.  Five of the 
studies reported antibiotic prescribing of increased duration and/or dose from the 
relevant recommendations. The data collected on the use of diagnostic tests was limited; 
in the studies that did report their use reduction in antibiotic prescribing was not apparent.  
 
Limitations 
Two major limitations in interpreting these results is the heterogeneity of the study 
populations across studies by the way in which patients were recruited and the limited 
availability of reported data that are relevant to my aims and objectives.  
The aim of this review was to determine variation in management between countries but 
caution in interpreting the results needs to be made with regard to bias of source 
populations and it’s representativeness of the countries’ population as a whole. 
Due to time and funding constraints my search was limited to English language only and 
I did not search the grey literature including unpublished studies. Limiting the search to 
English only may have restricted the number of studies included in the review particularly 
as Europe is such a multi-lingual continent. I do not feel publication bias would be a 
significant factor in my review as I only included observational studies of routine practice 
and as such ‘negative findings’ are implausible.  
Robust systematic reviews should involve the participation of two or more reviewers for 
identifying relevant studies, critically appraising studies and extracting data. This review 
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was limited to two reviewers for a proportion of the critical appraisal and data extraction 
which may have limited findings or caused bias in the outcomes. 
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Chapter 2: Observational study – Presentation and 
management of patients with uncomplicated UTI in 
four European countries (POETIC Phase 2) 
 
Introduction: R-GNOSIS and the POETIC study 
R-GNOSIS (Resistance in Gram-Negative Organisms: Studying Intervention Strategies) 
funded by the EU Seventh Framework Programme (FP7), combines five international 
clinical intervention studies to determine - in the most relevant patient populations - the 
efficacy and effectiveness  of interventions to reduce acquisition, carriage, infection and 
spread of Multi-Drug Resistant Gram-negative Bacteria (MDR-GNB). All information will 
be integrated by into innovative models to better understand and predict future trends 
and effects of interventions. 
The POETIC (Point of Care Testing for Urinary Tract Infection in Primary Care) study is 
the only primary care work package within the R-GNOSIS study. POETIC is an 
evaluation of a novel Point of Care Test (FlexicultTM SSI-Urinary Kit) guided urinary tract 
infection (UTI) management strategy for use in adult women presenting in primary care 
with suspected uncomplicated UTI. The Point of Care Test (POCT) will provide clinicians, 
at the point of care, within 24 hours, with a diagnosis of bacterial UTI and antibiotic 
resistance profiles of any identified pathogen to the antibiotics most commonly used for 
UTI in primary care. The study will determine whether or not this information aids 
clinicians to more appropriately prescribe antibiotics for uncomplicated UTI’s (i.e. avoid 
the use of antibiotics for women where no bacterial infection is identified, and where a 
bacterial infection is identified, to ensure the narrowest spectrum antibiotic is prescribed 
appropriate to the sensitivity of the infecting organisms). The study is being carried out 
in 4 European countries: Wales, England, Netherlands and Spain, and is divided into 
four phases: 1) pilot study; 2) observational study; 3) randomised controlled trial; and 4) 
implementation study. My research focuses on the second phase, the observational 
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study, the purpose of which is to assess the variation in current management that could 
be changed (and potentially improved) by utilising a new POCT.  
Hypothesis 
There is variation in the management of patients with uncomplicated UTI in primary care 
in different countries including Wales, England, Spain and the Netherlands. The variation 
in management is not due to patient demographic or presenting sign or symptoms. 
 
Aim 
To evaluate whether the patients’ resident country, age, history of UTI, symptom severity, 
days off work, days with symptoms, dipstick urinalysis testing, urine appearance and oral 
temperature are associated with different management decisions (including the use of a 
diagnostic POCT, requesting a urine culture, antibiotic prescribing and follow-up 
recommendations).  
 
Objectives 
 To describe the patient demographics and signs and symptoms (attributable to 
UTI) at presentation in primary care, and the clinical management decisions for 
patients included in the POETIC Observational study of uncomplicated UTI in the 
four participating countries; 
 To examine the individual (patient) level factors associated with differences in 
patient management using multilevel statistical modelling. 
 
Methods  
Declaration 
The study methods were developed and executed by the POETIC study team (of which 
I am part) and networks following the POETIC Observational study protocol. I have been 
involved in the POETIC study from its set-up; attended the meetings, provided comments 
on study design and helped to develop the data collection tools including case report 
forms (CRF) and patient diaries, contributed to clinical site training and the development 
 125  
of the study website. The brief outline of the study methods below are for the readers’ 
information and are taken from the study protocol. 
The data analysis, statistics and interpretation included in this section are solely my own 
and undertaken with the approval of the POETIC study team. 
Study Design and Population 
The POETIC study was conducted in four study networks based in Southampton 
(England), Cardiff (Wales), Madrid/Catalonia (Spain) and Utrecht (the Netherlands). The 
study networks were selected on the basis of having well-established primary care 
research networks and may represent different European cultures and healthcare 
systems. Each network aimed to recruit in the region of 10 general practices. Each 
practice aimed to recruit 20 patients (total 800 participants). 
POETIC phase 2 is an observational cohort study where clinicians registered sequential 
patients presenting with uncomplicated UTI symptoms. Participating clinicians and 
nurses identified eligible patients during routine general practice consultations. The 
participating clinician assessed eligibility, provided potential participants with a verbal 
description of the study, and if interested, provided a comprehensive participant 
information leaflet (PIL). Participants provided written informed consent prior to 
participation. Once a patient was consented, clinicians recorded information about their 
usual care diagnostic procedures, treatment and urine sampling on a study case report 
form (CRF).  Information on the patients’ clinical course was gathered through use of a 
symptom diary completed by the patients daily over a two week period. 
Inclusion criteria 
Female adult patients age 16 years and above presenting to primary care with at least 
one of three key urinary tract symptoms (dysuria, urgency including nocturia, and 
frequency) and where the clinician suspected uncomplicated UTI. Patients participating 
in the study must have been able to provide written informed consent.  
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Exclusion criteria 
Women with one or more of the following were not eligible for inclusion: 
 Terminally ill 
 Currently receiving treatment for life-threatening cancer (e.g. basal cell 
carcinoma) 
 Other severe systemic symptoms 
 On long-term antibiotic treatment or have received antibiotics for urinary tract 
infection within the past four weeks 
 History of bladder surgery (including cystoscopy) within the past four weeks 
 Known or likely to have significant immune compromise (i.e. known 
immunodeficiency state, on long-term corticosteroid or chemotherapy treatment, 
insulin dependent diabetes) 
 Known functional or anatomical abnormalities of the genitourinary tract 
 History of pyelonephritis 
 Known pregnancy 
Ethical Approval 
This study protocol was approved by the Research Ethics Committee (REC) recognised 
by the United Kingdom Ethics Committee Authority (UKECA) and relevant European 
Committees in the Netherlands and Spain.  
Study Sample Size 
The original sample size, calculated by the POETIC study statistician, was based around 
the precision of describing the proportion of population women presenting in primary care 
with suspected uncomplicated UTI that are prescribed antibiotics. A desired level of 
precision was such that a 95% confidence interval around an estimate of 50% is 45.0% 
to 55.0%; 50.0% was chosen as this gave the most conservative estimate (higher or 
lower percentages will have produced narrower confidence intervals). This required 385 
participants before taking clustering (at the practice level) into account. Data on 800 
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participants was the aim, with approximately 200 in each network, with 10 practices per 
network and an average cluster (practice) size of 20 participants. From this, the relevant 
design effect is 2.082 so the maximum potential level of clustering accounted for is 
described by an intra-cluster correlation coefficient of ρ= 0.0570, or 5.70% (88). No 
additions were made to this sample size for potential dropout as data on prescribing 
antibiotics are collected at the initial baseline visit immediately after recruitment. 
Data Collection 
Case Report Forms (CRF) 
From November 2012 through to October 2013 (for the Utrecht network this was 
extended until January 2014) participating clinicians were asked to register sequential 
patients with UTI symptoms, recording details of patient demographics and presenting 
symptoms, diagnostic procedures employed (i.e. dipstick testing) and treatment onto 
POETIC designed CRFs (appendix 3.2.2).  
Follow-up 
Patients were followed up using a two-week diary covering symptoms and medication 
use (appendix 3.2.3). If the patient diaries were not received by the study centre within 
an acceptable timeframe (within a month of the due date), participants were contacted 
by members of the study team to request the return of the diaries. 
Missing data 
All missing data were marked as -9 and considered as missing completely at random. 
No imputations were used for my analysis. 
Data cleaning and outliers 
Data cleaning was performed by the study’s data management team prior to my data 
analysis. This process was completed through the database. Common items that were 
looked for in the data set were: 
 Missing values 
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 Range checks 
 Inconsistencies (e.g. do values cross check appropriately) 
 Protocol violations (e.g. study visit outside acceptable range)  
Once data cleaning was complete the data set was locked prior to the data and statistical 
analysis performed by myself.  
If during my data analysis I found any additional outliers or unusual results these were 
discussed with the Chief Investigator and clinical Co-Investigators and any changes or 
exclusions indicated.  
Guidelines  
For each network, guidelines were developed by the POETIC study team clinicians 
based on country relevant guidelines for the management of women with suspected 
uncomplicated UTI. These were provided to all network participating practices during the 
study. The network specific guidelines are included the appendices (3.2.4 – 3.2.6).  
Laboratory data 
For sites in Wales and England, urine samples were sent to the Specialist Antimicrobial 
Chemotherapy Unit (SACU), Public Health Wales Microbiology Cardiff, at University 
Hospital of Wales. In The Netherlands, samples were sent to the Department of Medical 
Microbiology of the Universitair Medisch Centrum Utrecht. In Spain, the samples were 
sent to the Microbiological Departments of the Hospitals Ramón y Cajal (Madrid), Joan 
XXIII (Tarragona), and Bon Pastor (Barcelona). All laboratories were provided with a 
POETIC microbiology manual and standard operating procedures. 
A urine (required for participation) sample was collected from participants on day 1 (day 
of recruitment). Participants were provided with written instructions on how to collect the 
urine samples. In the UK urine samples were collected using a mid-stream urine 
collection kit (Peezy MSU collection kit) to ensure a clean catch. Urine samples were 
transferred to a container containing boric acid for transport to the research laboratory, 
to arrive at the laboratory within 24 hours for identification and testing of antibiotic 
resistance.  
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Urine microscopy was performed using standard local procedures. Culture was 
performed on neat and diluted urine (10-3, 10-6) spiral-plated onto Columbia blood agar 
(CBA) (for total colony counts) and UTI Chromogenic agar (for species specific counts). 
Enumeration of bacteria was performed 18-24 hours following incubation at 35-37oC.  
Bacterial counts were summarised into purity of growth (pure, predominant, mixed 2 
organisms & >2 mixed organisms).  
Pure or predominant organisms from positive urines were identified initially with 
chromogenic agar and confirmed using MALDI-ToF or other suitable laboratory methods. 
The definition of a UTI is defined for the POETIC trial as ≥105 colony forming units per 
millilitre (cfu/ml) of a pure/predominant recognised uropathogen, 
Susceptibility testing of positive isolates was performed following regional research 
laboratory procedures.  
Data was recorded onto a standardised Microsoft excel spreadsheet provided to each 
laboratory. 
Data Analysis 
Software 
The data was managed, and descriptive analysis performed using IBM SPSS Statistics 
20. Multi-level logistic modelling was performed using software package MLwiN 2.30. 
Descriptive Analysis 
The descriptive outcomes I investigated included; 
 Network characteristics (CRF) 
 Patient Characteristics (CRF and diary) 
 Presence and severity of (clinician reported) signs and symptoms (CRF) 
 Use of diagnostic tests and other medical tests (i.e. if urine had an offensive 
smell, if urine was visibly turbid) (CRF) 
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 Antibiotic prescribing; yes/no, type, duration delayed prescribing, secondary 
prescriptions, concordance with relevant clinical guidelines (including antibiotic 
type, dose and duration) (CRF) 
 Prescribing and advising paracetamol and ibuprofen (CRF) 
 Further clinical advice, follow-up recommendations and routine consultation type 
(CRF) 
The prevalence (numbers and percent), range, means, medians, standard deviations 
and inter-quartile ranges were described as appropriate for each outcome. The 
outcomes were described for the total study population and by network.  
Grouping and Recoding Variables 
Some variables were grouped or recoded for further analysis.  
The 11 symptoms included; burning when passing urine; urgency; daytime frequency; 
night time frequency; fever; pain in the side; blood in the urine; smelly urine; tummy pain; 
restricted activities and feeling unwell. The seven point symptom severity grading score; 
0 = Normal/not affected 
 
1 = Very little problem 
 
2 = Slight problem 
 
3 = Moderately bad 
 
4 = Bad 
 
5 = Very bad 
 
6 = As bad as it could be 
 
The symptoms were recoded into present or absent; any symptom with severity score 
graded 1 – 6 was recoded as present and any symptom with a severity of 0 (equates to 
normal) recoded as normal. Burning when passing urine, urgency, daytime frequency 
and night-time frequency were also dichotomised into low and high symptom severity 
based on the histogram distribution (night time frequency scores 0-1= low and 2-6 = high; 
and for the remaining 3 symptoms 0-2 = low and 3-6 = high). The total symptom severity 
score was estimated for each patient by calculating the mean severity score of the 11 
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symptoms and scaled out of 100 so that it could be interpreted as a percentage of 
maximum symptom severity. 
To investigate the prevalence of clinicians requesting urine for routine culture I added up 
the additional ‘other’ culture tests (including ‘MSU’ mid-stream urine, ‘MCS’ microscopy, 
culture and sensitivity, and ‘culture and susceptibility’ free text in the ‘other tests’ question 
5 of the CRF) and urine dip-slides (as performed routinely in the Netherlands). If the data 
in the routine culture question of the CRF (question 6) was classed as missing, these 
were added to the total number to indicate at least one routine urine culture requested. 
Oral temperature was grouped into low (<36.0°C); normal (≥36.0°C and ≤37.2°C); and 
high (>37.2°C); to look at the distribution of patients with or without fever. Fever is usually 
described as >38°C (17, 25) but as the measurement of temperature was not controlled 
(different methods may have been used at different sites) I decided to allow for a more 
generous cut-off for fever.  
I based my analysis of the dipstick urinalysis results on the recommended urinalysis rules 
from the guidelines developed for each network, the rules included were; 
 Positive nitrite (≥+); UK, Spain and the Netherlands guidelines suggest probable 
UTI 
 Positive leucocyte (≥+); UK and Spain guidelines suggest equal probability UTI 
as other diagnosis 
 Leucocyte(≥+), nitrite (≥+) and blood (trace) positive; UK, Spain and the 
Netherlands guidelines suggest probable UTI  
 Leucocyte and blood positive; The Netherlands guidelines suggest performing a 
dip-slide/sediment test for confirmation of UTI 
 Leucocyte, nitrite and blood negative; UK, Spain and the Netherlands guidelines 
suggest UTI unlikely 
 Leucocyte and nitrite negative; UK and Spain guidelines suggest UTI unlikely 
 
To determine if an antibiotic was prescribed I coded the missing data as ‘no antibiotic 
prescribed’. Clinicians were asked to record details of all antibiotics prescribed; if they 
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did not indicate anything about prescribing I have assumed that this meant no antibiotic 
was prescribed (the CRF did not include a specific data collection question for this). 
If an antibiotic had been prescribed I analysed the concordance of the prescription with 
the relevant network guidelines for first-line treatment for women with suspected 
uncomplicated UTI. This included the total dose and duration as well as antibiotic type. 
For the analysis the dose and times per day were multiplied with the duration to give the 
overall dose for each patient; this was done to avoid classing prescriptions as discordant 
if for example trimethoprim was prescribed as 50mg 4 times per day (QDS) for 3 days 
instead of 200mg twice per day (BD) for 3 days. This was then compared to the antibiotic 
type prescribed and the combination of the two compared to the networks guidelines. 
The recommended first-line antibiotic treatments (for women with uncomplicated UTI) for 
each network are as follows: 
Cardiff and Southampton: 
Trimethoprim 200mg BD 3 days; total dose 1200mg. 
Nitrofurantoin 100mg BD 3 days; total dose 600mg. 
Madrid/Catalonia: 
Fosfomycin 3g OD 1 day; total dose 3g. 
Nitrofurantoin 50mg QDS 7 days; total dose 1400mg. 
Utrecht: 
Nitrofurantoin 100mg BD or 50mg QDS 5 days; total dose 1000mg. 
 
When categorising ‘any other advice’ I collated all the free-text advice and coded them 
into themes. For example, for the category ‘increase fluid uptake’ the free-text themes 
included (but not limited to): ‘drink more’;’ fluids ++’; ‘push fluids’; ‘plenty of water’. For 
the category ‘return/contact on worsening symptoms’ the free-text themes included (but 
not limited to); ‘to re-contact if pyrexial/blood in urine/abdo pain’; ‘to come again if not 
settling’; ‘see again if no better’; ‘advised to contact surgery if concerned’; ‘out of hours 
if necessary over the weekend’.  
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Factor analysis  
Factor analysis of the 11 symptom variables was performed in SPSS to determine if 
there were any unobserved variables that could reduce the data into fewer number of 
factors. Participants with at least 1 missing symptoms score were removed from the 
analysis. I used the maximum likelihood extraction method with Eigenvalues >1 and 
oblimin rotation method with Kaiser normalisation. For any resulting factors the total 
symptom severity score was estimated for each patient by calculating the mean severity 
score of the symptoms included in each factor and scaled out of 100 so that it could be 
interpreted as a percentage of maximum symptom severity. These factored total 
symptom scores were included as variables in the multilevel model procedures.  
Intra-Class Correlation (ICC) 
To explore the importance of the two level sampling (patients within practices) the intra-
class correlation (also known as intracluster correlation) has been calculated. This 
estimated the proportion of variability on the outcome attributable to the practice level 
sampling rather than the patient level sampling. The ICC is calculated by dividing the 
between-practice variance by the sum of the within- (between individuals) and between 
practice variances. The ICC has a value between 0 and 1; a higher ICC indicates more 
clustering and most of the variation in the outcome is due to practice-related factors over 
patient differences (89).   
Multilevel Modelling 
If the ICC shows a high level of clustering then the practice level variation will need to be 
accounted for (by partitioning random effects) using multilevel modelling in the analysis. 
I have used a two level random intercept model to include patients as the first (individual 
level with fixed effects) and practice as the second (group level with random effects) 
level. 
As the response variables (described below) are binary, logistic regression analysis was 
used. This involves taking the loge of the odds (iterative generalised least squares) and 
then applying a linear model to the transformed data (using quasi-likelihood methods); 
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the software package is programmed to do this. One and two level logit models were 
used to fit the univariate and multivariate data in the MLWiN 2.30 software package. 
University of Bristol Centre for Multilevel Modelling provided guidance on using this 
software and fitting the models(90). 
Dependent/Response Variables 
I performed three analyses that linked with this PhD: the use of routine culture in general 
practice; adherence to appropriate guidelines  which included prescribing recommended 
first-line antibiotic treatment for suspected uncomplicated UTI in terms of antibiotic type 
only; and antibiotic type with recommended duration and total dose.  
To investigate routine culture in practice I considered any patient with a ‘yes’ indicated 
for the questions: 
 ‘Would you under normal practice, send a sample for culture for this patient?’ 
(CRF question 6) or; 
  if ‘Dip-slide’, ‘MSU’, ‘MCS’ or  ‘culture and susceptibility’ was written in the ‘other 
tests’ question (CRF question 5) ; as a yes answer. 
If ‘no’ had been written; 
 in question 6 and question 5 did not have any of the comments described above 
then the answer was considered to be ‘no’.  
If data was missing; 
 from both questions or; 
  just question 6 and question 5 did not have any of the comments above; this 
was excluded from the multilevel analysis. 
 
To investigate adherence to guidelines when prescribing first-choice antibiotic for 
suspected uncomplicated UTI I only included patients who had been prescribed an 
antibiotic. The adherence to guidelines was analysed in the same way as the descriptive 
data described in the ‘grouping and recoding variables’ section above.  I did not take into 
account other factors that may affect adherence to guidelines such as if the patient 
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should have been prescribed an antibiotic at all (with regard to signs, symptoms and 
dipstick/dip-slide results or the use of second or third-choice antibiotics).  
Explanatory Variables and Univariate Analysis 
I firstly explored the patient demographic, signs and symptom severity scores and 
management choices available from the study data collected as single explanatory 
variables in univariate (two level) logistic regression models. Patient demographics 
included: network (country); patient age; days with symptoms (≤28 days); months since 
last UTI; times treated for UTI in the past. All 11 symptoms were included: burning when 
passing urine; urgency; daytime frequency; night time frequency; fever; pain in the side; 
blood in the urine; smelly urine; tummy pain; restricted activities and feeling unwell. For 
all symptoms I entered the variables as binary; absence (grade 0) or presence (grade 1 
-6).  If, from the descriptive data, the symptom also had a normal distribution (over the 
grading scores) I checked for linearity against the two response variables using logistic 
regression. If there was linearity the symptoms were entered as continuous variables; if 
not the symptoms were entered as categorised/multinomial variables (0 – 6). The total 
symptom severity score (out of 100) was also included as an explanatory variable. 
Of the management variables: oral temperature (both continuous and categorised into 
low, normal and high); under normal circumstances requesting a urine sample for routine 
culture and/or the use of dip-slides (for adherence to prescribing guidelines response 
variable only); cloudy urine; smelly urine; and antibiotic choice categorised into no 
antibiotic, trimethoprim, nitrofurantoin, fosfomycin or other (for routine culture response 
variable only) were included. The six dipstick rules described in the previous ‘grouping 
and recoding variables’ section were also analysed, these were all categorised into 
positive (or yes), negative (or no) and not done (if at least one of the dipstick tests in the 
rule was missing). 
All multinomial variables need to have a reference variable chosen to which all other 
variables were compared in the analysis. My general rule when choosing the reference 
was the variable most distinct from the other variables: Utrecht for network; 0 times 
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treated for UTI in the past; 0 for symptom severity; normal for temperature; yes/positive 
for the dipstick rules.  
Incorporated into the final two-level multivariate model were the explanatory variables 
that showed significance at 10% level. This 10% threshold was chosen to allow more 
variables to be included in the final model than usual (when using a more standard 5% 
significance threshold) and to avoid excluding variables that may change in significance 
once fitted into the multivariate model.  
Multivariate Multilevel Model 
Firstly a null (empty) 1 level (patient level only) logit model was fitted with the response 
variable and no explanatory variables. This was estimated using MQL1 (1st order 
marginal quasi-likelihood), estimation methods are discussed briefly in the next section. 
From this the second level was added (practice level) to produce a two level null model, 
firstly estimated using MQL1 then PQL2 (2nd order predictive quasi-likelihood). From this 
binary 2-level logit PQL2 estimated model the explanatory variables were added (only 
variables showing significance at the 10% threshold in the univariate analysis) to produce 
the final model. If variables were closely related (for example the dipstick rules) they 
were added to the model separately and only the most significant variable remained in 
the final model. This was to avoid collinearity which could cause erratic changes in the 
model due to the highly correlated nature of the explanatory variables. 
Estimation procedures  
Various methods in multilevel modelling can be used to produce the outcome estimates. 
First order Marginal Quasi-Likelihood (MQL 1) estimation is deemed to be the crudest 
method. Estimates may be biased, especially if sample sizes within higher level units 
(practices in this case) are small. Second order PQL is considered to be the best 
approximation, but convergence problems may be encountered. For this reason and as 
recommended by the programmers of MLwiN, first order MQL estimates were run initially 
to obtain starting values of second order PQL estimates(90). 
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A measure that can be used to determine the most appropriate model is the Deviance 
Information Criterion (DIC); this is used to determine the best fit for non-linear models 
such as binary logit models. This requires the model to be estimated using Markov chain 
Monte Carlo (MCMC) estimation rather than Quasi-likelihood estimation procedures. 
When comparing the DIC obtained from the MCMC estimation of the null 2 level model 
to the final 2-level model (with explanatory variables) the DIC should have reduced to 
show a better fit (90). 
Alongside these estimates, standard errors (SE), odds ratios (OR) with associated 95% 
confidence intervals and p-values (calculated using chi-square methods) are also 
presented. 
Measure of Variation 
To quantify the amount of variation at each level the Variance Partitioning Coefficient 
(VPC) was calculated. In a two level model the VPC for level two (practice in this case) 
is the between practice variation divided by the sum of the between and within practice 
variation. The value can be interpreted as a percentage; the higher the VPC the more 
variance attributable to the second level (practice) which indicates a higher level of 
clustering. Logistic models do not include an individual error component (within practice 
variation/level 1 variance); the Linear Threshold Model is recommended which uses the 
variance of a standard logistic distribution /3 = 3.29 as the within practice variation 
(level 1 variance) and I also used this method (90).  
Median odds ratios were calculated to translate area level variance into odds ratio scale 
which is directly comparable to individual odds ratios. The calculation used was; 
MOR = exp[√(2 x VA) x 0.6745] 
.         ≈ exp (0.95√VA) 
VA is the area level variance and 0.6745 is the 75th centile of the cumulative distribution 
function of the normal distribution with mean 0 and variance 1. If MOR is equal to 1 there 
would be no difference between areas (91). 
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Laboratory data analysis 
The prevalence of microbiologically confirmed UTI and associated antibiotic resistance 
was determined for each network and overall. 
Associations between GP reported visual turbidity, urinalysis dipsticks and requesting 
urines for routine culture (including dip-slides) and microbiologically proven UTI were 
investigated. 
 
 
Results  
Descriptive Analysis 
Network and Patient Characteristics 
A total of 795 women were recruited onto the POETIC observational study. This was 
reasonably equally distributed between three of the networks with Cardiff, Southampton 
and Madrid/Catalonia recruiting a total of 212, 245 and 205 respectively, and Utrecht 
recruiting a total of 133 patients. There were 49 participating general practices across 
the networks and the number of patients recruited per practice ranged from 2 to 45 with 
an average of 16.2 (Table 3.2.1). 
Participants ranged from 16 to 91 years of age with a mean age of 45.7 years. The 
number of days with symptoms prior to consulting ranged from 0 to 325 (325 most likely 
a data error); after discussion with the trial management team and clinicians any record 
with >28 days symptoms is most likely not considered an acute uncomplicated UTI so 
were excluded from further analysis. The majority of women did not take any time off 
work although slightly more women took at least one day off in Southampton with 21.3% 
compared to 13.3% in total.  
 
 
Table 3.2.1. Network Characteristics 
Country Site(s) Patients 
Practices (min - 
max, mean number 
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patients per 
practice) 
 
Wales 
 
Cardiff 2121 (26.7) 11 (5 – 45, 19.2) 
 
England 
 
Southampton 2451 (30.8) 11 (9 – 33, 22.2) 
Spain 
Madrid 
 
205 (25.8) 17 (2 – 28, 12.1) 
Catalonia 
 
The Netherlands 
 
Utrecht 133 (16.7) 10 (5 – 28, 13.3) 
 
Total 
 
795 (100) 49 (2 – 45, 16.2) 
1 – 1 missing baseline CRF  
 
Proportion of diaries returned ranged from 61.8% in Cardiff to 78.9% in Utrecht with a 
total of 567/795 (71.3%) diaries returned. Overall 81.7% women recorded they had a UTI 
in the past and 27.7% of women indicated they had been treated for a UTI at least three 
times in the past year; this varied across countries with 16.1% in Utrecht to 39.6% in 
Madrid/Catalonia. The median number of months since last UTI was the same for each 
country at four months, and in total 93.2% women recorded they had been prescribed 
an antibiotic for their last UTI. As this was recorded in the patient diaries women that did 
not know or did not complete this question were not included in the calculation reducing 
the sample size to n=398 (Table 3.2.2). 
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Table 3.2.2. Patient Characteristics. 
 
Cardiff 
(n=212) 
Southampton 
(n=245) 
Madrid/ 
Catalonia 
(n=205) 
Utrecht (n=133) 
Total 
(n=795) 
Mean Age 
(SD)1 
42.1 
(17.52) 
48.0 
(18.51) 
45.88 
(19.17) 
45.68 
(18.44) 
45.68 
(18.44) 
Range of Days 
with symptoms2 
1 - 90 1 - 45 0 - 60 0 – 325* 0 – 325* 
Median Days with 
symptoms (IQR)3 
3 
(2, 6) 
4 
(2, 6) 
2 
(1, 5) 
4 
(3, 7) 
3 
(2, 6) 
1 or more days off 
work 
12/126 
(9.5%) 
29/136 
(21.3%) 
13/85 
(15.3%) 
3/80 
(3.8%) 
57/370 
(13.3%) 
Diaries Returned 
131/212 
(61.8%) 
177/245 
(72.2%) 
154/205 
(75.1%) 
105/133 
(78.9%) 
567/795 
(71.3%) 
History of UTI 
104/129 
(80.6%) 
153/176 
(86.9%) 
114/153 
(74.5%) 
88/104 
(84.6%) 
459/562 
(81.7%) 
Times 
Treated 
for UTI in 
past year4 
0 
38/99  
(38.4%) 
42/143  
(29.4%) 
22/111 
(19.8%) 
38/87  
(43.7%) 
140/440 
(31.8%) 
1 
15/99  
(15.2%) 
34/143  
(23.8%) 
22/111 
(19.8%) 
21/87 
 (24.1%) 
92/440  
(20.9%) 
2 
24/99  
(24.2%) 
25/143  
(17.5%) 
23/111 
(20.7%) 
14/87 
 (16.1%) 
86/440  
(19.5%) 
≥3 
22/99  
(22.2%) 
42/143  
(29.4%) 
44/111 
(39.6%) 
14/87  
(16.1%) 
122/440 
(27.7%) 
Median Months 
since last UTI (IQR) 
4 
(3, 6.25) 
4 
(2, 6.75) 
4 
(2, 8) 
4 
(2, 6) 
4 
(2, 7) 
Patients 
Prescribed 
antibiotic 
treatment for 
last UTI4 
84/95 
(88.4%) 
131/139 
(94.2%) 
101/106 
(95.3%) 
55/58 
(94.8%) 
371/398 
(93.2%) 
1 - total age range 16-91 years; 2 -  clinician reported; 3 - >28 days excluded; 4 - don’t know or missing 
results excluded; *likely data error
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Clinician Reported Signs and Symptoms 
UTI symptoms of daytime frequency and urgency were present in over 90% of the 
women recruited into the study and the median severity score for both these symptoms 
was 4 (bad). Burning when passing urine and night-time frequency were symptoms also 
present in the majority of women; 85.3% and 80.7% respectively with overall median 
severity scores of 3 (moderately bad). 
Symptoms of tummy pain, feeling unwell, smelly urine and restricted activities were 
present overall (with median symptoms severity scores) in 64% (2; slight problem), 
63.8% (1; very little problem), 58.8% (1) and 48.6% (0; normal) women respectively. 
Symptoms of pain in the side, blood in the urine and fever had median severity scores 
of 0 across all networks and were present in a total of 41.5%, 28.0% and 21.2% women 
respectively. The majority of symptoms had some variation across the four networks with 
fever having the widest variation with only 5.5% women in Utrecht reporting presence to 
the clinicians compared to 38.9% women in Southampton as shown in table 3.2.3. 
The total symptom severity score is calculated from the mean severity scores of the 11 
symptoms for each patient and then scaled to range between 0 – 100. The box and 
whisker plot in Figure 3.2.1 shows the median and inter-quartile ranges (IQR) of the total 
symptom severity scores for the four networks. 
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Table 3.2.3. Presence* of Clinician Reported Symptoms 
 
Cardiff  
(n=211) 
Southampton  
(n=244) 
Madrid/Catalonia 
(n=205) 
Utrecht  
(n=133) 
Total  
(n=793) 
n % 
M
e
d
ia
n
 
G
ra
d
e 
n % 
M
e
d
ia
n
 
G
ra
d
e 
n % 
M
e
d
ia
n
 
G
ra
d
e 
n % 
M
e
d
ia
n
 
G
ra
d
e 
n % 
M
e
d
ia
n
 
G
ra
d
e 
Fever 46/198 23.2 0 93/239 38.9 0 17/205 8.3 0 7/127 5.5 0 163/769 21.2 0 
Pain in the Side 91/203 44.8 0 118/239 49.4 0 63/205 30.7 0 51/131 38.9 0 323/778 41.5 0 
Blood in the Urine 61/202 30.2 0 71/238 29.8 0 63/205 30.7 0 22/131 16.8 0 217/776 28.0 0 
Smelly Urine 126/203 62.1 2 150/239 62.8 1 106/205 51.7 1 75/130 57.7 2 457/777 58.8 1 
Burning when 
passing urine 
167/204 81.9 4 196/239 82.0 3 192/205 93.7 3 111/133 83.5 3 666/781 85.3 3 
Urgency 181/204 88.7 4 226/239 94.6 4 183/205 89.3 3 115/133 86.5 3 705/781 90.3 4 
Daytime Frequency 187/203 92.1 4 235/239 98.3 4 189/205 92.2 3 123/133 92.5 4 734/780 94.1 4 
Night-time 
Frequency 
168/202 83.2 3 205/239 85.8 3 155/205 75.6 2 100/132 75.8 3 628/778 80.7 3 
Tummy Pain 122/204 59.8 2 171/239 71.5 2 114/205 55.6 1 91/130 70.0 2 498/778 64.0 2 
Restricted Activities 107/202 53.0 1 120/239 50.2 1 69/205 33.7 0 82/132 62.1 1 378/778 48.6 0 
Unwell 130/203 64.0 2 153/239 64.0 1 148/204 72.5 2 66/133 49.6 0 497/779 63.8 1 
*present = very little problem (1) to as bad as it could (6); absent = normal/not affected (0)
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The overall range for the symptom severity score was 4.55 to 78.99 with an overall mean 
of 32.7 (standard deviation 14.47). Madrid/Catalonia had the lowest median total 
symptom severity score and IQR (28.03; 19.7 – 36.4) and Cardiff had the highest (34.8; 
22.7 – 50.0). 
 
Figure 3.2.1. Total symptoms severity scores across the four networks (scaled out of 
100). 
 
 
Factor analysis of symptom severity scores 
I decided to only accept factors that have an eigenvalue greater than 1, after extraction 
has taken place. This would therefore imply that only the first factor has a group of 
symptoms that cluster together strongly enough (Table 3.2.4). The scree plot (Figure 
3.2.2) shows a steep drop between factor 1 and factor 2, and confirms that only factor 
one will be used for further analysis. Table 3.2.5 summarises the initial three factors with 
Eigenvalues >1. 
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Table 3.2.4. Total Variance Explained. 
Factor 
Initial Eigenvalues 
Extraction Sums of Squared 
Loadings 
Rotation Sums 
of Squared 
Loadingsa 
Total 
% of 
Variance 
Cumulative 
% 
Total 
% of 
Variance 
Cumulative 
% 
Total 
1 3.296 29.959 29.959 2.726 24.779 24.779 2.350 
2 1.476 13.421 43.380 .920 8.363 33.142 1.938 
3 1.018 9.252 52.632 .328 2.985 36.128 1.288 
4 .943 8.570 61.202     
5 .816 7.420 68.622     
6 .796 7.237 75.859     
7 .697 6.337 82.196     
8 .614 5.580 87.776     
9 .540 4.908 92.684     
10 .455 4.135 96.819     
11 .350 3.181 100.000     
Extraction Method: Maximum Likelihood. 
a. When factors are correlated, sums of squared loadings cannot be added to obtain a total variance. 
 
Figure 3.2.2. Scree plot of factors. 
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Table 3.2.5. Summary of Factor Analysis 
 
Pattern matrix 
Factor 1 - accepted Factor 2 - rejected Factor 3 - rejected 
S6. Urgency S9. Tummy pain S5. Burning 
S7. Day time frequency S11. Unwell  
S8. Night time frequency   
 
The overall range for the factor 1 symptom severity score was 0.00 to 100.00 with an 
overall mean of 52.89 (standard deviation 23.35). Madrid/Catalonia had the lowest 
median total symptom severity score and IQR for factor 1 (44.4; 27.8 – 61.1) and Cardiff 
had the highest (61.1; 38.9 – 79.2) (figure 3.2.3). 
 
Figure 3.2.3. Total symptom severity scores for factor 1 (urgency, daytime frequency 
and night time frequency) across the four networks (scaled out of 100). 
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Patient Management: Diagnostic and other Tests 
Dipsticks were the most commonly used test across all networks; the use was highest in 
Utrecht with 95.5% and lowest in Madrid/Catalonia at 68.8%, Cardiff and Southampton 
vary from 81.3% to 94.7% respectively. Of the urines checked for turbidity and smell a 
total of 42.5% were turbid and 29.8% had an offensive smell. There was some variation 
across the networks as shown in Table 3.2.6 with Madrid/Catalonia having the lowest 
proportion of urines with turbidity and smell. Overall 47.7% patients would under normal 
practice have had a routine culture requested. Cardiff and Southampton have the highest 
culture requests at about 61% for both networks, Madrid/Catalonia was 38.7% and 
Utrecht had the lowest culture requests at 16.5%. However, Utrecht are the only network 
in this study to perform dip-slides at the point of care; 37.6% patients had a dip-slide 
performed indicating 44% of the patients would have had at least one routine culture 
under normal circumstances (either dip-slide or routine laboratory culture). 
The majority of women had a normal recorded temperature (84.2% with a temperature 
from 36°C to 37.2°C) and this was similar across the networks; a total of 6.8% women 
had an elevated temperature (>37.2°C) which could indicate fever, this was lowest in 
Madrid/Catalonia 1.5% and highest in Southampton 9.6%. 
Regarding the individual dipstick urinalysis tests, nitrite was most commonly recorded 
for Madrid/Catalonia and Utrecht and leucocytes for Cardiff and Southampton networks, 
although the differences were minimal. Blood urinalysis results were less likely to be 
recorded across all networks (Table 2.2.5).  Positive leucocytes (≥+) were the most 
common result with a total of 80.7% (61.2% in Utrecht and 81.2% to 89.2% in the other 
3 networks); nitrite positive (≥+) was indicated in 35% cases; lowest in Cardiff 25% and 
highest in Utrecht 46.5%. Of the other dipstick rules investigated; 51.5% had positive 
leucocyte and blood; 18.4% had positive leucocyte, nitrite and blood; 16.4% had negative 
leucocyte and nitrite; and 11.9% had negative leucocyte, nitrite and blood urinalysis 
results. The results for these dipstick rules varies across the networks as shown in Table 
3.2.7 and I do not know how these urinalysis results were used by the clinicians or nurses 
reading them. 
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Table 3.2.6. Use of diagnostic and other tests in the four networks. 
 
Cardiff  
(n=211) 
Southampton  
(n=244) 
Madrid/Catalonia 
(n=205) 
Utrecht 
(n=133) 
Total  
(n=793) 
n % n % n % n % n % 
Dipstick Used 170/209 81.3 231/244 94.7 141/205 68.8 127/133 95.5 669/791 84.6 
Urine Cloudy 88/170 51.8 96/225 42.7 42/141 29.8 56/127 44.1 282/663 42.5 
Urine Smelly 50/170 29.4 80/225 35.6 28/141 19.9 40/128 31.3 198/664 29.8 
Laboratory Culture 
routinely sent 
121/201 60.2 135/219 61.6 79/204 38.7 20/121 16.5 355/745 47.7 
Dip-slides 0 0 0 0 0 0 50/133 37.6   
Other culture 
indicated
1
 
32/211 15.2 2/244 0.8 0 0 0 0   
At least 1 culture
2
 122/202 60.4 135/219 61.6 79/204 38.7 55/125 44.0 391/750 52.1 
Other Tests 
1 Blood Glucose; 1 
pregnancy  
1 Chlamydia None 
6 Sediment; 5 Microscopy; 2 
Nitrate 
 
Oral 
Temperature 
(L,N,H)
3
 
L 19/204 9.3 10/239 4.2 33/205 16.1 8/122 6.6 70/770 9.1 
N 170/204 83.3 206/239 86.2 169/205 82.4 103/122 84.4 648/770 84.2 
H 15/204 7.4 23/239 9.6 3/205 1.5 11/122 9.0 52/770 6.8 
1 – recorded as ‘MSU’, ‘MCS’, ‘culture and susceptibility’ in ‘other tests’ section of CRF; 2 – calculated by adding additional ‘other’ culture tests and dip-slides to routine culture, if 
results were classed as ‘missing’ in original routine culture calculation (i.e. not included) these were added to total number; 
 3 – Oral Temperature: L: Low (<36.0°C), N: Normal (≥36°C and ≤37.2°C), H: High (> 37.2°C) 
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Table 3.2.7. Dipstick Urinalysis Results. 
 
Cardiff (n=170) Southampton (n=231) 
Madrid/Catalonia 
(n=141) 
Utrecht 
 (n=127) 
Total (n=669) 
n % n % n % n % n % 
POSITIVE Nitrite1 38/152 25.0 81/226 35.8 48/141 34.0 59/127 46.5 226/646 35.0 
POSITIVE Leucocyte2 134/165 81.2 191/229 83.4 124/139 89.2 60/98 61.2 509/631 80.7 
Leucocyte, nitrite AND 
blood POSITIVE1 
16/109 14.7 27/184 14.7 22/101 21.8 20/69 29.0 85/463 18.4 
Leucocyte AND blood 
POSITIVE3 
68/114 59.6 87/186 46.8 59/101 58.4 26/69 37.7 240/470 51.1 
Leucocyte, nitrite AND 
blood NEGATIVE4 
15/109 13.8 20/184 10.9 4/101 4.0 16/69 23.2 55/463 11.9 
Leucocyte AND nitrite 
NEGATIVE5 
28/149 18.8 32/225 12.5 11/139 7.9 29/98 29.6 100/611 16.4 
1 – UK, Spain, The Netherlands guidelines suggest probable UTI;  
2 – UK and Spain guidelines suggest equal probability UTI as other diagnosis;  
3 - The Netherlands guidelines suggest perform dip-slide/sediment test for confirmation;  
4 - UK, Spain, The Netherlands guidelines suggest UTI unlikely;  
5 – UK and Spain guidelines suggest UTI unlikely. 
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Patient Management: Antibiotic Prescribing  
Participating clinicians in Cardiff, Southampton and Madrid/Catalonia prescribed 
antibiotics to over 90% of the patients in this study, whilst Utrecht clinicians prescribed 
to 59.4% of patients. The duration of the antibiotic course ranged from 1 to 28 days with 
Madrid/Catalonia having a median of 2 days (fosfomycin, a commonly used antibiotic in 
Spain is given as a single dose), Cardiff 3 days and Southampton and Utrecht 5 days as 
shown in Table 3.2.8. There was minimal delayed prescribing across the networks with 
Southampton having the highest delayed prescribing of 3.9% (9/232 patients). Additional 
antibiotics within the same consultation were prescribed to 5 patients; 3 in Cardiff and 2 
in Madrid/Catalonia. 
 
Table 3.2.8. Antibiotic prescribing across the networks. 
 
Cardiff 
(n=211) 
Southampton 
(n=244) 
Madrid/ 
Catalonia 
(n=205) 
Utrecht 
(n=133) 
Total  
(n=793) 
At least one 
antibiotic 
prescribed 
196/211 
(92.9%) 
232/244 
(95.1%) 
195/205 
(95.1%) 
79/133 
(59.4%) 
702/793 
(88.5%) 
Duration of 
Course 
(days)1 
3.0 
(2, 7) 
5.0 
(3, 28) 
2.0 
(1, 10) 
5.0 
(1, 28) 
3.0 
(1, 28) 
Delay 
advised 
2/196 
(1.0%) 
9/232 
(3.9%) 
1/195 
(0.5%) 
0/79 
(0%) 
12/702 
(1.7%) 
Additional 
antibiotic 
prescribed2 
3/211 
(1.4%) 
0/232 
(0%) 
2/205 
(1.0%) 
0/79 
(0%) 
5/793 
(0.6%) 
1 – Median (Min, Max); 2 – within same consultation 
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Figure 3.2.4 shows the antibiotics prescribed by network. Trimethoprim was the principal 
antibiotic prescribed by the Cardiff network in 76.5% cases followed by nitrofurantoin 
17.3% and minimal prescribing of amoxicillin (2%), cephalexin (1.5%), coamoxiclav (1%), 
ciprofloxacin (1%) and metronidazole (0.5%); in total 93.8% followed the recommended 
first-line treatment. Southampton prescribed trimethoprim and nitrofurantoin more 
equally at 46.1% and 48.7% respectively; other antibiotics prescribed by the 
Southampton network include amoxicillin (2.6%), cephalexin (2.2%) and coamoxiclav 
(0.4%); in total 94.8% followed the recommended first-line treatment. The 
Madrid/Catalonian network predominantly prescribed fosfomycin 75.4% followed by 
coamoxiclav (9.7%) and ciprofloxacin (9.2%) and minimal prescribing of nitrofurantoin 
(3.1%), cefuroxime (1%), amoxicillin (1%) and pipemidic acid (0.5%); in total 78.5% 
followed the recommended first-line treatment. In 79.7% cases the Utrecht network 
prescribed nitrofurantoin (recommended first-line treatment) followed by trimethoprim 
(11.4%), fosfomycin (6.3%), coamoxiclav (1.3%) and ciprofloxacin (1.3%).  
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Figure 3.2.4.Type of antibiotic prescribed per network. 
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Patient Management: Antibiotics prescribed following recommended type, 
dose and duration 
Due to the high levels of prescribing in three of the networks, I wanted to compare the 
prescribing of antibiotics including type, dose and duration to the networks relevant 
country guidelines for first-line choice antibiotic treatment for uncomplicated UTI. Cardiff 
and Utrecht followed their respective guidelines in 75.0% and 73.7% of the cases, whilst 
Southampton and Madrid/Catalonia demonstrated congruence with their guidelines in 
only 32.6% and 28.6% of cases (Table 3.2.9). 
 
Table 3.2.9. First-line antibiotic type, dose and duration prescribed as per relevant 
guidelines. 
 
Cardiff
1
 
(n = 211) 
Southampton
1
 
(n=244 
Madrid/ 
Catalonia
2
 
(n=205) 
Utrecht
3 
 (n=133) 
Total 
(n=793) 
n % n % n % n % n % 
YES 
147/19
6 
75.0 75/230 32.6 55/192 28.6 56/76 73.7 333/694 48.0 
NO 49/196 25.0 
155/23
0 
67.4 137/192 71.4 20/76 26.3 361/694 52.0 
1 – Trimethoprim 200mg BD 3 days; Nitrofurantoin 100mg BD 3 days 
2 – Fosfomycin 3g OD 1 day; Nitrofurantoin 50mg QDS 7 days 
3 – Nitrofurantoin 5 days; 100mg BD or 50mg QDS 
 
The main discordancy between the prescriptions and guidelines across the Cardiff and 
Southampton networks were due to the dose and duration of nitrofurantoin, as the 
Southampton network prescribed nitrofurantoin more frequently than the Cardiff network 
this was reflected in the lower level of overall concordance to guidelines. The 
trimethoprim prescriptions were generally in accordance with the guidelines although the 
Southampton network often prescribed for longer than the recommended 3 days (48.1% 
of all trimethoprim prescriptions).  In 21.9% of cases the Madrid/Catalonia network 
prescribed antibiotics other than the recommended fosfomycin or nitrofurantoin. The 
major discordance when prescribing fosfomyicn was the duration; the majority of 
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prescriptions were for 2 days (55.6%) rather than 1 (38.9%) of 3g dose.  The main reason 
for the Utrecht networks’ discordancy was antibiotic type other than the recommended 
nitrofurantoin (21.1%); further details are included in summary box 3.2.5. This may not 
be surprising as the Netherlands only recommend one type of antibiotic as first-line 
treatment. 
Figure 3.2.6 shows the distribution of concordant and discordant prescriptions by clinic 
in each network. Across all networks the majority of clinics/practices have a mix of 
concordant and discordant prescriptions; although Cardiff, Madrid/Catalonia and Utrecht 
have clinics (two per network) that are completely concordant and Southampton and 
Madrid/Catalonia have clinics that have not prescribed according to the guidelines for 
any of their patients (two and six clinics respectively).
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Figure 3.2.5. Summary box detailing antibiotic type, dose, times per day and duration 
prescribed per network and in accordance with the relevant guidelines. 
Cardiff 
12/196 (6.1%) prescribed Antibiotics other than Trimethoprim or Nitrofurantoin 
Trimethoprim (200mg BD 3 days) (n=150) 
DOSE (100% in-line): 150/150 200mg (correct) 
TIMES per day (98.7% in-line): 1/150 OD; 148/150 BD (correct); 1/150 TDS. 
DURATION (94.0% in-line): 141/150 3 days (correct); 2/150 5 days; 1/150 6 days; 6/150 7 days. 
Nitrofurantoin (100 mg BD 3 days) (n=34) 
DOSE (41.2% in-line): 20/34 50mg; 14/34 100mg (correct).  
TIMES per day (0% in-line*): 34/34 QDS. 
*% in-line increases if 50mg QDS (58.8% in-line) 
DURATION (41.2% in-line): 1/34 2 days; 14/34 3 days (correct); 2/34 5 days; 17/34 7 days. 
Southampton 
12/230 (5.2%) prescribed Antibiotics other than Trimethoprim or Nitrofurantoin 
Trimethoprim (200 mg BD 3 days) (n=106) 
DOSE (100% in-line): 106/106 200mg (correct) 
TIMES per day (98.1% in-line): 1/106 OD; 104/106 BD (correct); 1/106 TDS 
DURATION (51.9% in-line); 55/106 3 days (correct); 36/106 5 days; 13/106 7 days; 2/106 14 days.  
Nitrofurantoin (100 mg BD 3 days) (n=112) 
DOSE (24.1% in-line)*: 84/112 50mg; 27/112 100mg (correct); 1/112 200 mg 
TIMES per day (17.0% in-line)*: 19/112 BD (correct); 93/112 QDS. 
*% in-line increases if 50mg QDS or 100mg BD prescribed (~103/112 total; 92.0%) 
DURATION (20.5% in-line): 23/112 3 days (correct); 51/112 5 days; 36/112 7 days; 2/112 28 days 
Madrid/Catalonia 
42/192 (21.9%) prescribed antibiotics other than Fosfomycin or Nitrofurantoin 
Fosfomycin (3g OD 1 day) (n=144) 
DOSE (91.7% in-line): 1/144 400mg; 7/144 500mg; 4/144 2g; 132/144 3g (correct). 
TIMES per day: 136/144 OD; 1/144 BD; 7/144 TDS. 
DURATION (38.9% in-line): 56/144 1 day (correct); 80/144 2 days; 1/144 5 days; 7/144 8 days. 
Nitrofurantoin (50mg QDS 7 days) (n = 6) 
DOSE (100% in-line): 6/6 50 mg (correct) 
TIMES per day (100% in line): 6/6 QDS  
DURATION (0% in-line): 6/6 6 days 
Utrecht 
16/76 (21.1%) prescribed antibiotics other than Nitrofurantoin 
Nitrofurantoin (100mg BD 5 days OR 50mg QDS 5 days) (n = 60) 
DOSE (100% in-line): 19/60 50 mg (correct); 41/60 100mg (correct). 
TIMES per day (96.7% in-line): 40/60 BD (correct); 1/60 TDS; 18/60 QDS (correct); 1/60 10dd (possible data error; 
most likely 1OD). 
DURATION (95.0% in-line): 57/60 5 days (correct); 1/60 7 days; 1/60 28 days. 
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Figure 3.2.6. Antibiotic prescribing according to the relevant guidelines by country and 
participating clinics; A) Cardiff Clinics; B) Southampton Clinics; C) Madrid/Catalonia 
Clinics; D) Utrecht Clinics. 
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B) Southampton 
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Patient management: other treatments 
Only the Dutch guidelines mention the use of analgesics (if watchful waiting without 
antibiotics). Paracetamol was prescribed by the Madrid/Catalonia network in 20.5% of 
cases and advised by the Southampton network in 28.7% cases (Table 3.2.10). 
Additionally Ibuprofen was prescribed by the Madrid/Catalonia network (5.9%) and 
advised by the Southampton network (9.0%). The Utrecht network did not advise or 
prescribe either type of pain relief; the Cardiff network did but to a much lower level than 
Madrid/Catalonia and Southampton. 
 
Table 3.2.10. Paracetamol and Ibuprofen prescribed or advised. 
 
Cardiff 
(n=211) 
Southampton 
(n=244) 
Madrid/ 
Catalonia  
(n=205) 
Utrecht 
(n=133) 
Total  
(n=793) 
Paracetamol 
Prescribed 
1/211  
(0.5%) 
2/244  
(0.8%) 
42/205  
(20.5%) 
0/133  
(0%) 
45/793  
(5.7%) 
Paracetamol 
Advised1 
8/211  
(3.8%) 
70/244  
(28.7%) 
1/205  
(0.5%) 
0/133  
(0%) 
79/793  
(10%) 
Ibuprofen 
Prescribed 
0/211 
(0%) 
0/244 
(0%) 
12/205 
(5.9%) 
0/133 
(0%) 
12/793 
(1.5%) 
Ibuprofen 
Advised1 
2/211 
(1.0%) 
22/244 
(9.0%) 
1/205 
(0.5%) 
0/133 
(0%) 
25/793 
(3.2%) 
 
Patient management: advice and follow-up 
 
All networks advised patients to increase fluid intake; this ranged from 54.6% in 
Madrid/Catalonia to 77% in Southampton. The Cardiff network also advised to return or 
contact their GP on worsening symptoms (10.4%) and use cranberry products (7.6%). 
The Southampton network also advised to return or contact their GP on worsening 
symptoms (18.9%); use pain relief (8.8%); rest (7.8%) and use cranberry products 
(7.4%). The Madrid/Catalonia network did not report giving as much advice as the other 
networks and other than increasing fluid intake recommend passing urine when needed 
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and emptying the bladder fully (3.4%). Clinicians in the Utrecht network also recommend 
passing urine when needed and emptying the bladder fully (21.8%) and using cranberry 
products (12%).  
Other advice given by the networks is detailed in Table 3.2.11.
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Table 3.2.11. Clinician Advice. 
Baseline Clinical Advice (Free Text) 
Cardiff (n=211) 
Southampton 
(n=244) 
Madrid/Catalonia 
(n=205) 
Utrecht (n=133) 
Total 
(n=793) 
n % n % n % n % n % 
Fluids/ 
consumption 
Increase fluid intake 137 64.9 188 77.0 112 54.6 74 55.6 511 64.4 
Cranberry product recommendations 16 7.6 18 7.4 0 0 16 12.0 50 6.3 
Reduce caffeine intake 3 1.4 3 1.2 0 0 0 0 6 0.8 
Avoid citrus fruit 0 0 2 0.8 0 0 0 0 2 0.3 
Avoid alcohol during treatment 0 0 0 0 0 0 1 0.8 1 0.1 
Worsening 
symptoms 
Return/contact on worsening symptoms 22 10.4 46 18.9 0 0 5 3.8 73 9.2 
Advice given on worsening symptoms 4 1.9 13 5.3 0 0 0 0 17 2.1 
Over the 
counter (OTC) 
Medication/ 
Treatments 
Pain relief recommendations (paracetamol, 
analgesics, hot pad) 
1 0.5 20 8.2 0 0 3 2.3 24 3.0 
Cystitis powders and alkalising agents 3 1.4 9 3.7 0 0 0 0 12 1.5 
Take vitamin C 0 0 0 0 0 0 2 1.5 2 0.3 
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Table 3.2.11. Clinician Advice (continued). 
Baseline Clinical Advice (Free Text) 
Cardiff (n=211) 
Southampton 
(n=244) 
Madrid/Catalonia 
(n=205) 
Utrecht (n=133) 
Total 
(n=793) 
n % n % n % n % n % 
Hygiene and 
Sexual Health  
Pass urine when needed and empty bladder fully 0 0 12 4.9 7 3.4 29 21.8 48 6.1 
Pass urine before/after sex 1 0.5 4 1.6 0 0 7 5.3 12 1.5 
Use contraceptive precautions 2 0.9 0 0 0 0 0 0 2 0.3 
General hygiene advice 0 0 2 0.8 0 0 3 2.3 5 0.6 
Vulva tablet post sex 1 0.5 0 0.0 0 0 0 0 1 0.1 
Antibiotic 
Use 
Increase duration of antibiotic course if no 
resolution 
0 0 2 0.8 0 0 0 0 2 0.3 
Decrease duration of antibiotic course if symptoms 
resolved 
1 0.5 3 1.2 0 0 0 0 4 0.5 
Delay antibiotic prescription 1 0.5 1 0.4 0 0 0 0 2 0.3 
Complete antibiotic course 0 0 1 0.4 0 0 0 0 1 0.1 
Follow up with urine/culture results 7 3.3 3 1.2 0 0 2 1.5 12 1.5 
Other advice 
Rest 0 0 19 7.8 0 0 0 0 19 2.4 
Avoid perfumed bath products 0 0 1 0.4 0 0 0 0 1 0.1 
Use shower instead of bath 0 0 1 0.4 0 0 0 0 1 0.1 
Avoid swimming 0 0 1 0.4 0 0 0 0 1 0.1 
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Although the Madrid/Catalonia network did not report giving as much advice as the other 
networks they did arrange follow-up in 54.9% cases, more than any other network; the 
majority of patients (38.2%) were asked to follow-up with the GP/nurse in 8-14 days 
(Table 3.2.12). The Cardiff and Southampton networks only arranged follow-up in 18.7% 
and 12.4% cases respectively. Clinicians in Utrecht arranged follow-up in 34.6% cases; 
23.8% had ‘other’ follow up arranged which included contacting the clinic for dip-slide 
results (14 cases) and having a follow-up urine test once the antibiotic course had been 
completed (6 cases).  
The clinicians were also asked to indicate whether they would normally manage the case 
by phone; this was highest in the Southampton network at 64.5% followed by Utrecht at 
62.2%. Madrid/Catalonian clinicians would have usually managed 40.2% cases by 
phone and clinicians in Cardiff 30.8% cases by phone (Table 3.2.12). 
 
Table 3.2.12. Consultation and follow-up. 
 
Cardiff Southampton 
Madrid/ 
Catalonia 
Utrecht Overall 
n 
(%) 
n 
(%) 
n 
(%) 
n 
(%) 
n 
(%) 
Follow-Up 
arranged 
with GP or 
Nurse? 
None 
 
165/203 
(81.3) 
212/242 
(87.6) 
92/204 
(45.1) 
85/130 
(65.4) 
554/779 
(71.1) 
1-3 
days 
10/203 
(4.9) 
9/242 
(3.7) 
3/204 
(1.5) 
11/130 
(8.5) 
33/779 
(4.2) 
4-7 
days 
7/203 
(3.4) 
14/242 
(5.8) 
28/204 
(13.7) 
1/130 
(0.8) 
50/779 
(6.4) 
8-14 
days 
2/203 
(1.0) 
2/242 
(0.8) 
78/204 
(38.2) 
2/130 
(1.5) 
84/779 
(10.8) 
Other* 
 
19/203 
(9.4) 
5/242 
(2.1) 
3/204 
(1.5) 
31/130 
(23.8) 
58/779 
(7.4) 
Case usually 
managed by 
phone? (%) 
No 
 
139/201 
(69.2) 
83/234 
(35.5) 
122/204 
(59.8) 
48/127 
(37.8) 
392/766 
(51.2) 
Yes 
62/201 
(30.8) 
151/234 
(64.5) 
82/204 
(40.2) 
79/127 
(62.2) 
374/766 
(48.8) 
*Description of other follow-up recommendations included in appendix 3.2.7 
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Factors associated with routine culture  
Intra-Class Correlation (ICC) 
The ICC value for the response variable ‘requesting a urine sample for routine 
culture/dip-slide’ was calculated as 0.231 (23.1%). The ICC value for the response 
variable for ‘antibiotics prescribed (type only) according to relevant guidelines indicating 
first-line treatment for women with uncomplicated UTI’ was calculated as 0.161 (16.1%) 
and ‘antibiotics prescribed (type, total dose and duration) according to relevant 
guidelines indicating first-line treatment for women with uncomplicated UTI’ was 
calculated as 0.325 (32.5%). All ICC values indicate the need for multilevel modelling for 
these datasets. 
Routine Culture: Univariate Multilevel Analysis 
From the univariate analysis the only patient demographic that was significant at the 10% 
threshold was age. Network was also selected to go into the model as a fixed effect 
because of the differences in routine practice within each network although the p-value 
was 0.1320. Days with symptoms, months since last UTI and times treated for a UTI in 
the past did not show significance at this level. Of the signs and symptom severity scores 
only burning when passing urine and presence of increased night time frequency were 
significant. Daytime frequency, symptoms of fever, pain in the side, blood in the urine, 
smelly urine, tummy pain, restricted activities, feeling unwell, total symptom severity 
score (11 symptoms) and total symptom severity score for the factored variable (urgency, 
day time frequency and night time frequency) were not significantly associated (p>0.1) 
with requesting urine for routine culture. Of the management decisions such as dipstick 
urinalysis tests (including: nitrite positive; leucocyte positive; leucocyte, nitrite and blood 
positive; leucocyte and blood positive; leucocyte, nitrite and blood negative; leucocyte 
and nitrite negative; and leucocyte positive with nitrite negative) only nitrite positive and 
‘leucocyte positive with nitrite negative’ were significant. As these variables are closely 
correlated (and to avoid collinearity) I introduced these variables into the model 
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separately and only the most significant variable was retained (nitrite).   The only other 
management decision found to be significant in the univariate analysis was the choice of 
antibiotic prescribed. Oral temperature, cloudy urine and offensive smelling urine were 
not found to be significant. 
Routine Culture: Multivariate Multilevel Analysis 
The final model was generated to include network (Cardiff, Southampton, 
Madrid/Catalonia with Utrecht as the reference variable), patient age (continuous), 
symptom severity of burning when passing urine (continuous from 0 – normal to 6 - as 
bad as it could be), if night time frequency was present (no - reference), dipstick urinalysis 
– nitrite only (negative, not done and ≥+ as the reference) and type of antibiotic 
prescribed (trimethoprim, nitrofurantoin, fosfomycin, other and no antibiotic prescribed 
as the reference); the final model is shown in Table 3.2.13. The significance threshold 
for this final model was 5%. 
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Table 3.2.13. Two level logistic regression multivariate model for requesting urine 
samples for routine culture (under normal practice conditions) from women with 
suspected uncomplicated UTI.  
    
Estimat
e 
Standard 
Error 
Odds 
Ratio 95% CI P-value 
Em
p
ty
 
M
o
d
el
s 
1L null 0.091 0.073 1.095 0.949 1.264 0.213 
2L null MQL1 0.036 0.160 1.037 0.758 1.419 0.822 
2L null PQL2 (n=750)  0.036 0.206 1.037 0.692 1.552 0.861 
2L null MCMC 0.066 0.229 1.068 0.682 1.673 0.773 
Fi
n
al
 
M
o
d
el
 
Intercept (n=734) -0.662 0.689 0.516 0.134 1.991 0.337 
P
at
ie
n
t 
D
em
o
gr
ap
h
ic
 Network (Utrecht - Reference)  
Cardiff 1.927 0.645 6.869 1.940 24.318 0.003 
Southampton 1.627 0.622 5.089 1.504 17.221 0.009 
Madrid/Catalonia 0.966 0.703 2.627 0.662 10.422 0.169 
Age 0.016 0.005 1.016 1.006 1.026 0.001 
Si
gn
s 
an
d
 
Sy
m
p
to
m
s Symptom Severity: 
Burning when Urinating 
(high) -0.267 0.191 0.766 0.527 1.113 0.162 
Night Time Frequency 
(present) 0.417 0.396 1.517 0.698 3.297 0.292 
M
an
ag
em
en
t 
Dipstick Nitrite (≥+ Reference)  
Negative 0.561 0.224 1.752 1.130 2.718 0.012 
Not done 0.160 0.319 1.174 0.628 2.193 0.616 
Antibiotic choice (No antibiotic - Reference)  
Trimethoprim -2.130 0.442 0.119 0.050 0.283 0.000 
Nitrofurantoin -1.815 0.415 0.163 0.072 0.367 0.000 
Fosfomycin -2.140 0.575 0.118 0.038 0.363 0.000 
Other -1.636 0.514 0.195 0.071 0.533 0.001 
M
ea
su
re
s 
o
f 
V
ar
ia
ti
o
n
 
Variance (SE);             
Empty Model 1.582 (0.411)        
Final Model 1.322 (0.366)        
 MOR (95% CI)       
Empty Model 8.128 (4.058; 22.978)    
Final Model 6.296 (3.616; 13.925)    
VPC (empty model) 0.287 (0.325)         
DIC;             
Empty Model 890.025           
Final Model 833.43           
 
From the two level null (empty) model (PQL2) the odds of requesting a urine sample for 
routine culture for a patient with suspected uncomplicated UTI picked at random from an 
average clinical practice  was 1.037 (95% CI 0.692 – 1.552); indicating almost even odds 
with not requesting a sample and the difference was not significant. The network variable 
showed significance within this model (P<0.05) with individual networks Cardiff and 
Southampton showing significant differences to Utrecht. The odds of requesting a urine 
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sample in the Cardiff network compared to the Utrecht network was 6.869 (95% CI 1.94 
– 24.32)); suggesting patients in Cardiff are approximately 7 times more likely than 
patients in Utrecht to have a urine sample for routine culture requested. Similarly patients 
in the Southampton networks are ~5 times more likely to have urine requested for culture 
than Utrecht. Madrid/Catalonia has an odds ratio of 2.627 but this was not significant.  
Age was also significant in this model with an odds ratio of 1.016 (95% CI 1.006 – 1.026); 
the older the patient the more likely they are to be requested a urine sample for routine 
culture with, for example, women in their 60s are almost twice as likely to have urine 
requested for routine culture than women in their 20s3.  
Neither of the patient signs and symptoms (burning when urinating and night time 
frequency) remained significant in the model.  
With regard to the management choices of clinicians both having a urinalysis dipstick 
positive for nitrite and deciding whether to prescribe antibiotics or not have a significant 
association with requesting urines for routine culture. If a clinician indicated that the 
urinalysis dipstick for a patient was nitrite negative this patient was 1.8 times more likely 
to have a routine culture requested than a patient with a dipstick positive (≥+) for nitrite 
or for a patient with no nitrite urinalysis performed (the OR for not using nitrite urinalysis 
is similar, 1.17, to a nitrite positive result with no significant difference).  
Finally, not prescribing an antibiotic was significantly associated with an increase in 
requesting urines for routine culture. The type of antibiotic did not affect this; the odds of 
having a urine sample requested for routine culture if prescribed trimethoprim, 
nitrofurantoin, fosfomycin or other antibiotics are 0.12, 0.16, 0.12 and 0.19 respectively 
(all significant p<0.05) so depending on the antibiotic between 5.25 – 8.33 times less 
likely than no antibiotic.   
The variance partition coefficient (VPC) in the final model was 0.287; this indicates that 
28.7% of the remaining variation was due to level 2 variation and the inter-cluster effect 
                                               
3 (estimate 0.016 x 40 years  = exp0.64 = 1.896 OR) 
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(difference between practices) remains relatively large (the empty model with no 
explanatory variables had a VPC of 32.5%). 
The residual heterogeneity between GP practices (MOR=6.3) indicates that a patient 
can be 6 times more likely to have a routine culture requested depending on the practice 
visited even after taking into account network, patient age, dipstick urinalysis (nitrites) 
and antibiotic prescribing. 
The DIC (deviance information criterion) is smaller in the final model (833.43) compared 
to the empty model (890.025) suggesting a better fit after the explanatory variables have 
been added. 
 
Factors associated with prescribing antibiotics for uncomplicated 
UTI according to network relevant guidelines 
Prescribing first-line antibiotic type: Univariate multilevel analysis 
The first response variable evaluated here was of the patients prescribed antibiotics 
(88.5%) what were the associations with prescribing following the networks’ relevant 
guidelines for first-line antibiotic type for women with suspected uncomplicated UTI. 
From the univariate analysis the patient demographics that were found to be significant 
at the 10% threshold included network and history of treatment. Those found not to be 
significant included age, days with symptoms and months since last UTI. Of the patient 
signs and symptoms; presence of increased daytime frequency, presence of symptoms 
of fever, presence of pain in the side, presence of feeling unwell and high level of burning 
when passing urine were all significantly associated. Urgency, night time frequency, 
blood in the urine, smelly urine, tummy pain, restricted activity and total symptom severity 
scores (all symptoms and factored variable) were not significantly associated. From the 
management decisions analysed oral temperature was significantly associated with 
prescribing antibiotics according to first-line treatment type in the relevant guidelines.  All 
dipstick analysis tests/rules, requesting urine for routine culture, cloudy urine and 
offensive smelling urine were not significantly associated.  
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Prescribing first-line antibiotic type: Multivariate multilevel analysis 
The final model was generated to include network (Cardiff, Southampton, 
Madrid/Catalonia with Utrecht as the reference variable), if day time frequency was 
present (no - reference), symptoms of fever present (no –reference), pain in the side (no 
– reference), feeling unwell (no – reference), high level of burning when passing urine 
(low – reference) and oral temperature (normal – reference); the final model is shown in 
Table 3.2.14. The significance threshold for this final model was 5%. Although history of 
treatment (1, 2, 3 or more times, do not know and none as reference) was significant in 
the univariate model the sample size decreased substantially to n=236 and could not be 
included in the final multi-level model.  
From the two level null (empty) model (PQL2) the odds of prescribing first-line treatment 
type according to the network relevant guidelines for a patient with suspected 
uncomplicated UTI picked at random from an average clinic/practice is 9.88 (95% CI 
6.15 – 15.87); the patient is 10 times more likely to be prescribed a recommended first-
line treatment than not (highly significant difference). 
The network association was highly significant (P<0.05); the odds of the Cardiff and 
Southampton networks prescribing following guidelines compared to Utrecht were 6.06 
(95% CI 1.51 – 24.48) and 10.48 (95% CI 2.53 – 43.38) respectively indicating that 
patients in these networks are 6 and 10 times more likely to get an antibiotic according 
to their networks first-line treatment guidelines for uncomplicated UTI. The difference 
between Madrid/Catalonia and Utrecht was not significant. Clinicians in Cardiff and 
Southampton (as part of the UK) have access to the same guidelines however clinicians 
in Cardiff are 42% less likely to prescribe first-line antibiotic treatment type according to 
the guidelines than Southampton. 
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Table 3.2.14. Two level logistic regression model of antibiotics prescribed (type only) 
according to relevant networks guidelines for first-line treatment for women with 
uncomplicated UTI. 
    Estimate 
Standard 
Error 
Odds 
Ratio 95% CI P value 
Em
p
ty
 
M
o
d
e
ls
 1L null 2.023 0.117 7.561 6.012 9.510 0.000 
2L null MQL1 1.849 0.194 6.353 4.344 9.293 0.000 
2L null PQL2 (n=694) 2.290 0.242 9.875 6.145 15.868 0.000 
2L null MCMC 2.277 0.238 9.747 6.114 15.541 0.000 
Final 
Mode
l 
Model Intercept 
(n=662) 0.976 0.753 2.654 0.607 11.610 0.195 
P
at
ie
n
t 
D
e
m
o
gr
ap
h
ic
s 
Network (Utrecht - Reference) 0.000 
Cardiff 1.802 0.710 6.062 1.507 24.376 0.011 
Southampton 2.349 0.725 10.475 2.529 43.380 0.001 
Madrid/Catalonia -0.148 0.600 0.862 0.266 2.795 0.805 
Si
gn
s 
an
d
 S
ym
p
to
m
s 
Daytime Time 
Frequency (present) 0.884 0.543 2.421 0.835 7.017 0.104 
Symptoms of Fever 
(present) -0.512 0.398 0.599 0.275 1.307 0.198 
Pain in the Side 
(present) -0.339 0.303 0.712 0.393 1.290 0.263 
Feeling Unwell 
(present) -0.886 0.392 0.412 0.191 0.889 0.024 
Burning when 
passing urine (high) 0.793 0.302 2.210 1.223 3.995 0.009 
M
an
ag
e
m
e
n
t 
Oral Temperature (normal – 
Reference)         0.002 
Low 0.980 0.566 2.664 0.879 0.083 0.049 
High -1.579 0.515 0.206 0.075 0.002 0.003 
M
e
as
u
re
s 
o
f 
V
ar
ia
ti
o
n
 
Variance (SE);             
Empty Model 1.529 0.545        
Final Model 0.912 0.403        
MOR (95% CI)       
Empty Model 7.695 (3.307; 32.491)    
Final Model 4.477 (2.745; 9.251)    
VPC (empty model) 0.217 (0.328)         
DIC Empty Model 452.25           
DIC Final Model 408.87           
 
The only variables in the signs and symptoms that remained significant at the 5% 
threshold when put into the final model were feeling unwell and burning when passing 
urine. Feeling unwell had an odds ratio of 0.41 (95% CI 0.19 – 0.89) so patients that 
were feeling unwell were 59% less likely to have a recommended first-line antibiotic type 
prescribed. Patients that experienced high levels of burning when passing urine 
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(symptom score ≥3) were over twice as likely to be prescribed an antibiotic that was 
recommended as first-line than patients with milder symptoms. 
Oral temperature remained significant in the final model and patients with a high 
temperature were 80% less likely to likely to have a recommended first-line antibiotic 
type prescribed than those with a normal temperature. 
The variance partition coefficient (VPC) in the final model was 0.217; this indicates that 
21.7% of the remaining variation is due to level 2 variation and the inter-cluster effect 
(difference between practices) remains relatively large. However, by adding the 
explanatory variables the VPC reduced by about 10% from the empty model.  
The median odds ratio of 4.48 (95% CI 2.75 – 9.25) in the final model suggests that 
patients are almost 5 times more likely to be prescribed an antibiotic type according the 
networks guidelines depending on which GP practice is visited. 
The DIC (deviance information criterion) is smaller in the final model (408.87) compared 
to the empty model (452.25) suggesting a better fit after the explanatory variables have 
been added. 
To investigate antibiotic prescribing according to relevant network guidelines further I ran 
another model with antibiotic prescribing according to the guidelines to include type, total 
dose and duration. The final model is included in appendix 3.2.8. From the two level null 
(empty) model (PQL2) the odds of prescribing first-line treatment (type, total dose and 
duration) according to the network relevant guidelines for a patient with suspected 
uncomplicated UTI picked at random from an average clinic/practice  was 0.968 (95% 
CI 0.551 – 1.698); indicating almost even odds not prescribing according to the 
guidelines with no significant difference. 
The variables that remained significant in the final model (P<0.05) included the network 
(Southampton and Madrid/Catalonia compared to Utrecht), history of treatment (3 or 
more times compared to no history of treatment) and having a urinalysis dipstick for 
leucocytes performed. The only variable that was significant for both models was 
network. However in this model GP practices in the Southampton and Madrid/Catalonia 
networks were 91% (95% C 0.019 – 0.421) and 96% (95% CI 0.009 – 0.199) less likely 
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to prescribe according to their networks recommended guidelines for antibiotic type, total 
dose and duration compared to the Utrecht network respectively. In the previous model 
GP practices in the Southampton network were more likely to prescribe the 
recommended antibiotic type according to the guidelines than Cardiff. However in this 
model Cardiff is 9 times more likely than Southampton to prescribe according to the 
recommended first-line antibiotic type with total dose and duration. 
The median odds ratio for this model reduced from 97.3 (95% CI 8.12 – 22172.72) to 
7.53 (95% CI 3.22 – 32.47) when the individual level explanatory variables were added. 
However patients are still 3 to 32 times likely to be prescribed an antibiotic according to 
the guidelines for type, total dose and duration depending on which GP practice they 
consult at. 
When comparing the two prescribing models the individual effects were relatively more 
important on prescribing antibiotic type over prescribing antibiotic type with total dose 
and duration; this is reflected in the final MOR of 4.5 compared to 7.5. Likewise the 
remaining unexplained level 2 variance for both models was 21.7% for antibiotic type 
and 31.4% for antibiotic type, dose and duration.  
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Laboratory data and use of point of care tests 
UTI prevalence and uropathogen identification  
Cardiff and Southampton had a very similar prevalence of microbiologically proven UTI 
at 28.4 % (95% CI 22.6 – 35.1%) and 28.2% (95% CI 22.7 – 34.6%) respectively. The 
prevalence in Spanish and Dutch networks were much higher at 49.8% (95% CI 35.6 – 
49.8%) and 64.6% (95% CI 55.9 – 72.4%) respectively (Table 3.2.15).  
 
Table 3.2.15. Prevalence of proven uncomplicated UTI  
 
 N 
UTI 
Negative 
UTI 
Positive 
Prevalence 
of UTI (%) 
95% CI 
Cardiff 197 141 56 28.4 22.6 35.1 
Southampton 216 155 61 28.2 22.7 34.6 
Madrid/ Catalonia 181 104 77 42.5 35.6 49.8 
Utrecht 127 45 82 64.6 55.9 72.4 
 
The most common uropathogen isolated across all networks from the microbiologically 
positive urine samples was E. coli ranging from 71.4% in the Spanish network to 89.3% 
in the Cardiff network (Figure 3.2.7). 
Use of point of care tests and routine culture  
The use of diagnostic and other tests has already been described in table 3.2.6. Figure 
3.2.8 compares the use of dipstick urinalysis, prevalence of turbid (cloudy) urine and 
request for routine culture with the prevalence of microbiologically proven UTI across the 
four networks.   
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Figure 3.2.7. Prevalence of urinary pathogens isolated from microbiologically UTI 
positive urine samples. 
 
 
Dipstick urinalysis is the most commonly used test across the networks regardless of the 
prevalence of UTI. Routine culture requests are more frequent in the Cardiff and 
Southampton networks even though the prevalence of UTI is lower than in 
Madrid/Catalonia or Utrecht networks.  
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Figure 3.2.8. Use of diagnostic and other tests and prevalence of microbiologically 
proven UTI. 
 
Figure 3.2.9 illustrates each diagnostic test result with the proportion of corresponding 
positive and negative UTI samples.  For the UK networks and to a lesser extent the 
Spanish network the most useful tests may be clear urines or nitrite negative results as 
predictors of not having a UTI.  For the UK networks leucocyte negative results may also 
be a good predictor of not having a UTI but the proportion of negative leucocyte results 
was much lower.  In Utrecht cloudy urine, positive nitrite and positive leucocyte results 
may be useful predictors of having a UTI.  There doesn’t seem to be any difference 
between requesting routine culture results and a patient having a UTI or not, except in 
the Utrecht network where patients with a microbiologically proven UTI are less likely to 
have a routine culture requested by their GP.
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Figure 3.2.9. Diagnostic test outcomes and proportion of positive and negative UTI.  
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As the prevalence of UTI is much higher in the Spanish and Dutch networks compared 
to the UK networks I have chosen to only include the diagnostic accuracy analyses for 
urine turbidity, nitrite and leucocyte dipstick urinalysis for the UK networks. The results 
for the other networks are included in appendix 3.2.9. 
The negative predictive values for urine turbidity, nitrite urinalysis and leucocyte 
urinalysis were 89.6% (95% CI 80.8 – 89.6), 83.2 % (95% CI 75.0 – 89.1) and 89.7% 
(95% CI 73.6 – 96.4) respectively for the Cardiff network.  The Southampton network 
showed similar results with 81.9% (95% CI 73.9 – 87.8), 83.2% (95% CI 75.9 – 88.6) 
and 81.6% (95% CI 66.6 – 90.8) NPV for urine turbidity, nitrite urinalysis and leucocyte 
urinalysis respectively. None of the tests showed high positive predictive values but 
nitrite urinalysis had the highest association with an odds ratio of 5.4 (95% CI 4.73 – 
5.75) for the combined UK networks.   
The laboratory evaluation study (section 2; chapter 4) showed that the best prediction 
rule was that if the urine was visually turbid AND nitrite OR leucocyte positive, it was 
likely to be positive for a UTI. I analysed the same rule on the observational data for the 
UK networks and found the results as follows; sensitivity 67.4% (95% CI 57.4 – 76.0); 
specificity 65.3% (95% CI 59.3 – 70.8); PPV 41.3% (95% CI 33.8 – 49.2) and NPV 84.7% 
(95% CI 79.0 – 89.0). Table 3.2.16 shows the raw data with likelihood ratios and odds 
ratios for each test.   
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Table 3.2.16. Diagnostic accuracy of visually assessing urine turbidity, nitrite and leucocyte dipstick urinalysis in determining microbiologically positive 
UTI. 
Network Test 
True 
Positives 
True Negatives False Positives False Negatives 
% correctly 
classified 
Likelihood Ratio 
(+ / -) 
Odds Ratio 
Cardiff 
 
Turbid urine 34 69 49 8 64.4 1.94 / 0.32 5.98 
Nitrite positive 21 89 14 18 68.8 3.96 / 0.53 7.42 
Leucocyte positive 38 26 88 3 40.0 1.20 / 0.32 3.74 
Urine cloudy and nitrite 
or leucocyte positive 
33 75 42 8 68.4 2.24 / 0.30 7.37 
Southampton 
Turbid urine 33 95 50 21 64.3 1.77 / 0.59 2.99 
Nitrite positive 33 109 37 22 71.4 2.37 / 0.54 4.42 
Leucocyte positive 48 31 118 7 32.2 1.10 / 0.61 1.80 
Urine cloudy and nitrite 
or leucocyte positive 
31 96 49 23 63.8 1.70 / 0.64 2.64 
UK 
Turbid urine 67 164 99 29 64.3 1.85 / 0.48 3.83 
Nitrite positive 54 198 51 40 70.2 2.80 / 0.54 5.24 
Leucocyte positive 86 57 206 10 39.8 1.14 / 0.48 2.38 
Urine cloudy and nitrite 
or leucocyte positive 
64 171 91 31 65.8 1.94 / 0.50 3.88 
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Discussion 
There are a limited number of studies observing the routine management of UTI in 
primary care; and comparing clinical practice between local GPs as well as between 
European countries. The POETIC observational study, from which I analysed and 
included the management data in this thesis achieved this. Unique aspects of this 
pragmatic study include a sample size of 793 evaluable patients from four different 
European countries collecting data using the same CRF to allow for adjustment for case 
mix.  
Recruitment  
Recruitment into the study was limited in the Utrecht network compared to the other 
networks. The Netherlands have a different management system for uncomplicated UTI 
compared to the other countries whereby patients drop a urine sample off to the practice 
without seeing a nurse or GP, the urine sample is tested using dipstick urinalysis and/or 
dip-slides and the woman is telephoned with the result and asked to collect a prescription 
if necessary (confirmed from communication with the Netherlands POETIC study team 
clinicians). If the study site staff were unable to see the patients to discuss the study 
and/or gain consent this will have influenced recruitment potential within this network. 
The presented results may be less generalizable for this network than the other three 
networks with higher recruitment figures. The number of participants recruited per 
practice was highly variable for all the countries. The high intra-class correlations could 
be partly a result of this (for example within practice variation may be limited with only 
two participants) although this does not affect the sample size as there is no comparison 
group and as the main outcome of antibiotic prescribing had a conservative estimate of 
50% this will result in narrower 95% confidence intervals.  
The number of diaries return ranged from 61.8% in Cardiff to 78.9% in Utrecht. The 
number of diaries returned overall and in the Cardiff network is similar to another 
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prospective observational study in a multi-European primary care setting (80). Other than 
telephoning the participants to request the return of the diary there were no other 
mechanisms to improve diary return at this stage, for example, telephone interview 
requesting essential information from the diary. Another multi-European, investigator-
driven prospective observational study of patients with acute cough (GRACE-01) 
suggested the following to improve diary response rate for similar trials: sending a letter 
when the patient is unable to be contacted by phone; registering a preferred contact 
number and time to call; flow diagram at the beginning of the patient diary detailing 
completion process; using different coloured paper for general questions that distinguish 
from the daily questions; advertise and hold a lottery for all patients who have returned 
diary as an incentive to complete and return the diary;  shortened version of patient diary 
with selected key main outcome questions when no patient diary has been returned (92). 
Patient Characteristics  
The mean age of women presenting with uncomplicated UTI was similar across the 
networks with the lowest in Cardiff and highest in Southampton; the overall mean age is 
similar to the mean age of women (44 years; range 16 to 99 years) presenting to an 
observational study of uncomplicated UTI in Canada (93) . Days with symptoms ranged 
hugely from zero to 325 days; I expect the latter to be a data error however there were 
still women recorded as having >28 days and up to 3 months symptoms. This suggests 
that some GPs interpret women with chronic symptoms to have an uncomplicated 
(acute) UTI. I did not find a  definition for the number of days with symptoms to be 
considered acute in the literature, however the Utrecht networks guidelines (based on 
guidelines from the Netherlands) in this study suggest <7 days as uncomplicated 
(appendix 3.2.6) and another review suggests an average of 6 days (94). The systematic 
review included studies that described women consulting with a mean or median of 3 
days symptoms (26, 28, 81, 82). Time off work was minimal suggesting generally 
uncomplicated UTI symptoms were not debilitating.  
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The majority of women had a history of UTI and this was similar across the networks; a 
study in Canada reported that 86% women recruited onto their study had also had least 
one episode of UTI previously (93). Number of treatments for UTI in the past year 
generally reflect the prevalence of antibiotic prescribing during this study (discussed 
later) although Cardiff had the highest proportion of women in the no treatment bracket 
(in the past year) within their network. This may reflect the slightly younger age of the 
women recruited onto the study. 
The number of months since last UTI episode was similar across the networks as is the 
high percentage of women having been prescribed an antibiotic for their last UTI episode. 
The latter results are in-line with having a history of UTI but slightly discordant with times 
treated for UTI in the past year, although this may be down to women having had 
antibiotic treatment longer than a year ago. The proportion of antibiotic prescribing for 
last UTI episode is in-line with the studies current prescribing for UTI in the Cardiff, 
Southampton and Madrid/Catalonia networks. The Utrecht network has a much higher 
figure for antibiotic prescribing for last UTI than the current UTI although this may be due 
to recall bias of the patient (previous antibiotic treatment was captured in the patient diary 
whereas current practice was recorded by the GP in the CRF at the time of consultation).  
Clinician Reported Signs and Symptoms 
Daytime frequency and urgency were both the most prevalent and severely graded (as 
‘bad’) symptoms across all networks. This is not surprising considering the inclusion 
criteria specified that women participating in the study had to have at least one symptom 
of dysuria, urgency including nocturia, and frequency. Dysuria and nocturia were also 
highly prevalent and with a median severity grading of ‘moderately bad’. Frequency and 
dysuria were also the most prevalent symptoms reported in the systematic review 
although urgency was reported by fewer studies and had a lower prevalence (26, 81-
84).  None of the other symptoms had a (median) severity grading greater than ‘slight 
problem’. Blood in the urine and symptoms of fever had low prevalence. The Utrecht 
network had much lower (half) reported blood in the urine than the other networks but 
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was much more in line with the reported prevalence from the systematic review (29, 81-
84). A qualitative study reported women with blood in their urine were more worried about 
their symptoms and this formed a strong driver for seeking help (95); in this study the 
Utrecht network did also have the lowest recruitment figures. Southampton had much 
higher reporting (at least double) of symptoms of fever which may also be linked to the 
slightly higher reported number of days off work for women in this network. Only two 
studies in the systematic review reported on the symptoms of fever and the prevalence 
was minimal (1.9 – 9.3%) (83, 84) and another study based in Canada reported minimal 
presence of fever (6.6%) (93).  
Women were recruited with suspected uncomplicated UTI and as such may have had 
fewer and less severe symptoms than seen in routine practice for all suspected urinary 
tract infections. The total symptom severity score had a wide range; some women had 
very low symptom severity prior to consulting their GP while others had much more 
severe symptoms. The low median total symptom severity scores across the networks 
could be associated with the women on the study having had a prior UTI and recognising 
the symptoms quickly and consulting earlier. For women with higher severity scores it 
could be that some women wait longer to see their GP or see if the symptoms resolve 
prior to seeing their GP for treatment. In a qualitative study of women’s experiences of 
self-care for symptoms of UTI and their journey to the GP failure to alleviate symptoms 
through lay remedies was the commonest cited rationale for consulting and regardless 
of prior experience, fear of the consequences of continued symptoms – particularly 
potential for kidney infection (95). 
The Canadian study by McIsaac et al. found 48% of women recruited had moderately 
severe symptoms; 28% mild; and 24% severe. It is difficult to compare severity of 
symptoms when grading scales are different and severity is subjective to the patient (93). 
Little et al. found that patients with more somatic symptoms and more severe symptoms 
at baseline were likely to have longer lasting symptoms; may be more in need of antibiotic 
treatment but that if doctors took a positive attitude about their patients diagnosis 
duration of symptoms could be reduced (82).   
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The factor analysis resulted in one unobserved variable which included the symptoms of 
urgency, daytime frequency and night time frequency. This factor had a higher mean 
total symptom severity score than with all the symptom variables included, however, this 
is because the these three factors had higher individual scores than the other variables. 
This factor was not associated with increased likelihood of prescribing antibiotics 
according to the guidelines with regard to antibiotic type or type, total dose and duration. 
Diagnostic management choices and prevalence of UTI 
Requesting urines for laboratory culture was higher than expected and is not 
recommended in UK and Spanish networks’ guidelines for women with uncomplicated 
UTI for every patient on a routine basis. This could be due to the influence of participating 
in the study or the way this data was collected. Requesting urines for culture was not 
associated with increased likelihood of prescribing antibiotics according to the guidelines 
with regard to antibiotic type or type, total dose and duration. Even when laboratory 
culture results are available the management of the patient does not necessarily change 
accordingly (86) and laboratory culture has been suggested to be more useful in 
resistance surveillance to inform empirical antibiotic choice (96).  A limitation of this study 
for this question is that all GPs had to send a urine sample for culture as part of the study 
procedures. This may result in false positive answers rather than actual routine practice.  
Not prescribing antibiotics was significantly associated with sending samples for culture. 
The Netherlands can choose to use dip-slides at the point of care and if used will show 
(after 24h) if there is bacterial growth or not which can guide the clinician in deciding 
whether or not a bacterial UTI is present and whether to prescribe. However, dip-slides 
are unable to test for antibiotic susceptibility and cannot guide most appropriate antibiotic 
choice.  From the systematic review I also found that studies which requested urines as 
part of the study procedures (and therefore would have had culture results available for 
the participating GPs after a few days) tended to have lower empirical prescribing levels 
(29, 32, 86). However, reverse causality where both outcomes are also predictors could 
be an issue with regard to requesting urines for routine culture and antibiotic prescribing. 
Antibiotics could be prescribed or not depending on whether a culture was requested or 
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conversely a culture could have been requested depending on whether antibiotics were 
prescribed or not. There is no way to know from my study data which is the true outcome 
or predictor.  
Other factors associated with sending urines for routine culture include increasing patient 
age and nocturia. Indicators of pyelonephritis and recurrent UTI may warrant culture as 
indicated by the UK’s HPA guidelines but presence of loin pain (pain in the side), fever, 
times treated for UTI in the past and months since last UTI were not significantly 
associated with sending urines for culture in my model. Exclusion criteria for the study 
included history of pyelonephritis and antibiotic treatment for UTI in the past 4 weeks; 
clinicians would therefore not consider their patient as having pyelonephritis or recent 
recurrent UTI if recruited into the study which fits with my results. 
Urinalysis dipsticks were the most commonly used tests across all four networks. This is 
similar to studies in Spain, Sweden, Germany and Canada where use of dipstick 
urinalysis ranged from 84% to 93% (26, 28, 29, 93). Nitrite and leucocyte tests were the 
most commonly recorded in fairly equal measure across the networks except the Utrecht 
network where the leucocyte test was recorded less than nitrite. The CRF does not ask 
the clinician to record if the individual urinalysis test result was used in the management 
of the patient. However, from the multilevel analysis I found that negative nitrite results 
are associated with an increase in the (indicated) use of routine culture and dip-slides (in 
Utrecht); this may be due to the clinicians’ uncertainty of an infection when obtaining this 
result. All networks’ guidelines indicate a positive nitrite result as probable UTI. However, 
only 35% of clinicians recorded positive nitrite tests from this study. Having a positive 
leucocyte result was significantly associated with prescribing an antibiotic that was 
different to that recommended by the guidelines (for type, total dose and duration). 
Leucocytes (white blood cells) are an indication of infection and as such may cause the 
clinician more concern and therefore to prescribe a different antibiotic to avoid treatment 
failure due to a concern about potential resistance (for example in the case of 
trimethoprim) or for a longer duration to avoid recurrence of the UTI. The UK and Spain 
guidelines indicate positive leucocyte tests as having equal probability of UTI as 
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compared to other diagnosis. In total 80% recorded a positive leucocyte test across all 
networks suggesting increased uncertainty and it being largely a redundant test in 
practice.  
Over half of all women had clear urine (or non-cloudy as indicated by the clinician). 
Previous studies have shown that clear urine is a good indicator of no microbiological 
infection and the HPA guidelines recommend another diagnosis with clear urine (if less 
than 3 symptoms or not severe). 
All women were requested to provide a urine sample for microbiological confirmation of 
UTI as part of the study procedures. The prevalence of microbiologically confirmed UTI 
in this study ranged from 28.3% in the UK networks to 64.6% in the Utrecht network with 
E. coli being the most common uropathogen isolated across all network. The higher 
prevalence of microbiologically confirmed UTI in Utrecht and Madrid/Catalonia could be 
due to using different laboratories to culture the urine samples (the UK networks used 
the same laboratory) or recruitment of women with higher incidence of UTI in different 
networks. The higher prevalence of UTI particularly in the Utrecht network shows that 
the usefulness of different diagnostic tests is variable depending on the network it is used 
in. For example in the Cardiff network, clear urines may be useful in identifying patients 
without a microbiologically confirmed UTI where as in the Utrecht network almost equal 
numbers of patients with and without microbiologically confirmed UTI had a clear urine 
sample. Likewise negative nitrite results may be an indicator of no UTI in Cardiff patients 
but in Utrecht a positive nitrite result is more useful in identifying patients with a UTI. 
This study was purely observational and not set up for the purpose of diagnostic 
evaluation. However, looking at only the UK networks (as they had the same prevalence 
of microbiologically confirmed UTI) if clear urines were used as in indication of a 
diagnosis other than UTI 54% (193/359) patients could be screened out; with 8% 
(29/359) of patients with a true UTI missed. If patients showed a nitrite negative result, 
69% (238/343) could be excluded from empirical treatment or further diagnostic tests but 
12% (40/343) of patients with a true UTI would be missed. If the patients showed a 
leucocyte negative result, 18.7% (67/359) could be excluded from empirical treatment or 
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further diagnostic tests with fewer patients with a true UTI missed (2.8%).    For the UK 
networks none of the urinalysis dipstick tests or evaluation of urine turbidity perform well 
at confirming a microbiologically positive UTI.  
  
Patient Management: Antibiotic Prescribing and other Treatments 
The UK and Spain networks prescribed antibiotics in over 90% of cases; the Netherlands 
network prescribed in just under 60% of cases. Delayed prescribing and prescription of 
second antibiotics were minimal across all networks.  
The systematic review shows similar levels of prescribing in the nine included European 
countries; with just under 60% prescribing in Ireland and Germany and up to 99% in 
Turkey. The two more recent English studies reported in the review (81, 82) show high 
levels of prescribing similar to the Southampton network in this study, likewise the 
Spanish study by Llor C et al. (26) included in the review reported the same prescribing 
levels as the Spanish network in this study. The Welsh study included in the review 
showed a much lower level of prescribing than this study although this may be due to 
the fact that the study by O’Brien et al. relied on patient recall of antibiotic prescription 
rather than GPs indicating this at the time of consultation (32). Another Welsh UTI study 
found patients’ recall of antibiotics used (in the previous 12 months) was too difficult for 
many patients and had to rely on prescription data from medical records instead (11). 
This study involved the recruitment of women with suspected uncomplicated UTI with at 
least one of three key urinary tract symptoms (dysuria, urgency including nocturia, and 
frequency); current HPA (UK) and Spanish guidelines recommend empirical antibiotic 
treatment for women with severe or ≥3 symptoms of UTI. I did not analyse the 
appropriateness of prescribing according to this guideline. Instead I allowed (from the 
study protocol) for the fact that clinicians suspected the patient had uncomplicated UTI 
(as they were recruited onto the study) and unless there were other factors of concern 
(such as recurrence or previous treatment failure and age) empirical first-line antibiotic 
prescribing may be deemed appropriate. For this reason I chose to analyse factors 
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associated with prescribing first-line antibiotics following the networks’ guidelines firstly 
with regard to antibiotic type and secondly with regard to antibiotic type with 
recommended total dose and duration. Not prescribing according to the first-line 
antibiotic type included the network the patient was in (UK networks associated with 
prescribing according to recommended type), the feeling of being unwell and having a 
high temperature and no/low burning sensation when passing urine. This may suggest 
that if a GP suspects the patient is more generally unwell or has fever a second 
line/alternative treatment is preferable. The main discordancy I found with the Cardiff and 
Southampton (and Madrid/Catalonia) networks were that they prescribed the correct 
antibiotics but for a longer duration than recommended. Other than the network the 
patient was recruited in, having 3 or more treatments for UTI in the past and having a 
leucocyte positive urinalysis dipstick test are associated with discordant antibiotic 
prescribing choices for type as well as total dose and duration in the relevant guidelines; 
this could be related to fear of recurrent infection or more serious infection. The 
systematic review included five studies in England, Germany, Spain, Sweden, and 
Turkey that also observed longer antibiotic treatments than recommended for 
uncomplicated UTI (26, 28, 29, 81, 84). A three day course of antibiotic treatment should 
suffice for most women with lower urinary tract infection, including elderly patients. Single 
dose treatment is less effective but has fewer side effects (19). A study in Wales 
investigating prior antibiotics use and the risk of antibiotic-resistant community-acquired 
urinary tract infection found there was significant increased risk of resistance associated 
with length of course of trimethoprim compared with no prescription with odds ratios 
(ORs) 4.62 >=7days and 1.60<= 7 days. The ratios of these ORs was 2.89 showing that 
the OR for the longer course was significantly greater than that for the short course 
prescription. The risk of trimethoprim resistance was also significantly associated with 
the number of prescriptions in the previous 12 months. Prescriptions of seven or more 
days showed significance within the last three months; for prescriptions of <7days the 
association was significant only in the following month (11). 
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 It may be that clinicians consider antibiotic resistance to be generally unaffected by their 
practice and that some clinicians prescribe antibiotics for longer to give their patients the 
best chance of recovery. Other UTI studies in European primary care have shown similar 
findings in that antibiotics are often prescribed for longer duration than recommended 
and are not compliant with the guidelines (28, 97). Over –prescribing either when the 
patient does not need an antibiotic at all or for longer duration and total dose may lead 
to risks of side-effects without achieving more meaningful rapid recovery. Another 
concern is generation of resistance in the community from over-exposure of antibiotics 
in the individual. Previous UK studies evaluating the effects of trimethoprim prescribing 
in primary care on bacterial resistance have shown higher rates of resistance with 
increasing duration, dose and recent exposure (11, 24, 98).  A study looking at factors 
associated with the probability of antibiotic resistance of uropathogenic E. coli found 
previous antibiotic use and the general practice visited as risk factors for a patient with a 
UTI being diagnosed with E. coli resistant to this agent (the study evaluated resistance 
to ciprofloxacin and trimethoprim) (99). There was limited data collected on the general 
practice or clinician level factors so I was unable to evaluate if these factors were 
associated with antibiotic prescribing.  I also could not account for any changes in 
antibiotic prescriptions either by the GP or pharmacist which were not captured in the 
study CRF at baseline nor adherence of the patient in taking the prescribed antibiotics 
(antibiotic consumption) for the duration of treatment. However, a study on LRTI in 
primary care found that patient reported levels of adherence to study medication 
(amoxicillin or placebo; two 500mg tablets three times a day for 7 days) was very high 
(88%) (100). Although I did not capture data on changes in prescriptions prior to 
dispensing the medication the aim of this study is to look at how patients are managed 
by the GP at the time of consultation; any changes to the prescriptions after the 
consultation are likely to be minimal (personal discussion with the POETIC study 
Investigators/GPs).  
The guidelines I used for comparison were developed by the POETIC study team 
principal investigators and clinicians for each network based on each countries 
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guidelines (appendix 3.2.4 – 3.2.6). There are other guidelines that the GPs may prefer 
to follow (for example the British National Formulary for UK GPs). Other barriers 
described in a systematic review of the literature include lack of familiarity and awareness 
(volume of information, time needed to stay informed, guideline accessibility); lack of 
agreement with specific guidelines and guidelines in general (interpretation of evidence, 
applicability to the patient, not cost-beneficial, too rigid to apply, not practical, lack of 
confidence in guidelines developer); lack of outcome expectancy; lack of self-efficacy; 
lack of motivation/inertia of previous practice; external barriers (patient preferences, lack 
of time, lack of resources, lack of reimbursement, presence of contradictory guidelines) 
(101).  The Cardiff and Southampton networks have the same guidelines but the Cardiff 
network showed a much higher accordance in first-line prescription duration than 
Southampton. This may be down to the fact that Southampton prescribed nitrofurantoin 
much more than Cardiff which mainly prescribed trimethoprim. Both are recommended 
first-line treatments but when nitrofurantoin is prescribed the discordancy in total 
dose/duration increases. The BNF (British National Formulary) agrees with the UK 
networks guidelines on the daily dose of nitrofurantoin with a recommendation of 3 -7 
days; the BNF also agrees with the daily dose of trimethoprim but has no 
recommendation on the duration (102). If the study clinicians are using this instead then 
the empirical prescriptions may still be considered appropriate.  
Another multi-European observational study (GRACE) describing antibiotic prescribing 
for adults with acute cough/lower respiratory tract infection found that Cardiff, 
Southampton and the Netherlands networks prescribed the preferred antibiotic choice 
(type) in over 75% cases. The Spain networks in this GRACE study (Barcelona and 
Mataro) had much lower preferred antibiotic choice and tended to prescribe alternative 
antibiotic options (103). This agrees with the results in this study that the Cardiff, 
Southampton and Utrecht networks prescribe first-choice antibiotic type and the 
Madrid/Catalonia networks are better at prescribing first choice antibiotics for UTI than 
acute cough although this did not include dose and duration. 
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The CRF captured data on other medications both prescribed and advised; I have only 
presented data on paracetamol and ibuprofen as other medications were minimal. The 
Madrid/Catalonia network was the only network to prescribe paracetamol (Cardiff and 
Southampton prescribed to one and two patients respectively). Paracetamol is an over 
the counter common medication which does not need a prescription in the UK. It may 
help to reduce fever and alleviate mild to moderate pain; the Southampton network had 
by far the highest advice on paracetamol and much higher than the Cardiff network (as 
both part of the UK). The Southampton network did have the highest prevalence of 
symptoms of fever and time off work which may explain this advice. The 
Madrid/Catalonia network was also the only network to prescribe ibuprofen although this 
was minimal and the Southampton network once again advised most on ibuprofen.   
Patient Management: Advice and Follow-Up 
The most common advice across all networks was to drink more fluids, water in 
particular.  
There were a lot of various pieces of advice given broadly covering fluids and 
consumption; worsening symptoms; treatments; hygiene and sexual health; and 
antibiotic use. Some of the less common advice included ‘using a shower instead of a 
bath’ and to ‘avoid citrus fruit’. A review of the literature by Car J., summarised that 
randomised trials indicate that drinking cranberry or taking cranberry concentrate tablets 
reduces the risk of symptomatic, recurrent infection by 10% to 20%; post-coital voiding 
does not prevent cystitis; there is no evidence that poor urinary hygiene predisposes 
women to recurrent infections; and there is no rational for giving women specific 
instructions regarding the frequency of urination, the timing of voiding, wiping patterns, 
douching, the use of hot tubs, or earing of pantyhose (19). 
It may be interesting to look at advice given by practice and/or clinician to see if the 
advice is specific to a practice/person or more generalised. The Southampton network 
offered the most and most varied advice whereas the Spain network only advised on 
increasing fluids and passing urine/emptying bladder fully.  
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Routine follow up is not recommended for lower urinary tract infections but is 
recommended for upper urinary tract infections after the treatment is completed (19). 
The UK networks had limited follow-up, Spanish GPs requested most follow-up with 
patients 8-14 days after the consultation and the Utrecht network generally requested 
patients follow up for urine test results. 
A report from the UK Department of Health’s Standing Medical Advisory Committee 
(SMAC) Sub-Group on Antimicrobial Resistance in 1998 advised that prescribing 
antibiotics after telephone consultation should be limited to exceptional cases, however, 
under normal conditions both the Southampton and Utrecht networks in this study would 
have managed more cases by phone than face to face. As the guidelines recommend 
prescribing empirically for patients with obvious symptoms of uncomplicated UTI then 
telephone consultations may be acceptable for those patients. The Utrecht network had 
problems recruiting because of this system although the Southampton did not and 
actually recruited the most patients overall. After personal communication with one of the 
Southampton’s networks Principal Investigators (Dr M Moore), I learnt that the 
Southampton trial sites changed their usual practice to be able to recruit for the trial. As 
an observational study this may have caused some selection bias but was unavoidable 
if recruitment was to be achieved. 
 
Limitations 
Patient outcomes were not evaluated as they were not part of my study aims and 
objectives.  
Although the CRFs were completed for almost all patients and diary returns was 
reasonable across the networks, individual questions were not always completed so the 
overall numbers for certain data points were reduced. This was particularly the case 
when developing the multilevel model for antibiotic prescribing as only patients with data 
for all response and explanatory variables could be included. As one of the variables 
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reduced the sample size significantly (history of treatment) this variable had to be 
excluded from this model.  
There was large variation in the number of practices recruiting per network and the 
number of patients recruited to each practice. This led to more clustering; the lower the 
number of patients recruited to a practice the less likely there will be within practice 
variation (although only cluster sizes of 5 or more were included in the models). The 
original sample size calculation was based on an assumption ICC of 5.7% however this 
was up to four fold higher in the multilevel analyses performed by myself. The sample 
size calculation was not generated with my research questions in mind but as part of the 
larger POETIC observational study as a result confidence intervals are wider  than 
initially specified. For example the ICC value for the response variable for ‘antibiotics 
prescribed (type only) according to relevant guidelines indicating first-line treatment for 
women with uncomplicated UTI’ was calculated as 0.16 (n=662) resulting in a  design 
effect of 4.059 and effective sample size of 163, +/- 8% precision margin. In order to 
have obtained the +/- 5% margin initially proposed, in a population with an ICC of 0.16 
and cluster size of 20, the number of completed CRFs would have had to be 1563. 
There was also limited data collected on the general practices such as the information 
about the clinicians taking part (who consulted with the patient, sex, age, years in 
practice), whether the practice was in a rural/city or affluent/deprived area, size of the 
practice in terms of staff and patients registered. This could not be used in the multilevel 
modelling to look at level 2 effects; which were shown to be important by the large VPC 
and MOR values. Likewise there was limited data collected on the patient demographics 
such as ethnicity, social status, education, marital status that may have had associations 
with the outcomes. 
Sources of Bias 
As this was a prospective observational study under the management of four established 
European primary care research networks there may have been some selection bias. 
Firstly the selection of the participating practices was not random or selected from the 
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whole of each country; therefore, the generalizability of the findings may not be 
appropriate to each country which the network represents. For example, practices 
agreeing to participate may have clinicians or nurses that are more interested in research 
or UTI than other general practices. Networks may have recruited practices that are 
research experienced and that have good recruitment potential. However, a random 
sample of practices across the whole of each country would not have been feasible and 
the networks should still represent the diversity and influence of contextual, health 
service and cultural variations across clinical outcomes.  
Participating clinicians were asked to register sequential patients with symptoms of UTI 
and assess their eligibility for the study. There may have selection bias by the recruiting 
clinicians; they may have selected women they thought were more likely to participate 
fully by completing diaries and providing urine samples; women who were less ill may 
have been easier to recruit; patients not fluent in the networks native language may have 
not been selected; consultation type could have led to selection bias i.e. patients that 
usually consult via telephone may not have been recruited and therefore only patients 
that were available for a face to face consultation were selected. I did not look at any 
differences between women who agreed to participate and those that declined or were 
not invited to participate as part of my research.  
The interpretation of what constitutes an uncomplicated UTI may be very clinician/GP 
specific and variable between participating clinicians and/or practices. The inclusion 
criteria was broad which avoids influences from the study team over the clinicians in 
determining which patients have an uncomplicated UTI. 
Although this was an observational study of routine practice, influences of the research 
networks study teams were unavoidable in that data had to be collected through study 
designed CRFs, patient diaries and direct contact during follow-up for the return of 
patient diaries. Clinicians and patients were aware they were participating in a research 
study and this may have influenced them in some way.  
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Systematic non-response to the CRF and/or diary (either by the patient or clinician) could 
lead to bias; ideally all data should have been collected for every patient recruited into 
the study, however this was not the case. 
Some of the questions in the diary used for my analyses included ‘history of UTI and 
treatment’ which may have led to recall bias.  
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Section 5: Overall Discussion 
In this chapter I will summarise what is already known in this area, discuss the main 
findings and implications of the research that make up this PhD thesis, how my research 
can contribute to the antibiotic resistance public health problem, the main strengths and 
limitations of my research,  and provide an overall conclusion. 
 
How the thesis developed 
This PhD originally focused on the development of chromatic sensing as a diagnostic 
test at the point of care for common infections. The first aim was to decide which common 
infection this test had the potential to diagnose; chronic obstructive pulmonary disease 
(COPD) and UTI were originally chosen but I quickly realised access to and working with 
sputum samples was problematic (working inside a containment level 3 laboratory and 
sputum samples are often small and very mucoid making them difficult to manipulate) 
and so the PhD focused on the diagnosis and management of UTI alone. In parallel the 
POETIC study was initiating and I joined this team with the aim of contributing to the UK 
FlexicultTM SSI-urinary kit evaluation and the analysis of the observational management 
data. Within the first year of my PhD my supervisors and I concluded that the chromatic 
sensing test was not at a stage for further clinical evaluation and required more research 
on the physical and mathematical development which was not the aim of my research. 
However, as I was evaluating the UK Flexicult kit in a laboratory analytic performance 
study for POETIC I decided to include the chromatic sensing test at this stage to get 
some preliminary data on using this test with clinical samples (urine) which may 
contribute to future development of the test. My contribution to the optimisation of the 
set-up of chromatic sensing technique for the evaluation of urine samples has led to a 
publication (70) which may help direct future research in this area and the further 
development of this technique as a point of care test. Describing UTI management in 
primary care is essential step to minimising unwarranted clinical variation and the 
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systematic review and POETIC observational data enabled me to evaluate this. I hope 
that this thesis not only reflects the individual studies but also brings the studies together 
into one comprehensive piece of research that contributes to the initiative to improve 
appropriate antibiotic prescribing for uncomplicated UTI in primary care. 
 
What is already known on this subject? 
UTI is one of the most common bacterial infections affecting humans.  Many women 
presenting to their clinician with classic (uncomplicated) UTI symptoms and/or history of 
UTI are prescribed an antibiotic agent empirically (prior to determination of an etiological 
diagnosis) by their GP without any additional testing to confirm if bacteria are present 
and if antibiotics are actually necessary; however, clinical score alone has been shown 
to have limited value (40, 44) and women of all ages are at increased risk of UTI after 
antibiotic use, exacerbating the problem (16, 21). 
Further investigations at the point of care predominantly include dipstick urinalysis; but 
its use is limited by low negative predictive value – it is not useful in ruling out infection 
(44, 50) and therefore its use for improving appropriate antibiotic prescribing for 
uncomplicated UTI is questionable. Laboratory culture is not recommended for 
uncomplicated UTI (25) and if requested by GPs does not necessarily result in a change 
in antibiotic prescribing (86). Additionally it has been shown that patients symptomatic 
for UTI are often not found to be microbiologically positive for a uropathogen (32); 
although this may be due to additional factors such as poor sampling, transportation and 
storage of urine leading to cell death, the semi-quantitative and subjective nature of 
microbiological culture, and the (varying) definition of positive UTI (38). 
Most countries have national or international guidelines for the management of 
(uncomplicated) UTI in primary care. Cultural factors play a substantial role in the 
production of guidelines, both in the selection of literature and in the formulation of 
recommendations. There are noticeable differences in selection of evidence between 
guidelines. For example Christiaens et al. compared four European guidelines and 
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showed that of 205 literature citations, only seven were shared between three guidelines 
and only one by all four guidelines (Germany, Netherlands, Norway, Belgium) (104). 
More references were shared in the therapeutic sections than in the diagnostic sections; 
this may be partly due to lack of diagnostic trials in general practice.  Most diagnostic 
data are from laboratory based studies which cannot be extrapolated to general practice; 
even the definition of UTI in a clinical setting is controversial (104). National antibiotic 
recommendations depend on local resistance rates and national drug licencing 
regulations. Even so, the current recommended treatment for uncomplicated UTI in most 
countries involves a limited number of first-choice options (one or two antibiotics) with 
higher dose, short duration antibiotic therapy (11, 22, 25, 105). The selection of 
mutational antibiotic resistance in bacteria is often promoted by prolonged antibiotic 
therapy, by infection sites where it is difficult to achieve high drug concentrations and by 
under-dosage (sub-lethal level for bacteria). It is generally accepted that the duration of 
antibiotic therapy influences the impact on gut flora, which may act as a reservoir of 
future opportunistic pathogens (6). There is also evidence that treatment with a variety 
of antibiotics causes a transient increase in both the proportion of E. coli from the normal 
flora that are drug resistant, and in the proportion of subjects who carry drug-resistant E. 
coli (106). National guidelines are often not adhered to and patient management 
including antibiotic prescribing varies between practices as well as countries. In a large 
study including a representative sample of general practices in the Netherlands, it was 
found that GPs followed UTI treatment guidelines in 42% cases and that level of 
adherence varied widely (0-95%) between practices (31).  Likewise in the UK, whilst 
there was a 21% fall in the number of antibiotic prescriptions between 1995 and 2000 in 
general practice there was also a six-fold variation in the number of prescriptions 
between different general practices (1). 
Surveillance of antibiotic usage is an important component of effective antibiotic 
stewardship but the data currently available often has significant limitations. In particular, 
although information is available on the overall levels of antibiotic prescribing in the 
community, information on the clinical conditions for which the drugs were prescribed is 
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limited, so it is not always possible to assess whether treatment guidelines are being 
followed (8). Nevertheless a recent UK survey has reported the proportion of women 
aged 16-74 years with selected UTI diagnoses linked to an antibiotic prescription who 
were prescribed trimethoprim was 53.5% in 2011 down from 62.1% in 1995 and the 
proportion prescribed a short course of antibiotic increased from 8.4% to 49.5% in 2011. 
There was increased prescribing of nitrofurantoin from 4.8% to 24.0%; and the proportion 
that was short course increased from 5.9% to 20.1%. Yet again the variation between 
practices was particularly marked for treatment duration; with an IQR for the proportion 
of trimethoprim course that were short course of 16 – 71% in 2011(8).  
Reducing unnecessary antibiotic prescribing is undisputedly important in minimising the 
selection of new resistance. Equally critical, though, is the choice of which antibiotic is 
used and at what dose and duration, for there are marked difference in selectivity both 
between and within drug classes. There is also a great need to improve and accelerate 
the development of suitable diagnostic tests for common infections and bacterial 
resistance, suitable for use at the point of care, thereby reducing or removing the need 
for protracted empirical treatment with broad-spectrum agents (107). 
 
Study Outcomes 
UK Flexicult SSI Urinary Kit 
Main findings 
The UK version of the Flexicult SSI-Urinary kit had never been evaluated for its analytic 
performance compared to the current UK reference standard prior to my study. As a 
result of this study I found; 
 Cephalothin and co-amoxiclav antibiotic sections of the UK Flexicult plates fail to 
inhibit the growth of a sensitive strain of E. coli within their recommended 8 week 
shelf-life; 
 The UK flexicult plate showed a high level of false positive results when 
compared to NHS routine microscopy and culture, after evaluating the plates for 
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quantification, identification, and predominance. The sensitivity of the test 
markedly improves when the plates are evaluated for quantification only so that 
any visible growth ≥105 cfu/mL (innumerable discreet colonies to growth covering 
the plate) may be a UTI but growth <105 cfu/mL is likely to be another diagnosis;  
 Diluting turbid urines prior to inoculation on the UK Flexicult plates did not 
improve the diagnostic accuracy when evaluating the plates for quantification, 
identification, and predominance; 
 Other than trimethoprim and 1st generation cephalosporins the UK Flexicult plates 
showed higher levels of resistance than routine NHS susceptibility testing; 
 The plates are highly subjective; after training the GPs and providing both the 
manufacturers manual and access to a website with guidance on reading the 
plates the GPs only showed moderate strength of agreement with myself 
compared to the more experienced biomedical scientists who showed substantial 
strength of agreement. 
 
Implications 
Implications and recommendations based on the UK Flexicult evaluation study include; 
 Informing the design and management of the POETIC RCT by:  
o developing the Flexicult CRF for the RCT;  
o the manufacturers’ revised the UK Flexicult brochure based on my 
experience of using the kits;  
o developing the POETIC Flexicult training website;  
o shortening the shelf-life of the UK Flexicult plates from 8 weeks to 6 weeks 
prior to using the kits in the RCT.  
 Recommending the use of the plate as a screening test rather than a diagnostic 
test in primary care. Not only does the sensitivity of the test improve, the plates 
are much simpler to read when quantification is the only criteria. 
 By diluting urines 1 in 1000 the detection limit of the plates is >105 cfu/mL; if this 
test is used for screening out negative samples only this could be a simple way 
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to differentiate between positive and negative samples i.e. if there is any bacterial 
growth after inoculating the plate with urine diluted 1 in 1000 the patient may have 
a UTI and further testing and/or empirical prescribing of antibiotics is 
recommended.  
 Co-amoxiclav and cephalothin should not be included in a point of care culture 
based test such as Flexicult that requires extended shelf-life for transport and 
storage. 
 The plates could be changed to remove the antibiotic sections altogether if just 
used as a screening test. Alternatively the plates could be used to test for 
susceptibility to recommended first-line antibiotics only i.e. in the UK this would 
include trimethoprim and nitrofurantoin. This would increase the surface area for 
inoculation and bacterial growth and should improve interpretation.  
 To use the UK Flexicult plates to their best performance there needs to be 
appropriate user training and guidance; this may be in the form of an interactive 
web based system or workshops. As the kits are used more frequently the 
understanding and performance of the user should increase. 
 
Chromatic sensing 
Main findings 
There was no published evidence that a novel chromatic sensing technique had ever 
been applied to identify bacterial infection of urine prior to my research, and my findings 
have shaped the research agenda regarding using chromatic sensing as a POCT for 
diagnosis of common infections in primary care. Chromatic sensing had a similar analytic 
performance to visually assessing urine with a sensitivity of 100%. However the system 
needs to be evaluated based on various users, equipment and locations, particularly as 
the fundamental process of this system uses ambient light and screen illumination. 
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Implications 
Chromatic sensing removes the subjectivity or uncertainty of assessing the turbidity of 
urine by the assessor and may be useful in practice if GPs unwilling to use their own 
perception for screening out negative samples. 
Further development of the chromatic sensing system is required to formalise the 
equipment set-up, automate the results for instant output and ideally improve the ability 
to identify true positive samples before further clinical and economic evaluations. 
 
Visual turbidity and dipstick urinalysis 
Main Findings 
The laboratory evaluation study showed that visually assessing urine as clear (non-
turbid) had a 100% sensitivity (no false negative results).  From the observational study 
I found that  half the urines from patients were assessed as clear by the study clinicians; 
so unless symptoms or patient history are highly indicative of UTI, antibiotic prescribing 
could possibly be reduced by 50% using this simple method. However, when I analysed 
the observational turbidity data with the associated microbiology results 8% of the 
samples had a false negative result. 
Urinalysis dipsticks are the most commonly used POCT for uncomplicated UTI across 
the four networks evaluated in the observational study and from the studies evaluated in 
the systematic review.  
Analysing the data from the UK networks only; recording a nitrite negative result could 
screen out more patients than recording a leucocyte negative result (69% versus 19%), 
however, more women with true UTI would be missed using the nitrite negative urinalysis 
result (12% versus 3%). The laboratory evaluation of dipsticks showed a similar trend in 
that negative nitrite results were more prevalent but negative leucocyte results had lower 
numbers of false negative results. All networks’ guidelines indicate a positive nitrite result 
as probable UTI. From the laboratory evaluation study, I found the most accurate 
prediction rule to be ‘visually turbid urine with either positive nitrite or leucocyte urinalysis 
dipstick result’ as indicative of a bacterial UTI. However this is not replicated when 
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analysing the data from the observational study. None of the urinalysis dipstick tests or 
evaluation of urine turbidity perform well at confirming a microbiologically positive UTI.  
Although urinalysis dipsticks are the most commonly used POCT for uncomplicated UTI 
this does not have an impact on antibiotic prescribing as in the UK as >92% patients 
were prescribed at least one antibiotic suggesting there may be different reasons for their 
use. I found that negative nitrite results are associated with an increase in routine culture 
requests and the use of dip-slides (in Utrecht). Having a positive leucocyte result was 
significantly associated with prescribing an antibiotic that was different to that 
recommended by the guidelines (for type, total dose and duration).  
Implications 
Current UK guidelines indicate that if a urine is not cloudy to consider another diagnosis; 
further diagnostic testing and/or empirical treatment is not recommended. Even though 
almost half the urines in the UK networks were assessed as clear the majority of patients 
still had a urinalysis dipstick test performed and were prescribed an antibiotic. This 
suggests that GPs are not confident in using this recommendation in practice. 
Although the visual assessment of turbidity was not as sensitive when evaluating the 
POETIC data as the laboratory evaluation data this study was not set up as a diagnostic 
evaluation study.  In the laboratory evaluation study I was the only assessor of whether 
the urine was turbid or not and I had a set of criteria that helped to assess the degree of 
turbidity in the urine. 
I believe there is importance in evaluating the visual assessment of urine as a simple 
screening test for UTI in a pragmatic diagnostic study. The use of set criteria for turbidity, 
a visual comparator/aid (similar to McFarlands standards) or the use of a turbidimeter 
may improve the sensitivity and reduce subjectivity in practice. Positive results from such 
a study may improve the adherence to HPA guidelines in practice. 
The results of my studies suggest that urinalysis dipsticks are not useful in guiding GPs 
management of UTIs. Negative nitrite results have too high a risk to patients with a true 
infection being missed and the proportion of patients with a leucocyte negative result are 
too small to make the test particularly useful. 
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Routine Culture and dip-slides 
Main findings 
Routine culture requests for patients with suspected uncomplicated UTI in the UK (60% 
in the Cardiff and Southampton networks) are much higher than should be expected if 
the management guidelines for UTI in primary care were being followed. Routine culture 
requests were significantly associated with increasing age, night-time frequency and a 
nitrite negative dipstick test results which could be causing the GP uncertainty in the 
diagnosis. 
In the POETIC study Utrecht was the only network to use dip-slides as a POCT. Utrecht 
is also the network with the lowest level of antibiotic prescribing although I am unable to 
say if this directly a result of using the dip-slides.  
However, I did find that not prescribing antibiotics was significantly associated with 
requesting samples for routine culture/or the use of dip-slides. There could be reverse 
causality involved and it is difficult to know if not prescribing an antibiotic results in a 
request for urine culture or if requesting samples for culture stops antibiotic prescribing.  
The prevalence of microbiologically confirmed UTI particularly in the Utrecht and to a 
lesser extent the Spanish networks was much higher than in the UK networks. The 
prevalence of microbiologically confirmed UTI in the UK networks of the POETIC study 
and the Flexicult laboratory evaluation study were similar. 
Implications 
GPs in the UK rely heavily on the NHS for routine urine culture even when it is not 
recommended and this could be due to diagnostic uncertainty. This could be alleviated 
by the introduction of a test such as Flexicult that could screen out negative samples at 
the point of care reducing the burden on the NHS  laboratories and supporting the GPs 
diagnosis and management decisions associated with suspected UTI or not. 
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Antibiotic prescribing 
Main findings 
 Antibiotic prescribing for uncomplicated UTI in the UK and Spanish networks was 
found to be over 90%. The Dutch network was lower at just under 60%.  
 The UK networks prescribed first-line antibiotics according to the country specific 
guideline recommendations in the majority of cases.  
 The Spanish and Dutch networks also prescribed antibiotics according to their 
country specific guidelines in over 80% cases.  
 Prescribing an antibiotic that was not recommended as first-line was associated 
with the feeling of being unwell, having a high temperature and having no or 
limited burning sensation when passing urine. History of UTI was also associated 
(but I was unable to include this in the multi-level model as the sample size was 
too small). 
 The duration of the prescribed antibiotic course was often longer than 
recommended.  
 Discordant treatment regimens including dose and duration were associated with 
network (Southampton or Spain), three or more prior antibiotic treatments for UTI 
in the past and having a leucocyte positive dipstick which could cause the GP to 
consider a more complicated/resistant infection.  
 Variation in prescribing according to the guidelines between practices was shown 
and unexplained level 2 variation from the multilevel models was large. 
 
Implications 
 Concern over diagnostic uncertainty of more complicated UTI is associated with 
prescribing alternative antibiotics to recommended first-line or for longer than 
recommended – removing this diagnostic uncertainty may help GPs follow the 
guidelines.  
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 For currently available antibiotics manufacturers could be asked to develop 
infection based, user friendly packaging/blister packs for various treatment 
regimens for community acquired infections, for example, uncomplicated UTI 
blister pack of trimethoprim would contain 6 doses of 100mg to be taken twice a 
day for three days. This would have cost implications that would need to be 
evaluated. 
 Research into antibiotics that are currently unlicensed in the UK such as 
fosfomycin and pivmecillinam would be worthwhile as resistance levels should 
be low (but this will need to be studied) and patient management and compliance 
should be more plausible (for example fosfomycin is a single dose).  
 Pharmacist led quality control checks of prescriptions could improve 
concordance with the guidelines. 
 Future studies would benefit from collecting data on the GPs, GP surgeries and 
other level 2 variables which may explain the difference between practices.  
 
 
What does my research add to fight against antibiotic resistance? 
The current recommendation is to prescribe empirically for suspected uncomplicated 
UTI; the systematic review and observational study show that antibiotics are being 
prescribed empirically when a GP suspects uncomplicated UTI. The systematic review 
showed that within published studies definitions of uncomplicated UTI vary greatly.  
Results from the POETIC observational study also suggest that diagnostic uncertainty 
leads to antibiotic prescribing outside of the recommended guidelines. In primary care, 
tests at the point of care tend be more useful in screening out samples rather than 
confirming a diagnosis (76). With further pragmatic evidence visually assessing urine for 
turbidity and the UK Flexicult kits could both be useful in screening out large proportions 
of patients from empirical prescribing. This could remove diagnostic uncertainty for those 
GPs and patients but also reduce empirical antibiotic prescribing by half. Where GPs do 
want a definite diagnosis, routine NHS culture and susceptibility testing is the reference 
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standard; however by screening out a large proportion of samples that do not need to be 
processed the NHS laboratories can focus more on uncertain or complicated UTIs. 
There was a recommendation by the UK Department of Health’s Standing Medical 
Advisory Committee (SMAC) Sub-Group on Antimicrobial Resistance in 1998 limiting 
prescribing for uncomplicated cystitis to 3 days in otherwise well women which this study 
has shown is still not being consistently adhered to in 2014. Of the remaining patients 
that do require empirical prescriptions GPs may be more assured in adhering to 
guidelines of short course high dose therapy which will limit the collateral effect of 
resistance. 
 
Strengths and weaknesses  
The limitations and sources of potential bias have been discussed previously for each 
study included in this thesis. This section will discuss what I consider to be main the 
strengths and weaknesses of my overall research. 
The laboratory evaluation study had a limited sample size of 200 samples; this was 
greatly reduced for the susceptibility analysis. There may be concern that the samples 
were from a highly selective population, however, samples were not selected based on 
any information other than suspected UTI. The proportion of microbiologically confirmed 
UTI positive samples in this study was within the approximate usual proportion given by 
Dr Robin Howe, Director and National Lead for Microbiology Services, Public Health 
Wales, University Hospital of Wales. It was also similar to the proportion of positive 
samples in the POETIC observational study (UK only). Although not all samples were 
derived from the target population where the test may be used i.e. patients consulting in 
primary care with suspected uncomplicated UTI, the laboratory based studies were to 
evaluate the analytical performance compared to the reference standards which are 
currently and routinely used in NHS practice. The prevalence of infection from the 
hospital based samples used in the performance evaluations most likely over-estimated 
the prevalence of infection and prevalence of resistance in the target population as these 
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samples were from in-patients and the samples from out-patients may well have been 
selected for referral to routine culture due to complications or concerns of a resistant 
infection by the GP. Likewise there were probably more contaminants from these 
laboratory samples than there would be in practice (requesting urine directly from the 
patient, possibly using a MSU collection device and performing the POCT within a few 
hours; no transport or storage/time delay effects on the samples) but this should result 
in the tests performing better at the point of care than in the laboratory. 
If the diagnostic tests were found acceptable at this stage the next step would be to test 
with the target populations and at the point of practice in a pragmatic randomised study. 
These laboratory studies also provide information on the clinical practicalities such as 
potential difficulties for naïve users; and flaws in the design and quality control issues; 
which can go on to inform further research.  
Using the defined search criteria the systematic review found there are limited published 
studies evaluating the routine management of uncomplicated UTI in primary care in 
Europe. Even within these studies the source populations vary due to different 
recruitment and enrolment processes. This has been highlighted as a major limitation 
and studies that had completely different recruitment processes were excluded from the 
synthesis of results.  
The POETIC observational data provides evidence of the actual routine management of 
patients consulting primary care with uncomplicated UTI. The main limitation for this part 
of my thesis was that the sample size was not generated with my research questions in 
mind and the maximum potential level of clustering accounted for was 5.70%. There 
were much higher levels of clustering for prescribing antibiotic type according to the 
guidelines, requesting a routine urine culture and prescribing antibiotic type, dose and 
duration according to the guidelines (ICC=0.16; 0.23; 0.33 respectively) at practitioner-
level within the sample than initially predicted. This has resulted in a larger design effect 
and smaller effective sample size. As I am unable to increase the sample size the 
precision around the confidence intervals are wider than initially specified. Because this 
study was underpowered, Type II errors, incorrect failure to reject a false null hypothesis 
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(false negatives), may have occurred. In order to be confident in future studies that no 
similar errors will occur, the sample size should be specifically calculated with the 
modelling of such predictors in mind. Additionally, the univariate analyses used to 
determine which predictors should go into the models involved multiple testing and may 
have caused Type I errors (false positives); the p-values and associations described 
within this preliminary analysis need to be interpreted within the context of the multilevel 
models framework.  
Much research data is routinely acquired, that is, it is derived from data entered into 
routine databases or samples received in hospital laboratories, with little knowledge of 
why it was referred and how representative it is to the general population. In practice, 
firstly, a symptomatic patient has to make the decision to consult a clinician, then the 
general practice system determines whether this complaint warrants consultation, then 
upon consultation (which may be by telephone), a clinician diagnoses the patient and 
decides whether to prescribe or not based on clinical symptoms or history alone or to 
use additional diagnostic strategies. Changes in antibiotic use can be due to changes in 
any of these decisions and procedures – simply comparing prescribing data at the level 
of clinician may not provide comparable data (9). Observational studies provide data at 
the individual level and provide information about clinical infections in large populations 
of representative patients but are highly vulnerable to bias and confounding. The 
POETIC study used broad patient inclusion criteria and a data collection protocol was 
used by all networks. However, there was limited data collected on secondary level 
effects such as clinician gender, age, experience, practice location 
(rural/city/affluent/poor) and practice size, which considering the level of clustering may 
have been useful to explain some of the between practice variance. The fact that both 
the POETIC study and systematic review have demonstrated similar findings (e.g. high 
levels of empirical prescribing and not following short term treatment) is convincing 
evidence that the associations are real and has not been produced by chance, 
confounding or bias.  Consistency with other studies means that the most persuasive 
evidence to support a judgement of a cause-effect relationship arises when ‘a number of 
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studies, conducted by different investigators at various time using alternative 
methodology in a variety of geographic or cultural settings and among different 
populations, all show similar results’ (108). 
 
Final Conclusions 
I have met the overall research aim of my thesis. Firstly, I have evaluated the analytic 
performance of various POCTs for uncomplicated UTI and provided recommendations 
for future research and use in clinical practice. Secondly, I have described the 
management of uncomplicated UTI in primary care in Europe both through a systematic 
review of the literature and from the analysis of observational data from a multi-centre, 
multi-national primary care based study. 
This thesis continues to support the evidence that antibiotics are being prescribed 
empirically for uncomplicated UTI. First-line antibiotics are generally being prescribed 
according to relevant guidelines, however, duration of the prescribed antibiotic course 
was often longer than recommended. Concern over diagnostic uncertainty of more 
complicated UTI is associated with prescribing alternative antibiotics to recommended 
first-line or for a longer course than recommended – removing this diagnostic uncertainty 
would help GPs follow the guidelines. 
POC tests in primary care are most useful in their clinical reasoning by ruling out UTI 
particularly in cases of ambiguous clinical signs and symptoms; confirming the need for 
further testing in more complicated cases; or empirical prescribing with a test of treatment 
in uncomplicated cases (109). This is apparent in two of the POC test evaluated in my 
study. By using quantification only, irrespective of predominance or identification, the 
sensitivity of UK Flexicult was increased to 100%; indicating this POC culture test is most 
useful in screening out negative urine samples prior to antibiotic prescribing and/or 
sending samples for diagnostic culture and susceptibility testing. Likewise my laboratory 
study showed a sensitivity of 100% for the visual assessment of urine turbidity again 
indicating its potential as a highly effective screening tool in primary care. Current UK 
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guidelines recommend that if a urine is not cloudy to consider another diagnosis to UTI 
and that further diagnostic testing and/or empirical treatment is not recommended. Even 
though almost half the urines in the UK POETIC networks were assessed as clear the 
majority of patients still had a urinalysis dipstick test performed and were also prescribed 
an antibiotic. This suggests that GPs are not confident in using this recommendation in 
practice. The use of set criteria for turbidity (such as the criteria used in my study), a 
visual comparator/aid (similar to McFarlands standards or the BronkoTest for sputum) or 
the use of a turbidimeter may improve the sensitivity and reduce subjectivity in practice. 
Positive results from pragmatic studies of these tests may also improve the adherence 
to guidelines in practice.  
 I have been able to describe the variations in management between countries and to a 
limited extent between practices. The variations did not prove to be warranted with 
respect to patient demographic or symptom severity when consulting and the 
management processes employed could be more efficient between practices and 
countries. Variations included lower empirical prescribing in the Netherlands network 
compared to the UK and Spanish networks. Additionally variations were seen in 
prescribing first-line antibiotics and duration of the course of prescriptions across the 
networks. Guidelines do vary from network to network, for example, the Netherlands only 
have one recommended first-line antibiotic so the higher level of prescribing an 
alternative antibiotic to first-line may not be surprising. Interestingly the UK networks in 
Wales and England which do use the same guidelines did still show differences in the 
adherence to prescribing the correct duration of treatment. It’s imperative that future 
studies collect data on the secondary level factors to do with the GPs and practices that 
can then be evaluated when looking at these variations which were not possible in my 
analyses.  Having a standardised guideline for the management of uncomplicated UTI 
between regions and countries may not be straightforward or appropriate. As one 
example, analysing the POETIC data has shown that countries such the Netherlands 
and Spain have a much higher prevalence of microbiologically confirmed UTI which in 
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turn shows the value of different diagnostic tests is variable depending on the region it is 
used in.  
Overall I found the most interesting outcomes from my PhD research to be the continued 
prescribing of antibiotics for a duration longer than recommended even though over 10 
years ago there was a report from the UK Department of Health’s Standing Medical 
Advisory Committee (SMAC) Sub-Group on Antimicrobial Resistance that recommended 
limiting prescribing for uncomplicated cystitis to three days in otherwise fit women (8). 
POC tests in primary care could be incredibly useful in helping clinicians decide whether 
to prescribe an antibiotic or not, however, these tests need to be simple, non-subjective 
and accurate, which currently they are not. For example, from both the systematic review 
and observational study urinalysis dipsticks were shown to be the most commonly used 
POCT for uncomplicated UTI, however their use did not show any associated reduction 
in antibiotic prescribing. Alternatively my studies have shown greater potential for both a 
basic visual assessment of turbidity and the use of a simple culture based test for 
screening out patients with uncomplicated UTI, however, pragmatic evaluations are 
needed to support and ultimately encourage their use in practice. 
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Appendices 
2.1.1 Flexicult laboratory evaluation ethical and research and 
development approval letters 
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2.1.2 Flexicult data worksheet 
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2.1.3 Diagnostic Performance Measures 
Sensitivity and specificity assess the tests diagnostic accuracy. Sensitivity shows the 
likelihood of a positive test result if an individual were to truly have the disease. The 
specificity shows the likelihood of having a negative test result if an individual does not 
have the disease. The sensitivity and specificity are characteristics of the test itself and 
are independent of the disease. 
Disease prevalence is combined with sensitivity and specificity to create the positive 
and negative predictive values. The positive predictive value (PPV) is the probability 
that the patient has the disease when the test result is positive.  The negative predictive 
value (NPV) is the probability that the patient does not have the disease if the test result 
is negative. The PPV and NPV are post-test probabilities, that is, they are the updated 
probabilities given the information provided by the positive and negative test results, 
respectively.   
The error rate is a weighted average of errors among persons with the disease (the 
false negatives) and among those without the disease (the false positives).   
The likelihood ratio combines into one number the sensitivity and specificity of the test. 
The likelihood ratio for a positive test is the sensitivity divided by one minus the specificity 
(Likelihood of a positive result in patients with the disease/likelihood of a positive result 
in patients without the disease). The likelihood ratio for a negative test gives the chances 
that a negative result will be expected in a patient who does not have the disease, as 
opposed to one who does. If test A has a higher positive likelihood ratio (PLR) and higher 
negative likelihood ratio (NLR) than test B, test A should be regarded as superior to test 
B; if one test has higher PLR but lower NLR, we cannot say unequivocally which is 
superior.  
The receiver operating characteristics (ROC) methodology was developed 
specifically to enable display of the trade-off between sensitivity and specificity for any 
ordinal or continuous variable as the dichotomy point is altered. It is technically possible 
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to do the same thing for a binary predictor variable, but this doesn’t add any value as 
there is just one point on the curve. The other important landmark on the plot is the 
diagonal line (at 45 if equal scales are used) from (0, 0) to (1, 1), which represents what 
a useless test would look like. The ROC curve is normally convex upwards. The most 
accurate ROC curve is one that arches up to the upper left-hand corner of the graph 
before moving to the upper right hand corner of the graph. 
The area under the receiver operating curve (AUROC) is the same as U/mn, the 
Mann-Whitney U-statistic divided by the product of the sizes of the positive and negative 
groups. It serves as a very general measure of discrimination. The AUROC can range 
from 0 to 1, with 0.5 corresponding to the null hypothesis of no difference between 
positives and negatives. 
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2.1.4 Reproducibility data form 
*Included are pages 1, 2 and 6; pages 3 – 5 are the same as page 2 with space for the remaining plate readings 
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2.1.5 Images of spiral plate cultures and corresponding Flexicult plates for 
four samples evaluated in this study 
  
FC011 
Spiral Plating (Left picture) 
Quantification = >105 cfu/mL 
Identification = Coliform 
Flexicult (Right picture) 
Quantification = >105 cfu/mL 
Identification = Mix, No predominant organism 
 
 
FC057 
Spiral Plating (Left picture) 
Quantification = >105 cfu/mL 
Identification = Proteus predominant (>10x) 
 
Flexicult (Right picture) 
Quantification = >105 cfu/mL 
Identification = Mix, Proteus probable predominant 
organism due to agar colour change 
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FC074 
Spiral Plating (Left picture) 
Quantification = 104 - 105 cfu/mL 
Identification = Enterococcus sp. 
Flexicult (Right picture) 
Quantification = >105 cfu/mL 
Identification = Enterococcus spp. 
 
 
FC150 
Spiral Plating (Left picture) 
Quantification = >105 cfu/mL 
Identification = E. coli predominant (>10x) 
Flexicult (Right picture) 
Quantification = >105 cfu/mL 
Identification = E. coli predominant (>10x) 
 
 
 
 
 235  
 
2.3.1 Development of chromatic sensing system set-up and preliminary 
analyses 
 
Study aim 
The aim of this study is to explore chromatic sensing as a potential point-of-care test to 
help GPs in their decision to prescribe antibiotics to patients with suspected urinary tract 
infection. This study represents two steps in the process: determining the feasibility (this 
section); and evaluating the analytic performance of this novel diagnostic test intended 
for clinical use (section 2 chapter 3 of the main thesis).  
 
Section objectives 
1. Refine and optimise the chromatic sensing technology set-up for capturing 
images of complex liquids including urine; 
2. Refine and optimise the chromatic analysis of complex liquids and urine 
samples; 
3. Explore the potential of chromatic sensing in determining the presence of 
bacteria in urine.  
 
Methods 
 
System Set-Up  
The set-up consisted of a portable computer (Toshiba Portege R500 Laptop), whose 
visual display unit (VDU) provided the main illumination and a web-cam connected to the 
computer which captured images of the plastic cuvette containing the liquid (Sigma 
polystyrene cuvette with stopper #C5677-100EA) . The chromatic information was 
extracted via software installed in the computer. A stand holding the cuvette(s) was 
placed approximately 2 cm in front of the laptop screen, with the required background 
(Microsoft Office PowerPoint template on screen, developed and provided by Liverpool 
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University), and the webcam positioned so that the screen was visualised through the 
liquid in the cuvette (see Fig. 1 below).  
 
Figure 1. Set-up and image capture of liquid samples using a laptop and webcam: a) 
diagram of set-up; (b) photograph of an example of the laptop set-up; (c) example of 
images captured using this set-up.  
a) b) 
 
 c) 
 
  
  
 
 
Various cuvette positions, screen templates and lighting conditions were assessed to 
obtain the most appropriate image for chromatic analysis.  
Once the image had been captured red, green and blue outputs from three positions on 
the image were calculated using specific software developed by Liverpool University 
(Figure 2). Two areas captured either side of the cuvette and this was used to control for 
extraneous effects such as room lighting and shadows. The third area was of the actual 
liquid being analysed. 
 
 
 
Figure 2; An example of the JPEG images captured for chromatic analysis: a) three 
areas of RGB analysis including the sample (ch2) and two comparator areas (ch1+ ch3) 
for quality control; (b) example of the RGB outs for each area on the image. 
Webcam 
to capture 
image  
Laptop with screen background 
illumination behind cuvette 
Cuvette 
with urine 
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a) 
 
b) 
 
Initial urine analysis 
The screen of the laptop had a Microsoft Power-point template slide containing different 
colours (purple, light blue, yellow, dark blue) to be used as a background for the initial 
urine samples.  
Six culture positive (> 1 x 105 cfu/mL) and six microscopy negative anonymised patient 
urine samples were provided by the Microbiology Laboratory, University Hospital Wales. 
Approximately 3 ml of urine was transferred to a plastic cuvette. The cuvette containing 
the sample was placed on a stand above the laptop keyboard, ~2cm in front of the 
coloured screen. 
Images were captured in the Microbiology Laboratory, University Hospital Wales by 
myself. Specifically developed software for RGB data extraction installed on the laptop 
was used at the time of image capture and both the JPEG images and RGB outputs 
were sent to Liverpool University via email. In Liverpool the R, G and B outputs of each 
positive and negative urine sample with each coloured background were analysed and 
mapped using different chromatic parameters (based on mathematical models) to 
determine the optimum differentiation between the known bacterially positive and 
negative samples.  
A further six culture positive (> 1 x 105 cfu/mL) and six microscopy negative urine 
samples were added to the previous 12 urine samples for further chromatic analysis. The 
chromatic parameters used for the total 24 samples varied from the initial 12 urines to 
look more specifically at the dominant wavelength between Blue (B) and Red (R) under 
blue (b) background illumination ((B/R)b); and the difference between dominant 
Chromatic outputs RGB: 
ch 1: R: 252 G: 252 B: 187 
ch 2: R: 166 G: 161 B: 212 
ch 3: R: 212 G: 215 B: 183 
ch
1 
ch
2 
ch
3 
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wavelengths (B or R) under blue and purple (p) background illuminations ((B/R)b – 
(B/R)p). 
Assessing complex liquids: Turbidity 
 
To indicate the form and features of chromatic cluster maps and to address the issue of 
the effect of complex liquid mixtures on chromatic signatures, preliminary tests were 
performed on controlled mixtures of some common clear and turbid liquids plus some 
sterile filtered urine spiked with known quantities of E. coli bacteria. Chromatic analysis 
assessed transmission (absorption) of light through the various liquids, reflection of light 
and fluorescence as shown in Figure 3. 
 
Assessing turbidity: Tea and milk mixtures  
Milk was chosen for the assessment of turbidity to form mixtures with water and tea 
(colour). The water – tea mixtures are representative of optical variations produced by 
changes in relative concentrations of two clear liquids with different polychromatic optical 
transmission properties. Tests with water – milk are representative of optical variations 
produced by changes in relative concentrations of components, one of which (milk) 
produces turbid conditions in an otherwise clear liquid. Tests with tea – water – milk 
represent the further complex condition of optically different clear liquids (water and tea) 
with a turbid medium (milk). The water/tea mixtures were made up as; water only – 1/3 
tea – 2/3 tea – 3/3 tea. Skimmed milk was added to the water or tea as drops from a 1 
mL Pasteur pipette (0, 5, 10, 30 drops). For each liquid 2.5mL was placed into a 
spectrophotometer cuvette ready for image analysis. 
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Figure 3. A description of the three light sources; screen, ambient and UV with examples 
of the final images captured under each light source. 
Screen Light Source 
(Transmitted Light - 
Impurity) 
 
• Attenuated white  
screen behind cuvette, 
absorption of light 
transmitted through the 
liquid 
 
Ambient Light 
Source 
(Reflection/Scattered 
Light - Turbidity) 
• Black card stuck to 
the back of the cuvette, 
measure of the reflection 
of ambient light by the 
liquid 
 
Ultra-Violet Light 
(Fluorescence in 
Sample) 
• UV light source 
shone through the bottom 
of the cuvettes upwards, 
• Black card as 
background  to measure 
the fluorescence  
 
Urine samples spiked with E. coli 
A pool of human urine was sterile filtered through 0.2µm filter (Millipore) to remove any 
commensal bacteria and larger particles. An inoculum of E. coli (ATCC #25922) was 
prepared in sterile water at 0.5 McFarland standard; this involved visually comparing the 
turbidity of the E. coli spiked urine with the McFarland standard until they are the same 
turbidity (this is a standardised microbiological process for determining bacterial 
suspensions). This 0.5 McFarland standard equates to approximately 1 x 108 cfu/mL E. 
coli inoculum. From this inoculum dilutions of 1:10; 1:100 and 1:1000 into the sterile urine 
were made to have additional inoculums of 1 x 107; 1 x 106 and 1 x 105 cfu/mL 
respectively.  For each urine E. coli inoculum 2.5mL was placed into a spectrophotometer 
cuvette ready for image capture and analysis. 
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Transmission (Absorption of light through the liquid) 
Tests were performed with polychromatic light from the VDU screen (attenuated white 
background) transmitted through the cuvette containing the sample in the presence of 
ambient light. The outputs from the three wavelength-dependent pixel elements (R, G, 
B) of the selected image regions were then extracted for further processing by the team 
at Liverpool University. 
For the water-tea-milk liquids chromatic cluster maps were used to examine various 
trends produced by the physically different forms of liquid mixtures: two clear liquids 
(water and tea) with different transmission spectra; turbid component in an otherwise 
colourless mixture (water and milk); and turbid component (milk) with two clear liquids of 
different concentrations (tea and water). The chromatic cluster maps were based upon 
the camera outputs R (long wavelengths) and B (short wavelengths), these were 
corrected (compared to the reference background colours to make sure each image was 
the same), normalised with the water result (0–1) and plotted against each other. 
Ambient light was mathematically, rather than physically, excluded from the transmission 
by means of subtracting the reflected ambient light from the combined result of VDU 
illumination plus reflected light: Rtrans = R(VDU illumination) – Rrefl; Btrans = B(VDU 
illumination) – Brefl.  
 
Reflection (scatter of ambient light from the liquid) 
To assess the reflection/scatter of ambient light caused by the turbidity of the various 
liquids I replaced the VDU illumination (attenuated white screen) with a piece of black 
card stuck to the back-side of the cuvette, allowing only ambient light to be captured and 
assessed from the liquid. 
Fluorescence 
E. coli has been reported to have a peak wavelength optical spectra of ~260nm  (75) 
which is in the ultraviolet spectrum with an overall wavelength range of 200-800nm; 
human vision and camera optics have a range of 400-650nm. To assess the lower end 
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of the spectrum for E. coli (200-400 nm) Liverpool university developed a self-contained 
ultra-violet (UV) light with cuvette holder that shone the UV light through the base of the 
cuvette containing the urine (inoculated with various amounts of E. coli as above), a 
black card was stuck to the back-side of the cuvette and the fluorescence captured 
through the image from the webcam.  Unlike the transmission and reflection of light the 
analysis focused on the G output; it may be expected that G covers a more suitable 
range at which output fluorescence may occur and it provided the most stable output of 
RGB (as advised by Liverpool University). 
Results 
 
System set-up 
Optimisation of the images from the laptop/webcam was based on trial and error and 
communication with the team in Liverpool, the steps are shown in Figure 4. 
The background template was developed by Liverpool University and varied in colours 
and formats; varying the colours increased or decreased the R, G or B outputs. To allow 
the camera to automatically adjust itself correctly for each test, the cuvette was 
positioned in the middle of the screen with the dividing horizontal line between the two 
back-ground colours half-way up the screen and the liquid meniscus close to this line. 
External light sources such as that falling from windows or artificial light were 
unavoidable as this study was performed in a busy microbiology laboratory. However I 
avoided placing the laptop in direct sunlight or directly below artificial lights to minimise 
glare and extraneous effects. 
Final camera settings were set to’ Auto’: Exposure 67; Brightness 20; Contrast 20; 
Saturation 50; Sharpness 3; and Gamma 3.  
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Figure 4. Optimisation of cuvette image through repositioning, zoom, lighting and 
background template. 
 
 
Problem: The area of urine to be analysed was 
very small and colours  too bright 
Action: Changed cuvette, new Power Point 
template produced 
 
 
Problem: Image better with only two background 
colours on each image  
Action: Zoom into Image 
 
 
Problem: Image too bright, halo effect 
Action: Reduced screen brightness, covered laptop 
 
 
Problem: Background colours too dark 
Action: Screen brightness set to auto, uncovered 
laptop and new Power Point template produced 
 
Problem: Background still too dark, resolution 
poor 
Action: New Power Point template produced, 
Image resolution increased by using manual focus 
of webcam 
 
 
 
Acceptable Image for Initial Urine Analysis 
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Initial urine analysis results 
The results showed similar values for the R and G under all illuminations but the B 
outputs showed more variation.  The output for B was approximately 0 for all negative 
and most positive samples under yellow screen illumination (Figure 5) indicating limited 
or no Blue wavelength with this set-up. This raw data indicated that the best chromatic 
parameters to follow up on were to analyse B and R or B and G outputs rather than R, 
G and B as the outputs for R and G are the same. 
 
Figure 5. Graphs showing camera outputs of Red, Green and Blue (Sa R, Sa G, Sa B) 
for 6 bacterial negative urine samples (pu, po, o, mk, lo and kl) and 6 bacterial culture 
positive urine samples (uEColi, plSau, mEcoli, jEcoliM, iSau, hEnt) each sample having 
four background illuminations (b – blue, y – yellow, lb – light blue, p – purple) 
 
 
 
Negative samples 
Positive samples 
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Further chromatic mapping using the parameters of dominating wavelength B or G with 
blue versus yellow background illuminations (Bb/Gb and By/Gy respectively) showed 
distinctive clustering of positive and negative samples (Figure 6). This analysis also 
showed that two distinct clusters of negative samples and one positive sample were 
located separately from the other positive samples. The reasons for this required further 
investigation; although the turbidity of the urine for both the differences in negative 
clusters and the single outlying positive urine was of key interest.  
 
Figure 6. Chromatic Map of the Blue (B) to Green (G) dominant wavelength under blue 
illumination (Bb/Gb) versus the amount of B to G dominant wavelength under yellow 
illumination (By/Gy) in bacterial positive and negative urine samples 
 
 
When the additional 12 urines samples were analysed with the initial 12 urines samples 
the results indicated a weak short wavelength component (B) compared to more 
dominant long wavelength (R) when B/Rb<1 under blue illumination. B/Rb – B/Rp → 0 
indicates little difference between the dominating wavelengths under blue and purple 
illumination i.e. results in a broad spectrum (~ white) and this could be an important 
indication of turbidity (Figure 7). Taking this into account the graph was grouped into cut-
offs to show clustering of chromatically turbid and non-turbid samples using B/Rb - B/Rp 
< 0.5 as turbid. When looking at the samples in this section the negative urines showed 
a dominant long wavelength (R) compared to the positive urine samples. Likewise when 
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looking at non-turbid samples (B/Rb – B/Rp > 0.5) the positive urine samples showed a 
stronger dominant short wavelength (B) compared to the negative samples. The turbidity 
of the urine warranted further evaluations.  
 
Figure 7. Chromatic Map showing the dominant wavelength between Blue (B) and Red 
(R) under blue illumination (B/Rb) and the difference between dominant wavelengths 
under blue and purple illuminations (B/Rb – B/Rp) for bacterial positive and negative 
urine samples 
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Assessing complex liquids: Turbidity 
Transmission of light 
Milk and tea mixtures 
Figure 8 shows an example of an Rtrans : Btrans cluster map for optical transmission 
(trans) of the VDU illumination for tea diluted with water, water with a few drops of milk 
(5 and 10 drops) and water, tea and milk mixtures (milk 5, 10, 30 drops).  
 
Figure 8. Chromatic Cluster Map of R:B light transmission through various water-tea-
milk liquids. 
 
 
 
The Rtrans : Btrans results for mixtures of water and tea (clear non-turbid liquid mixtures) 
show that the short wavelengths (B) reduce in strength with increasing tea concentration 
more rapidly than the long wavelengths (R). As such the Rtrans:Btrans locus for this 
liquid mixture lies above the equal strength locus Rtrans = Btrans. 
The Rtrans : Btrans  results for mixtures of water and milk (turbid mixtures) show that 
the long wavelengths (R) reduce in strength with increasing milk concentration more 
rapidly than the short wavelengths (B) and may be associated with polychromatic light 
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scattering by the turbidity. The Rtrans : Btrans locus lies well below the equal strength 
locus Rtrans = Btrans for this liquid mixture.  
Results for polychromatic light transmission through the more complex mixtures of tea – 
milk show how the Rtrans and Btrans strengths have both been substantially reduced 
from the water - tea values by the same milk concentrations (5 and 10 drops) used for 
the water – milk tests. They lie close to the origin i.e. Rtrans ~ Btrans0. 
 
Urine samples spiked with E. coli 
The Rtrans:Btrans transmission cluster maps were also applied to the sterile urine spiked 
with various concentrations of E. coli as shown in Figure 9.  This showed that both Rtrans 
and Btrans decrease as the E. coli concentration in the urine increases (although there 
was an anomalous result with 106 cfu/mL). 
Figure 9. Chromatic Cluster Map of R:B light transmission through various urine E.coli 
inoculums. 
 
The urine-E. coli >105 cfu/mL results lie below the equal strength locus (Rtrans=Btrans) 
implying that the changes in Rtrans are greater than the changes in Btrans. These results 
are similar to the water-milk trends rather than the water-tea trends (Figure 10) 
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suggesting the urine E. coli liquids have a complex mixture of pure liquid and turbidity 
effects, the former dominating for low levels of E. coli and the latter becoming 
increasingly significant at higher E. coli levels, but not to the same extent as the tea-milk 
mixtures where Rtrans ~ Btrans0. Figure 4.1.11 illustrates the Rtrans:Btrans chromatic 
maps of all these liquids.  
Figure 1. Rtrans:Btrans chromatic map of various complex liquid mixtures. 
 
 
Reflection (scatter of ambient light from the liquid) 
The Rrefl and Brefl values for water were ~0.04 and 0.01 respectively indicating only low 
levels of ambient light scattered. For water- tea liquid the Brefl was of a similar low value 
to water although the Rrefl values increased with tea concentration, leading to the water-
tea locus being close to the Rrefl axis. For water with increasing milk concentration 
(increasing turbidity) the Rrefl, Brefl chromatic map shows that the longer wavelengths 
(R) increase in strength with increasing milk/turbidity more rapidly than the shorter (B) 
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wavelengths. The Rrefl:Brefl locus lies well above the equal strength locus Rrefl:Brefl 
(Figure 11).  
Figure 11. Chromatic Map of Rrefl : Brefl for various complex liquids. 
 
For the urine inoculated with various concentrations of E. coli the results for the 
Rrefl:Brefl showed that higher levels of E. coli (>105 cfu/mL) followed the Rrefl=Brefl 
locus. For E. coli at 105 cfu/mL the result was not much different to the urine alone 
(without E. coli) and the water value, indicating little scatter effect due to the E. coli 
contamination at this inoculum concentration. 
Fluorescence 
The outputs for R:G and B:G UV light source with water and the four inoculums of E. 
coli in sterile filtered urine are shown in Figure 12. There was reasonable discrimination 
between all the E. coli concentrations with both R:G and B:G (although 106 and 107 
cfu/mL similar) however urine with E. coli at 105 cfu/mL had similar properties to water 
suggesting this detection limit in practice may not be useful using fluorescence.  
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Figure 12. Chromatic cluster map of R:G and B:G UV fluorescence through various urine 
E.coli inoculums. 
 
 
Final chromatic analysis maps and cut-off values for analytic performance 
evaluation  
The chromatic methods used for analysing the urine samples were based upon the 
transmission chromatic parameters Rtrans, Btrans and reflection chromatic parameters 
Rrefl, Brefl plotted against each other to form chromatic cluster maps. 
Rtrans, Btrans are the long and short optical wavelength components respectively, 
recorded by the web-camera, of the light transmitted from a white VDU screen through 
the urine samples with correction for ambient light. [Rtrans, Btrans are also corrected for 
camera and screen variations (via screen reference areas) and are normalised to 
accommodate ambient light variations  scale 0 - 1 (via black + white cards)]. 
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Figure 13. R:B Transmission chromatic cluster map comparing sterile filtered urine inoculated with known quantities of E. coli; water-tea-milk liquids 
and preliminary clinical urine samples; Area indicated by G denotes clinical urine samples with outputs in this are considered UTI positive, area indicated 
by NG denotes clinical urine samples with outputs in this area considered UTI negative. 
G 
NG 
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On the Rtrans : Btrans chromatic map (Figure 13), light having equal magnitude of 
components  Rtrans and Btrans lie on the line Rtrans = Btrans; since urine samples tend 
to be yellow – orange in colour are expected to lie above this line on the map (Rtrans > 
Btrans). The map is subdivided into two further sectors by the line Rtrans + Btrans = 1. 
The earlier tests showed that the regions; 
 Rtrans, Btrans  1 correspond to the transmitting liquid being clear (high optical 
transmission);  
 Rtrans, Btrans  0 correspond to the transmitting liquid being turbid (optical 
absorption); 
 The line Rtrans + Btrans = 1 forms the boundary between these two regions. 
The urine samples that have Rtrans:Btrans outputs that fall within the section of the 
graph indicated by a green triangle and letter G (0<(Rtrans=Btrans)<0.5 and 0.5 < 
Rtrans, Btrans < 0.5) were considered positive for a UTI at >105 cfu/mL. Urine samples 
that had Rtrans:Btrans outputs that fall within the section of the graph indicated by a red 
triangle and letters NG (0.5<(Rtrans=Btrans)<1 and Rtrans + Btrans ≥ 1) were 
considered negative for a UTI at ≤105 cfu/mL. 
Similarly for the reflection (scatter) chromaticity Rrefl:Brefl based on the E. coli inoculated 
urine  results and some preliminary clinical urine samples the following criteria has been 
set (Figure 14); 
 No significant bacterial growth samples (<105 cfu/mL) fall in the red NG sector 
Rrefl + Brefl < 0.3; Brefl ≤ Rrefl; Brefl ≤ 0.15 
 Significant bacterial growth (>105 cfu/mL) samples fall in the green  G sector Rrefl 
+ Brefl > 0.3; Brefl ≤ Rrefl; 0.15 < Brefl ≤ 1 
 The threshold bacterial growth is in the range Rrefl + Brefl = 0.3; Brefl ≤ 0.15.
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Figure 14. R:B Reflection chromatic cluster map comparing sterile filtered urine 
inoculated with known quantities of E. coli and water -milk liquids; Area indicated by G 
denotes clinical urine samples with outputs in this area considered bacterially UTI 
positive, area indicated with NG denotes clinical urine samples with outputs in this area 
considered bacterially UTI negative. 
 
   
Both types of chromatic analysis were used in the analytic performance evaluation 
(laboratory evaluation study). During the laboratory evaluation study which is described 
in the Section 2 Chapter 3 the first 67 urines (out of 195) were chromatically analysed 
un-blinded to the NHS microbiology urine culture results (quantification cfu/mL and 
bacterial identification); this was to allow for changes in chromatic analysis algorithms or 
cut-offs, although no changes were eventually made.   
The transmission data is referred to as Chromatic Indication and the reflection data as 
Chromatic Turbidity in this thesis. 
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2.3.2 Chromatic sensing power point template for VDU screen 
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2.3.3 Sensitivity, specificity, positive predictive value and negative predictive 
value of various urinalysis prediction rules in determining UTI 
Urinalysis Test 
Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Nitrite 
 
36.6 
(26.4 – 48.2) 
87.2 
(80.2 – 92.0) 
61.9 
(46.8 – 75.0) 
70.8 
(63.2 – 77.4) 
Leucocyte (positive ≥ 
trace) 
71.8 
(60.5 – 81.0) 
73.6 
(65.3 – 80.5) 
60.7 
(50.0 – 70.5) 
82.1 
(74.02 – 88.1) 
Leucocyte (positive ≥ 
+) 
 
62.0 
(50.3 – 72.4) 
80.8 
(73.0 – 86.7) 
64.7 
(52.8 – 75.0) 
78.9 
(71.1 – 85.1) 
Nitrite OR leucocyte 
(≥+) positive 
77.1 
(66.1 – 85.4) 
69.6 
(61.1 – 77.0) 
58.7 
(48.5 – 68.2) 
84.5 
(76.3 – 90.2) 
Blood (H ≥ trace) 
 
54.9 
(43.4 – 66.0) 
68.0 
(59.4 – 75.5) 
49.4 
(38.6 – 60.2) 
72.6 
(64.0 – 79.9) 
Blood (NH ≥ trace) 
 
22.5 
(14.4 – 33.5) 
85.6 
(78.4 – 90.7) 
47.1 
(31.5 – 63.3) 
66.0 
(58.5 – 72.9) 
Blood H or NH (≥trace) 
 
64.8 
(53.2 – 74.9) 
56.8 
(48.0 – 65.2) 
46.0 
(36.6 – 55.7) 
74.0 
(64.4 – 81.7) 
Protein (≥trace) 
 
50.7 
(39.3 – 62.0) 
58.4 
(49.6 – 66.7) 
40.9 
(31.2 – 51.4) 
67.6 
(58.3 – 75.7) 
Nitrite, Leucocyte (≥+) 
AND Blood (Trace) 
positive 
12.7 
(6.8 – 22.4) 
98.4 
(94.4 – 99.6) 
81.8 
(52.3 – 94.9) 
66.5 
(59.4 – 72.9) 
Nitrite AND Leucocyte 
(≥+) OR Blood (Trace) 
positive 
26.8 
(17.9 – 38.1) 
95.2 
(89.9 – 97.8) 
76.0 
(56.6 – 88.5) 
69.6 
(62.3 – 76.0) 
Nitrite OR Leucocyte 
(≥+) AND Blood 
(Trace) Positive 
67.6 
(56.1 – 77.3) 
80.8 
(73.0 – 86.7) 
66.7 
(55.2 – 76.5) 
81.5 
(73.7 – 87.3) 
Nitrite, Leucocyte 
AND Blood (H) 
negative 
83.1 
(72.7 – 90.1) 
48.8 
(40.2 – 57.5) 
48.0 
(39.3 – 56.7) 
83.6 
(73.4 – 90.3) 
Nitrite AND Leucocyte 
negative 
67.6 
(56.1 – 77.3) 
80.8 
(73.0 – 86.7) 
66.7 
(55.2 – 76.5) 
81.5 
(73.7 – 87.3) 
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Section 
and Topic 
Item 
# 
 On 
page # 
TITLE/ABST
RACT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic accuracy (recommend MeSH 
heading 'sensitivity and specificity'). 
36-37 
INTRODUCT
ION 
2 State the research questions or study aims, such as estimating diagnostic 
accuracy or comparing accuracy between tests or across participant groups. 
36-37 
METHODS    
Participants 3 The study population: The inclusion and exclusion criteria, setting and 
locations where data were collected. 
38 
 4 Participant recruitment: Was recruitment based on presenting symptoms, 
results from previous tests, or the fact that the participants had received 
the index tests or the reference standard? 
38 
 5 Participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in item 3 and 4? If not, specify 
how participants were further selected. 
38 
 6 Data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study)? 
39 
Test 
methods 
7 The reference standard and its rationale. 36, 39-
40 
 8 Technical specifications of material and methods involved including how and 
when measurements were taken, and/or cite references for index tests and 
reference standard. 
39-41 
 9 Definition of and rationale for the units, cut-offs and/or categories of the 
results of the index tests and the reference standard. 
39-41 
 10 The number, training and expertise of the persons executing and reading 
the index tests and the reference standard. 
38 
 11 Whether or not the readers of the index tests and reference standard were 
blind (masked) to the results of the other test and describe any other 
clinical information available to the readers. 
38-39 
Statistical 
methods 
12 Methods for calculating or comparing measures of diagnostic accuracy, and 
the statistical methods used to quantify uncertainty (e.g. 95% confidence 
intervals). 
43-44 
 13 Methods for calculating test reproducibility, if done. 46-50 
RESULTS    
Participants 14 When study was performed, including beginning and end dates of 
recruitment. 
51 
 15 Clinical and demographic characteristics of the study population (at least 
information on age, gender, spectrum of presenting symptoms). 
51 
 16 The number of participants satisfying the criteria for inclusion who did or did 
not undergo the index tests and/or the reference standard; describe why 
participants failed to undergo either test (a flow diagram is strongly 
recommended). 
39 
Test results 17 Time-interval between the index tests and the reference standard, and any 
treatment administered in between. 
39, 91 
 18 Distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition. 
52 
 19 A cross tabulation of the results of the index tests (including indeterminate 
and missing results) by the results of the reference standard; for continuous 
results, the distribution of the test results by the results of the reference 
standard. 
54 
 20 Any adverse events from performing the index tests or the reference 
standard. 
NA 
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty 
(e.g. 95% confidence intervals). 
54 
 22 How indeterminate results, missing data and outliers of the index tests were 
handled. 
52 
 23 Estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done. 
NA 
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2.3.4 STARD checklist for reporting of studies of diagnostic accuracy  
 24 Estimates of test reproducibility, if done.      59-62 
DISCUSSIO
N 
25 Discuss the clinical applicability of the study findings. 83-86, 
93-94 
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Literature Review: Data Extraction Table 
Study Details Population and Setting Research Parameters Methods of analysis 
Results 
Key Outcomes/Findings 
(relevant to the review) 
Notes 
Authors: 
 
What setting(s) (country; location; 
setting): 
 
What was/were the 
research questions: 
 
 
 
 
 
 
 
 
Brief description of 
method and process of 
analysis: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical methods (if 
applicable): 
Primary Outcomes: 
 
 
 
 
 
 
 
 
 
 
 
 
econdary Outcomes: 
 
 
 
 
 
 
 
 
 
 
 
 
Overall conclusions: 
Limitations identified by 
author: 
 
 
 
 
 
 
 
 
 
Limitations identified by 
review team: 
 
 
 
 
 
 
 
Evidence gaps and/or 
recommendations for 
future research: 
 
 
 
 
 
Source of funding: 
Year: 
 
Citation: 
What population were the sample 
recruited from: 
 
 
How were they recruited: 
 
 
How many participants were 
recruited: 
 
 
Response Rate: 
Aim of Study: 
 
 
 
 
 
 
 
 
Study Design: 
How were the data 
collected  
 
Unit of data collection 
(individual, group, 
community): 
 
What method (s): 
 
 
 
 
By whom: 
 
 
 
 
 
When: 
 
Were there specific exclusion 
criteria: 
 
 
Were there specific inclusion criteria: 
 
 
Population demographic (age, sex, 
ethnicity, occupation, education, 
socioeconomic position – if 
applicable) 
 
Differences between responders and 
non-responders: 
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3.2.2 POETIC study CRF 
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3.2.3 POETIC study Diary (page 2 only) 
  
 266  
3.2.4 UK guidelines: management of uncomplicated UTI in primary care 
  
 267  
  
 268  
3.2.5 Spain guidelines: management of uncomplicated UTI in primary care 
  
 269  
  
 270  
3.2.6 The Netherlands guidelines: management of uncomplicated UTI in 
primary care 
  
 271  
  
 272  
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3.2.7 ‘Other’ follow-up recommendations from POETIC observational study data 
Follow Up Advice 
Cardiff 
(n=20) 
Southampton 
(n=5) 
Spain 
(n=3) 
The Netherlands 
(n=31) 
Total 
(n=59) 
n % n % n % n % n % 
Follow Up for Test 
Results 
Patient to visit if MSU negative 1 5.0 0 0.0 0 0.0 1 3.2 2 3.4 
Follow up for blood test result 0 0.0 1 20.0 0 0.0 0 0.0 1 1.7 
Contact for dip-slide result 0 0.0 0 0.0 0 0.0 14 45.2 14 23.7 
Contact for urine test results 2 10.0 0 0.0 0 0.0 0 0.0 2 3.4 
Follow up for STI test results 0 0.0 0 0.0 0 0.0 1 3.2 1 1.7 
Follow up for Bladder USS with results 0 0.0 1 20.0 0 0.0 0 0.0 1 1.7 
Further Testing 
Follow up urine test after finishing antibiotics 1 5.0 0 0.0 0 0.0 6 19.4 7 11.9 
Repeat urine test if symptoms persist 0 0.0 1 20.0 0 0.0 0 0.0 1 1.7 
Repeat urine sample requested; day 2 morning 
sample 
0 0.0 0 0.0 0 0.0 1 3.2 1 1.7 
Symptomatic Follow 
Up 
Follow up if symptoms worsen or persist 15 75.0 0 0.0 3 100.0 5 16.1 23 39.0 
Other 
Telephone back (in 4 days) 0 0.0 1 20.0 0 0.0 0 0.0 1 1.7 
Same day appointment made 1 5.0 0 0.0 0 0.0 2 6.5 3 5.1 
Follow up if any problems 0 0.0 1 20.0 0 0.0 0 0.0 1 1.7 
Follow up in 3 weeks 0 0.0 0 0.0 0 0.0 1 3.2 1 1.7 
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3.2.8 Multilevel Model: Antibiotics prescribed according to recommended 
network guidelines for type, total dose and duration 
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3.2.9 POETIC POCT  Data 
 
Cloudy Urine     
 Total Cardiff Southampton 
Madrid and 
Catalonia 
Utrecht 
TP 132 34 33 20 45 
TN 256 69 95 60 32 
FP 127 49 50 18 10 
FN 89 8 21 26 34 
Sensitivity 0.597285 0.809524 0.611111 0.434783 0.56962 
Specificity 0.668407 0.584746 0.655172 0.769231 0.761905 
PPV 0.509653 0.409639 0.39759 0.526316 0.818182 
NPV 0.742029 0.896104 0.818966 0.697674 0.484848 
LR+ 1.801261 1.949466 1.772222 1.884058 2.392405 
LR- 0.602499 0.325742 0.593567 0.734783 0.564873 
Odds 
ratio 
2.989649 5.984694 2.985714 2.564103 4.235294 
      
Dipstick Urinalysis     
 Total Cardiff Southampton 
Madrid and 
Catalonia 
Utrecht 
TP 222 42 55 46 79 
TN 56 21 6 26 3 
FP 387 118 149 78 42 
FN 54 14 6 31 3 
Sensitivity 0.804348 0.75 0.901639 0.597403 0.963415 
Specificity 0.126411 0.151079 0.03871 0.25 0.066667 
PPV 0.364532 0.2625 0.269608 0.370968 0.652893 
NPV 0.509091 0.6 0.5 0.45614 0.5 
LR+ 0.920739 0.883475 0.937947 0.796537 1.03223 
LR- 1.547748 1.654762 2.540984 1.61039 0.54878 
Odds 
ratio 
0.594889 0.533898 0.369128 0.494624 1.880952 
      
Dipstick Nitrite     
 Total Cardiff Southampton 
Madrid and 
Catalonia 
Utrecht 
TP 126 21 33 22 50 
TN 291 89 109 59 34 
FP 78 14 37 19 8 
FN 93 18 22 24 29 
Sensitivity 0.575342 0.538462 0.6 0.478261 0.632911 
Specificity 0.788618 0.864078 0.746575 0.75641 0.809524 
PPV 0.617647 0.6 0.471429 0.536585 0.862069 
NPV 0.757813 0.831776 0.832061 0.710843 0.539683 
LR+ 2.721812 3.961538 2.367568 1.963387 3.322785 
LR- 0.538483 0.53414 0.53578 0.689757 0.453462 
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Odds 
ratio 
5.054591 7.416667 4.418919 2.846491 7.327586 
      
Dipstick Leucocyte     
 Total Cardiff Southampton 
Madrid and 
Catalonia 
Utrecht 
TP 169 38 48 39 44 
TN 81 26 31 6 18 
FP 291 88 118 71 14 
FN 35 3 7 6 19 
Sensitivity 0.828431 0.926829 0.872727 0.866667 0.698413 
Specificity 0.217742 0.22807 0.208054 0.077922 0.5625 
PPV 0.367391 0.301587 0.289157 0.354545 0.758621 
NPV 0.698276 0.896552 0.815789 0.5 0.486486 
LR+ 1.059026 1.200665 1.102003 0.939906 1.596372 
LR- 0.787945 0.320826 0.61173 1.711111 0.536155 
Odds 
ratio 
1.344035 3.742424 1.801453 0.549296 2.977444 
      
Requesting routine culture    
 Total Cardiff Southampton 
Madrid and 
Catalonia 
Utrecht 
TP 113 32 34 25 22 
TN 176 48 52 62 14 
FP 246 85 90 42 29 
FN 150 23 22 51 54 
Sensitivity 0.429658 0.581818 0.607143 0.328947 0.289474 
Specificity 0.417062 0.360902 0.366197 0.596154 0.325581 
PPV 0.314763 0.273504 0.274194 0.373134 0.431373 
NPV 0.539877 0.676056 0.702703 0.548673 0.205882 
LR+ 0.737055 0.910374 0.957937 0.814536 0.42922 
LR- 1.367525 1.158712 1.072802 1.125637 2.182331 
Odds 
ratio 
0.53897 0.785678 0.892929 0.723623 0.196679 
 
